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Abstract

VE-Cadherin Expression and Regulation of Sensitivity to Apoptosis in Philadelphia
Chromosome Positive Acute Lymphoblastic Leukemia
Heather A. O’Leary
The bone marrow microenvironment serves as the primary site for post-natal hematopoiesis
allowing for HSC development and maturation. More specifically, B lineage cells rely on key signals
from both the physical and soluble components of the marrow for their survival and maturation. In
addition to normal hematopoiesis the bone marrow has been shown to be a sanctuary for leukemic
cells, as well as other tumors, that can interact with cues from the microenvironment allowing for
their protection during chemotherapy. The studies described in this dissertation focus on two
supportive components of the bone marrow microenvironment, osteoblasts and bone marrow
stromal cells (BMSC), in the settings of post high dose chemotherapy and survival of leukemic cells
during chemotherapy, respectively.
In the first study we investigated the effects of high dose chemotherapy on human
osteoblasts (HOB). Previous studies from our laboratory have shown that high dose chemotherapy
causes increases in the amount of active TGF-β released from BMSC and subsequently leads to
diminished ability to support pro-B cells. Here we describe the novel observation that HOB treated
with chemotherapy have increased levels of active TGF-β as well as a diminished capacity to
interact with, and support, human embryonic stem cells and pro-B cells.

Additionally, we

determined that HOB treatment with chemotherapy or rTGF-β led to increased levels of active
TGF-β,

as well as decreased CXCL12 mRNA and protein leading to a decreased adherence of

pro-B cells to HOB. Chemotherapy or rTGF-β treatment also lead to the diminished ability of HOB
to support pluripotent OCT-4 positive stem cell colonies and microarray analysis of HOB treated
with Melphlan, rTGF-β or Conditioned Media from BMSC treated with Melphlan led to dramatic
changes in the gene expression profiles of the HOB. This study elucidates the importance of
osteoblasts in the marrow following ablative therapy and indicates how different components of the
marrow are altered by chemotherapy.

Our laboratory and others have previously shown that BMSC are able to protect tumor cells from
chemotherapy however the mechanisms by which the bone marrow microenvironment regulates tumor
cell survival are diverse. This study describes the novel observation that in addition to Philadelphia
chromosome positive (Ph+) acute lymphoblastic leukemia (ALL) cell lines, primary patient cells also
express Vascular Endothelial Cadherin (VE-cadherin) which is regulated by Abl kinase and has been
associated with aggressive phenotype and poor prognosis in other models. Targeted knockdown of VEcadherin rendered ALL cells more susceptible to chemotherapy, even in the presence of BMSC derived
survival cues. Pre-treatment of Ph+ ALL cells with ADH100191, a VE-cadherin antagonist, resulted in
increased apoptosis during in vitro chemotherapy exposure. Consistent with a role for VE-cadherin in
modulation of leukemia cell viability, lentiviral-mediated expression of VE-cadherin in Ph- ALL cells
resulted in increased resistance to treatment-induced apoptosis. Collectively, these data contribute to
our understanding of the alterations that occur to the different supportive components of the bone
marrow microenvironment during chemotherapy and the mechanisms that alter their ability to support
both normal and neoplastic cells.
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Chapter 1

Architecture of the Bone Marrow
Microenvironment: Hematopoesis & Normal
B-Cell Development
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1. Architecture of the bone marrow microenvironment/ hematopoietic
niche, hematopoiesis and normal B cell development
I. Physical Structure of the Niche
The stem cell niche can be characterized as a specialized environment which can vary
in content and location based on the tissue and stem cell type that it supports. Early work of
Curry and Trenton in 1966 first coined the phrase “hematopoietic inductive microenvironment”
(HIM) and the first description of a stem cell niche was hypothesized by Shofield in 1978 who
suggested that stem cells were in association with other cells that influence their behavior

1;2

.

More recently, the Scadden lab has proposed that the niche is a group of cells that allow a stem
cell to maintain its identity

3;4

. Our focus has been the bone marrow microenvironment which is

anatomical space that houses the unique niche for hematopoietic stem cells (HSC) and is the
primary site of post-natal hematopoiesis.
The primary function of the niche is to facilitate the anchorage, growth and expansion of
stem cells. Early studies characterizing the progression and renewal of stem cells were
completed in Drosophila and C. elegans models

5-7

. Further studies to characterize the

expansion of stem cells in a mammalian model have shown that stem cell survival and self
renewal is accomplished by supporting cells providing both physical and soluble cues to stem
cells that hone towards, and bind to, the physical architecture of the stem cell niche

8;9;10

. Until

recently, the composition and location of the stem cell niche components remained somewhat
elusive. Shackney, followed by others, suggested a model of gradient hematopoiesis in the
bone marrow with more primitive cells located near the endosteum, with differentiation and
maturation increasing as the cells moved toward the vascularized bone marrow cavity to be
mobilized to the periphery 11;12 (Figure 1).
Current studies have segregated the HSC niche into two main support systems, the
osteoblastic or endosteal niche and the vascular niche
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11;13;14

. The supportive components of

these stem cell niches are mesenchymal stem cells that differentiate into supportive lineages
including osteoblasts (both spindle-shaped N-cadherin positive (SNO) and negative), fibroblastic
cells (also known as bone marrow stromal cells, BMSC and mesenchymal stem cells, MSC),
15-19

endothelial cells, chondrocytes, adipocytes, and myocytes

.

Recent studies from the

Taichman lab suggest an interesting role for HSC in the regulation of differentiation of
supportive cells suggesting that HSC directly participate in niche activities 20;21. Our studies have
focused on two of the main components of each niche, osteoblasts and bone marrow stromal
cells.
The endostosteum, found lining the bone surface, consists mostly of osteoblasts and
serves as the primary site in which quiescent HSC reside

22-25

. Osteoblasts are mononucleate

cells that are responsible for the production of bone and are further separated into spindleshaped N-cadherin positive, or SNO cells, or N-cadherin negative16;26. Prior to the knowledge of
the specific architecture of the niche, Gong and Lord showed in 1975 that more primitive
hematopoietic progenitor cells were in close proximity to the endosteal surface, while more
differentiated cells were seen in the center of the bone marrow space24;25. Literature summarized
by the work of multiple groups

14;19;26-28

then revealed the first true glimpses of the structure, in

vivo location, function and signaling of the cells in the niche, showing the N-cadherin positive
osteoblasts that line the endosteal surface play a role in the regulation of HSC. Additionally,
these studies showed that the number of osteoblasts, as well as HSC adhesion to them, directly
regulate both the number and quiescence of the HSCs found in the niche 26;14 .
There is a discrepancy in the literature regarding the importance of N-cadherin
regulating HSC in the niche. Zhang et al. showed that N-cadherin expression on osteoblasts is
critical to the regulation of the number of HSC in the niche

26

. Subsequent papers by Kiel et al.,

from the Morrision lab, deleted N-cadherin from HSC using Mx-1-Cre(+)N-cadherin(fl/-) mice
and showed that N-cadherin deficiency did not affect bone marrow cellularity or lineage
composition, the numbers of colony-forming progenitors, the frequency of HSC, the ability of
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HSC to sustain hematopoiesis over time, or their ability to reconstitute irradiated mice in primary
or secondary transplants29;30. These observations confirm that the osteoblasts may be
important, but that N-cadherin expression is not critical for HSC development in the endosteal
niche. Studies using the ability to inducibly ablate osteoblasts in transgenic mice expressing the
herpes virus thymidine kinase gene, under the control of the osteoblast specific collagen α1
promoter, were performed by Visnjic et al. and showed that the loss of osteoblasts led to
substantial decrease in the number of progenitor cells (lymphoid, myeloid and erythroid) in the
bone marrow

31;32

. Additionally, these studies showed a decrease in the total number of HSC

and decreased bone marrow cellularity, all of which could be restored by the reconstitution of
the osteoblasts

31;32

. In parallel, the Taichman lab has shown that the in vitro survival of

hematopoietic progenitor cells on osteoblasts is dependent upon the engagement of VLA-4
(Very Late Antigen) and VLA-5, and that HSC are able to regulate the osteoblast secretion of
certain factors necessary for stem cell survival and differentiation suggesting an active
reciprocal relationship between HSC and the supportive cells of the niche 21;33-35.
The second major physical component of the bone marrow niche includes stromal cells
which are adherent, clonogenic, non-phagocytic cells that express a variety of molecules
necessary for immune function36;37. In 1968, Friedenstein, Owen, and colleagues were the first
to determine that bone marrow stromal cells, or fibroblastic colony forming units (CFU-F) as
they called them, were able to be derived and propagated from the bone marrow of post-natal
animals

38-43

.

The bone marrow contains adventitial (outer) reticular marrow cells which line the sinus
wall and fibroblastic reticular marrow cells (referred to as bone marrow stromal cells, BMSC)
that are found scattered in the mid bone region, and form a three-dimensional cellular network
integrating the underlying sinusoidal network and play a major role in regulation of
hematopoiesis, specifically B cell development. These fibroblastic BMSC have classically been
described as not expressing hematopoietic or co-stimulatory molecules but are able to express

4

extracellular matrix proteins including collagen I, III, IV, V, VI, fibronectin, vitronectin, laminin,
thrombospondin, hemonectin, and
tenascin

44-46

. They have the surface markers CD105 (SH2), CD73 (SH3/4), CD44, CD90(Thy-

1), CD71, and Stro-1 as well as adhesion molecules CD166 (activated leukocyte cell adhesion
molecule [ALCAM]), intercellular adhesion molecule (ICAM)-1, CD29, Stro-1 and VCAM-1
(Vascular Cell Adhesion Molecule-1, CD106) which are important for hematopoiesis

47-49

.

Additionally, they produce soluble factors, including CXCL12 (chemokine (CXC motif) ligand 12,
also known as SDF-1 (Stromal Cell Derived Factor-1) and Interleukin-7, that are important for
the differentiation and maturation of HSC 50-52.
Interestingly, bone marrow stromal cells (BMSC) expression of physical and soluble
factors allows them to both positively and negatively influence hematopoiesis, and multiple
studies have suggested that they play an important role in both the osteoblastic and vascular
niches 53. Expression of cytokines which positively influence hematopoiesis include granulocytemacrophage colony stimulating factor (GM-CSF), interleukin-1 (IL-1), IL-3, IL-5, IL-6, IL-7, IL-11,
IL-12, leukemia inhibitory factor (LIF), fibroblast growth factor (FGF), stem cell factor (SCF), Flt3 ligand (FMS-like tyrosine kinase 3), c-kit, macrophage colony stimulating factor (M-CSF),
insulin-like growth factor-1 (IGF-1) and tumor necrosis factor-α (TNF-α)

54-60

. In contrast,

interferon-γ (INF-γ), transforming growth factor-β (TGF-β), and macrophage inflammatory
protein-1α (MIP-1α) act as negative regulators of hematopoiesis61-64.

Importantly, BMSC lack

phenotypic markers of osteoblasts, such as osteopontin and osteocalcin, showing they are
distinct from osteoblasts consistent with their documentation of performing unique functions65.
Stromal cells were initially shown to support hematopoietic cells by Dexter, Whitelock, and Witte
and have been shown to be crucial in the early stages of B cell development, or B
lymphopoiesis. Additionally, stromal cells have the ability to protect of B-lineage leukemias, as
well as other malignancies, from chemotherapy 66-71.
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While not a focus of work presented in the current studies, it is important to touch on the
endothelial, or vascular, niche. The endothelial niche is an environment which provides signals
for HSC proliferation, differentiation into progenitors, and subsequently mature blood cells, as
well as mobilization into the blood stream72;73. Bone marrow endothelial cells (BMEC) interact
with HSC through constitutive expression of chemokines such as CXCL12 and through the
expression of adhesion markers VCAM-1, PECAM1 (platelet endothelial cell adhesion
molecule-1), E-selectin (endothelial-selectin) as well as others11;18;74. HSC vacillate between the
osteoblastic and vascular niche, potentially by utilizing BMSC, during normal homeostatic
conditions. This migration is increased during times of stress when the need for blood cells is
increased. Endothelial cells have been shown to be a crucial component of the niche, as upon
ablation of endothelial cells in vivo by utilizing anti-VE-cadherin antibody, hematopoietic failure
ensued and the addition of endothelial cells has been shown to increased hematopoietic
reconstitution 75-77.
A close relationship between endothelial cells and HSC is not surprising as both
lineages are derived from a common precursor, though there is discrepancy in the literature
whether the common lineage is a hemangioblast, haemogenic endothelium or both

78;79

.

Hemangioblasts are mesodermal progenitors with both endothelial and haematopoietic potential
while haemogenic endothelium is phenotypically differentiated endothelial cells with
haematopoietic potential

80

. The hemangioblast theory initially arose from studies in the late

1990’s identifying that during embryonic stem cell differentiation a clonal precursor, the blast
colony-forming cell (BL-CFC), was able to give rise to blast colonies with both endothelial and
haematopoietic components81;82. Further research has provided evidence for the presence of
this bipotential precursor, or BL-CFC in vivo, however, the mechanism by which hematopoietic
cells are generated from the hemangioblast, and the role of the haemogenic endothelium, is still
being investigated.

6

Recently, to address this discrepancy, the Lacaud laboratory, and other groups, followed
individual blasts cell development by time-lapse photography and demonstrated that the
hematopoietic cells are generated from the hemangioblast, using the haemogenic endothelium
as an intermediate step. They utilized the endothelial markers Tie2/Tek13, as well as the
hematopoietic commitment markers CD41/IIb integrin and c-kit to investigate the sequential,
developmental steps, as well as identify transitional populations, and also determined that the
transcription factors Scl/Tal110 and Runx1/AML1 are necessary for the establishment of the
haemogenic endothelium and the generation of hematopoietic cells, respectively79;80;83;84.
Another factor further solidifying the relationship between endothelial cell and HSC
interactions are expression of cell surface receptors of the SLAM (signaling lymphocyte
activation molecules) family. These molecules, expressed on the surface of HSC, consist of
CD150, CD244 and CD48 and are commonly associated with the population of HSC that
interacts directly with the endothelial cells and are self-renewing HSC that can be mobilized
rapidly, if needed, and replaced by cells recruited from the endosteal niche 72.

II. Characteristics of a hematopoietic stem cell (HSC).
In the early 1900’s Alexander Maximow gave the first description of a hematopoietic
stem cell stating that, "In the mammalian organism exists one cell type, the lymphocyte in the
widest sense of the word, which may look different according to the site of residence as well as
to the local conditions and which can produce different products of cellular differentiation85.” The
1960’s brought about the next phase in the investigation of the HSC with the work of Goodman
and Hodgson who coined the term HSC86. Additionally, groups such as Till and McCulloch,
Bradley and Metcalf , Pluznik and Sachs, and Castro-Malaspina and Moore clearly delineated
the importance of the bone marrow in regulation of hematopoiesis

87-93

. Critical techniques were

also developed in order to analyze HSC in vitro with spleen colony forming assays, and the
growth of niche cells in vitro, respectively94;95.
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More current studies of HSC characterize them as pluripotent, self-renewing, non-cycling
cells with a surface marker phenotype of CD34+, Lineage-, SCA1+, KIT+96;97. HSC give rise to all
cells of the immune system including lymphoid (T, B, and Natural Killer (NK) cells) and myeloid
lineage cells (monocytes, macrophages, neutrophils, basophils, eosinophils, erythrocytes,
megakaryocytes/platelets, and dendritic cells) while maintaining their ability to self renew
(Figure 2,

100

98;99

) . Many adhesion and soluble factors are necessary for the maintenance of the

stem cell phenotype. The important adhesion molecules of the niche include N-cadherin/catenin, VCAM/integrin and osteopontin/1 integrin

5;101

. Though the exact functions of these

adhesion molecules are largely unknown, studies blocking the function of integrins have shown
their importance in the adhesion and homing of HSC to the niche. Soluble factors that have
been shown to be important in the maintenance of HSC include CXCL12, which plays a role in
homing, transendothelial migration, proliferation and survival, and G-CSF (Granulocyte colonystimulating factor) which induces HSC and progenitor mobilization. The most primitive HSC are
quiescent and found in the endosteal niche interacting with osteoblasts and subsequently
interacting with BMSC and BMEC as they differentiate into progenitors and mature into
competent immune cells that will migrate into the peripheral blood.
Innovative mouse studies from Akashi and Weissman proved the existence of specific
and restricted common lymphoid (CLP) and myeloid progenitor (CMP) stem cells that arose
from the HSC population and specifically gave rise to B, T and NK cells (CLP) and
Monocyte/Granulocyte, Megakaryocyte/Erythrocyte progenitor lineages (CMP), respectively102106

. These studies were the first to prove the existence of these intermediate progenitor stem

cells and further classified them as Lin-, IL-7R+, Thy-1-, Sca-1lo, c-Kitlo (CLP) and Lin-, IL-7R-,
Thy-1-, Sca-1-, c-Kit+, FcRlo (CMP). Further discussions of stem cell progenitor development
will focus on the CLP, more specifically, its B-lineage progeny.
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III. Normal B cell development.
B (bursa or bone marrow derived) lymphocytes, both normal and malignant, were
discovered and characterized throughout the mid 1960’s and early 1970’s by Max Cooper and
Robert Good utilizing both patients with immune deficiencies as well as experimental animal
models107-110. B lymphocytes consist of a population of bone marrow derived cells that express
clonally diverse cell surface immunoglobulin receptors recognizing specific antigenic epitopes
107

. Early B cell development requires stromal cell physical contact and soluble factors in order

to complete differentiation steps which involve rearrangement of immunoglobulin variable region
gene segments to produce a mature, and functional, B lineage cell. B lymphopoiesis occurs
initially in primary lymphoid tissue (fetal liver and then fetal/adult bone marrow), with functional
maturation occurring in secondary lymphoid organs (lymph nodes and spleen) with the final
endpoint being functional plasma cells that are terminally differentiated 107;111-114.
B lymphopoiesis occurs as HSC differentiate to a committed lymphoid progenitor stem
cell (CLP) which then become pro-B, pre-B cells as their immunoglobulin variable region gene
segments are rearranged (Figure 3,

100

). This rearrangement occurs in both the heavy () and

light () chain variable regions by a tightly regulated process that utilizes the Tdt, or terminal
deoxynucleotidyl transferase, and recombinase-activating enzymes (Rag1 and Rag2) leading to
the expression of IgM, on the surface of the immature B cell. Immature B cells additionally
express CD19, CD20, CD40, MHC class II and CD45R, and cells that exit the marrow acquire
surface IgD, as well as CD21 and CD22, and have functionally important changes in the density
of other receptors107;115;116.
The crucial factors driving B lymphocyte development, in vivo, include Interluekin-7 (IL7), CXCL12/CXCR4, Flt-3L/FLT3, SCF, RANKL, and VCAM-1 and will be discussed below. IL-7
provides both survival/proliferation signals, promotes V to DJ heavy chain rearrangement by
altering the accessibility of DNA substrates to the recombinase, and was the first cytokine
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shown to be essential for B cell development

117-119

. IL-7 is secreted from the bone marrow

stromal cells and binds to the IL-7R on the pre-B cell. Ligand binding stimulates maturation
resulting in down-regulation of adhesion molecules on the pre-B cell so that it can proliferate
and is no longer stromal, but still IL-7, dependent. The receptor for IL-7 is comprised of two
chains: IL-7Rα and the cytokine-receptor common γ-chain (γc), and IL-7- and IL-7Rα-deficient
mice have severe defects in the development of B and T cells 120. IL-7 has been shown to play a
vital role in the pro-B cell stage of development which has been confirmed by studies in IL-7- or
IL-7Rα- deficient mice showing that their bone marrow is composed of normal numbers of prepro-B cells but has severe deficits of pro-B cells, pre-B cells and the more differentiated B cells
with other studies suggesting the importance of IL-7 at the CLP stage of development 107;117-121 .
CXCL12 and its receptor CXCR4 have been shown to be important in the retention of B
lineage cells in primary lymphoid tissues and colonization in the bone marrow of B-lineage cells
as well as HSC122;123. Murine studies of CXCL12 deficient embryos or WT mice reconstituted
with CXCR4 deficient fetal cells, show severely reduced numbers of very early B- precursors in
the fetal liver as well as decreases in the pre-pro-B cells of the adult marrow, respectively,
suggesting that CXCL12–CXCR4 axis is absolutely crucial for the earliest stages of B-cell
development in the fetus and adult 124;125. CXCR4/CXCL12 signaling has also been shown to be
important in the homing of end stage B cells to the bone marrow, however, the specific
mechanisms by which CXCL12 functions in the regulation of B-cell development still remain
unknown. Another receptor for CXCL12, CXCR7 has been identified and been shown to
heterodimerize with CXCR4 to enhance CXCL12 signaling, and aid in transendothelial
migration of B lineage ALL cells; however, a specific role for CXCR7 in B cell development has
not yet been identified as conditionally deficient

CXCR7-/- mice have normal B cell

development 126;127.
FLT-3L/FLT3 is a ligand for the FLT-3 receptor which has sequence and structural
homology to the class-III-receptor tyrosine kinases including the macrophage colony-stimulating

10

factor (M-CSF) receptor (c-fms), the SCF receptor (KIT), and the α- and β-platelet-derived
growth factor (PDGF) receptors 128. Flt3 deficient mice have reductions in the number of pre-pro
and pro-B cells with generally normal numbers of pre-B cells, immature B cells and mature B
cells

129

. In contrast, FLT3L deficient mice have substantial reductions in the number of pre-pro-

B-cells, marginally diminished numbers of pro-B cells and pre-B cells, and normal numbers of
more differentiated B cells

130

. These data indicate that, similar to CXCL12, FLT3L is pivotal for

the development of pre-pro-B cells but the phenotypic difference between FLT3 and FLT3L
deficient mice suggests the potential for another receptor for FLT3L.
SCF binds to the KIT class-III-receptor tyrosine kinase and has been shown to play a
role in the development of many cells types including hematopoietic cells

131

. SCF or c-kit

deficient mice have been shown to have normal B cell development with significantly reduced
numbers of CLP in mice younger than 4 weeks of age, and at 195 days (approximately 28
weeks), the numbers of pre-pro-B cells were normal but the numbers of pro-B and pre-B cells
were severely reduced suggesting that in younger mice SCF/C-kit may be redundant but that it
plays a critical role in adult B cell development and maintenance

132-134

. During B cell

development, c-kit on the surface of the pro-B cell interacts with SCF on the surface of the
stromal cell which activates the tyrosine kinase activity inducing pro-B to pre-B division and
differentiation.
RANKL (receptor activator of nuclear factor-κ B ligand) binds to the RANK receptor, and
its expression on B cells has been shown to be important for B cell development. Reconstitution
of immunodeficient recombination-activating gene 1 (Rag1–/–) mice with Rankl–/– fetal liver
cells led to reduced numbers of pre-B cells and B220+IgM+ immature B cells, where
reconstitution of Rankl–/– mice with wild-type bone-marrow cells led to normal B-cell
development 135.
VCAM-1 provides physical interaction between pro and pre-B cells and allows for
retention in the bone marrow. Additionally, interactions between VCAM-1 on the stromal cells
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and VLA-4 on the B cells hold them in close proximity to each other so that the B cells can
interact with soluble factors being produced by the BMSC. Although some early studies
suggested that VCAM-1 may not be essential to B lymphopoiesis,

136

more recent studies have

shown the importance of VCAM in both normal and neoplastic B cell survival137-141.
IV. Damage to the microenvironment alters support of stem and progenitor cells.
As mentioned previously, in a healthy bone marrow microenvironment, the supportive
cells of the niche, osteoblasts and bone marrow stromal cells, act as crucial mediators in both
the survival of primitive stem cells as well as the maturation of these cells into functional cells of
the immune system. As such, it is important to address the functional consequences and deficits
that occur when supportive cells of the bone marrow microenvironment are damaged by myelosuppressive or ablative chemotherapy or radiation as a common complication in the setting of
bone marrow transplantation.
Early studies from the Fried lab showed that both chemotherapy and irradiation led to
lasting deficits in stromal cell function and subsequently to a decrease in the number of
fibroblastic colony forming units (CFU-F)142-144. Patient retrospective studies from the late 1990’s
show that even at 12 years, post-transplant patients' CFU-F frequencies were reduced by 60%90% compared to controls145;146. More recent studies show that Acute Lymphoblastic Leukemia
(ALL) patients who received ablative therapy prior to bone marrow transplantion were found to
have diminished hematopoietic support that was attributed to an increase in transforming growth
factor beta (TGF-)147. In contrast, studies from Isaikinia et al. investigated the ability of
mesenchymal stem cells (MSC) from both normal donors and patients exposed to
chemotherapy and/or radiation (Non-Hodgkin’s, Hodgkin’s Lymphoma or Ewings sarcoma) to
support CD34+ cells148. They saw no difference in expansion or differentiation of hematopoietic
cells at 7, 14, or 21 days.
Further studies are clearly needed to better understand the mechanisms that underlie
the damage that occurs with different chemotherapy regimens and how functional changes alter

12

long term hematopoietic recovery. Previous publications of in vitro studies, from our laboratory,
as well as others, established that chemotherapy increases the amount of active TGF- in bone
marrow stromal cells and data shown in chapter 1 elucidates the functional consequences of
chemotherapy mediated increases in TGF- in osteoblasts on their capacity to support human
stem and hematopoietic progenitor cells149-151.

Figure 1: Architecture of the stem cell niche
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Figure 2: Hematopoiesis, Immunology, 5th edition100
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Figure 3: Normal B cell development (lymphopoiesis), Immunology 5th edition100
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Abstract :
Sustained long-term hematopoietic reconstitution, following bone marrow or stem cell
transplantation, requires a microenvironment niche capable of supporting stem cells with the
capacity to differentiate and expand to provide hematopoietic recovery, with osteoblasts
comprising one important component of this niche. We determined that treatment of human
osteoblasts (HOB) with chemotherapy resulted in an increase in phospho-Smad2, consistent
with increased TGF- activity coincident with reduced HOB capacity to support immature B
lineage cell chemotaxis and adherence. The supportive deficit was not limited to committed
progenitor cells, as human embryonic stem cells (hESC) co-cultured with chemotherapy or
rTGF- pre-treated HOB had diminished Oct-4 expression when compared to hESC co-cultured
with untreated HOB. These functional deficits were downstream of significant changes in HOB
gene expression profiles following chemotherapy. In addition, HOB gene expression patterns
were impacted by either recombinant TGF-, or conditioned media from Melphalan treated bone
marrow stromal cells, suggesting response to direct genotoxic stress as well as to factors
potentially elaborated by neighboring cells that would be found in the marrow. Chemotherapy
induced damage of HOB suggests vulnerability of the stem cell niche to therapeutic agents
frequently utilized in pre-transplant regimens and suggests that dose escalated chemotherapy
may contribute to post-transplantation hematopoietic deficits by damage structural components
of the stem cell niche.
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Introduction:
The stem cell niche hypothesis was first presented in 1978 by Schofield who suggested
that stem cells were associated with accessory cells that influence their behavior 1. Studies
from several labs have expanded our appreciation of the unique anatomical niches within the
marrow microenvironment and have characterized areas of optimal stem cell support

2-4

. The

niche structure and cellular components have been more recently elucidated to consist of
osteoblasts

(HOB), bone marrow stromal or mesenchymal stem cells (BMSC, MSC), and

endothelial cells

5-7

. Recent work has demonstrated the importance of the interaction of

osteoblasts and stem cells in the niche, suggesting that hematopoietic stem cells (HSC) can
regulate MSC differentiation into osteoblasts and that they, in turn, play an important role in the
8;9

support of B lymphocytes and differentiation of HSC

. Additionally, it has been shown that

resting HSC are maintained in a quiescent state as a result of their close proximity to
osteoblasts and that the number of HSCs change as a result of the number and type of
osteoblasts present

10;11

. Studies describing BMSC have shown that damage by chemotherapy

and radiotherapy can affect the ability of the BMSC to self-repair and leads to decreased
numbers of functional immune system cells in the blood, with deficits persisting years after
transplant

12-14

. The effects of chemotherapy on osteoblasts, and subsequently HSC support,

have not been as well characterized as those on BMSC, and warrant further investigation.
The stem cell niche is characterized, in part, by expression of specific cytokines,
including TGF-β and CXCL12, to facilitate signaling between the niche components and HSC.
Studies by our laboratory, and others, demonstrate that chemotherapy increases the levels of
active TGF- resulting in decreased ability of BMSC to support HSC

15;16

. It has also been

shown that TGF-β has potential crosstalk with CXCL12 and can stimulate the differentiation of
progenitor cells to erythroid and myeloid cells resulting in a deficit of the primitive stem cell pool
17;18

. The importance of CXCL12 is demonstrated by its requirement for homing of progenitor

cells to the bone marrow following transplantation
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19;20

. We have previously demonstrated that

diminished levels of CXCL12 in the supernatants of VP-16 treated BMSC results in loss of an
optimal chemokine gradient to which CXCR4+ pro-B cells respond and

CXCL12 was

subsequently shown to also be important in regulation of stem cell phenotype by Guo et al.

21;22

.

Sugiyama et al showed that mice deficient in the CXCL12 receptor, CXCR4, had a reduction in
HSC, in both vascular and endosteal niches, and increased sensitivity to myelotoxic stress
compared to their wild-type counterparts

23

. Other studies of CXCR4 in the HSC niche have

shown that CXCR4 is essential to maintain the quiescence, and retention, of stem cells in their
specific niches

24

.

In the current study we investigate chemotherapy-mediated damage of

osteoblasts with emphasis on CXCL12 and TGF-β levels following chemotherapy.

HOB cells

were evaluated for their ability to support maintenance of undifferentiated human embryonic
stem cells as a model of one critical element of the stem cell niche.
In addition to soluble factors that define the stem cell niche, adhesion molecules are also
known to be critical to physically tether immature cells in areas of concentrated cytokines and to
initiate intracellular signaling following integrin engagement

25

. VCAM-1 has been shown to be

one adhesion molecule that stem cells rely upon to anchor to the marrow stroma which plays a
crucial role in lymphopoiesis

26;27

. Animal studies have shown that VCAM-1 neutralizing

antibodies, or VCAM-1 conditional knockout, block engraftment of HSC in mice 28;29.
In the current study, global changes in HOB gene expression in response to Melphalan,
a clinically relevant pre-transplant agent, were investigated to determine the general
vulnerability of this particular component of the stem cell niche to genotoxic stress. In addition,
TGF-, CXCL12 and VCAM-1 were investigated as representative osteoblast proteins involved
in three critical functions of the endosteal niche; support of pluripotency, homing and stem cell
retention

30-32

. Our results indicate diverse changes in gene expression profiles following HOB

exposure to Melphalan, conditioned media from BMSC treated with Melphalan, and following
exposure to rTGF- as one of the factors elaborated by chemotherapy damaged stroma 15. HOB

36

treated with chemotherapy had increased levels of active TGF-, consistent with the earlier
documented effect on BMSC

15

. Melphalan, VP-16, or rTGF- pre-treated HOB demonstrated

reduced ability to support OCT-4 positive embryonic stem cell colonies. Additionally, HOB
treatment with chemotherapy or rTGF- resulted in decreased levels of CXCL12, and reduced
chemotactic support and adhesion of CXCR4+ pro-B cells. In contrast to our earlier reports of
decreased expression of VCAM-1 by BMSC exposed to VP-16, treatment of HOB with VP-16,
Melphalan, or rTGF- did not lead to significant reductions in VCAM-1, suggesting that signaling
through this adhesion molecule is maintained. These data suggest that while stem cells may be
spared direct cytotoxic insult by chemotherapeutic agents, the niche in which they reside may
be more vulnerable to damage than previously appreciated.
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Materials and Methods:
Cell Lines and Reagents
Human osteoblasts (HOB) were purchased from Promocell (Heidelberg, Germany) and
maintained in osteoblast growth media. The CXCR4+/VLA-4+ pre-pro-B leukemic cell line JM-1
was purchased from the ATCC (CRL-10423, Manassas, VA). The BMSC and IL-7 dependent
murine pro-B cell line C1.92 was kindly provided by Dr. Kenneth Landreth and has been
described in detail
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. Melphalan (Sigma-Aldrich, St. Louis, MO) was reconstituted at a stock

concentration of 2.5mg/ml or 50mg/ml immediately prior to use. VP-16 (Etoposide, Bristol Myers
Squibb, New York, NY) was stored at a concentration of 33.98mM and diluted immediately prior
to use. Human rTGF- (R&D, Minneapolis, MN) was used at a concentration of 10ng/ml. In all
experiments that include rTGF-, it was added to the culture every 6 hours based on its short
half-life. Human embryonic stem cells (H9, WiCell, Madison WI) were maintained on irradiated
mouse embryo fibroblasts (MEF) and grown in DMEM-F12 media (Mediatech, Manassas, VA)
supplemented with Knockout Serum Replacement (Gibco/Invitrogen, Carlsbad, CA) 2 mM Lglutamine (Mediatech), 0.05 µM 2-mercaptoethanol (Sigma-Aldrich), non-essential amino acids
and B-FGF solution. H9 cells were moved to HOB feeder layers where indicated.
Adhesion assay
HOB were pre-treated with 50g/ml Melphalan, 50µM VP-16, or 10ng/ml rTGF- for 24
hours. C1.92 pro-B cells were stained with Cell Tracker Green (Invitrogen) according to the
manufacturer’s instructions. The HOB adherent layer was thoroughly rinsed following treatment
and 1x105 fluorescently labeled C1.92 pro-B cells were added in co-culture for 24 hours.
Subsequently, the media containing non-adherent C1.92 was aspirated and the cultures were
gently rinsed. Remaining HOB and adherent C1.92 were trypsinized and C1.92 cells were
enumerated using a FACSCalibur flow cytometer (BD, Franklin Lakes, NJ) with events counted
for 30 seconds on high flow rate. Data were analyzed using WinMDI software.
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Chemotaxis assays
HOB were plated in the bottom chamber of a transwell at 100% confluence and were left
either untreated or treated with 50µg/ml Melphalan, 50µM VP-16, or 10ng/ml rTGF- for 24
hours. After 24 hours, 350 µL of supernatant was placed in the bottom of a transwell and 150 µL
of JM-1 cells (1x106 cells/mL) were added to the top chamber, and incubated at 37°C for 4
hours. JM-1 cells migrated through the 5µm pores to the bottom chamber towards media
supplemented with 100 ng/mL CXCL12 (positive control), towards media alone (negative
control), or towards media conditioned by the chemotherapy treated or non-treated HOB.
Migrated JM-1 cells were collected using a FACSCalibur flow cytometer (BD) with events
counted for 30 seconds on high flow rate with data analyzed using WinMDI software.
ELISA
CXCL12 and TGF- ELISAs were purchased from R&D. To complete the CXCL12
ELISA, HOB were plated at 100% confluence in a 96 well plate and left untreated or treated with
50µg/ml Melphalan, 50µM VP-16, or 10ng/ml rTGF- in complete media for 24 hours. The
media was then removed, cells were rinsed and fresh serum-free media was added to each
well. After 24 and 48 hours of incubation supernatants were collected and analyzed for CXCL12
following the manufacturer’s instructions. The TGF- ELISA was completed using HOB plated at
100% confluence in a 96 well plate in serum free media and left untreated or treated with
10ng/ml rTGF- every 6 hours for a total of 24 hours. The media was removed, cells were
rinsed, and fresh serum-free media was added to each well. After 24 and 48 hours supernatants
were collected and analyzed for TGF- secretion following the manufacturer’s instructions.
Fluorescent Microscopy
HOB cells were cultured on coverslips and left untreated or treated with 50µg/ml
Melphalan, 50µM VP-16, or 10ng/ml rTGF- for 24 hours, washed thoroughly with media and
H9 stem cells added. Stem cell colony expansion and differentiation were monitored for 2 days
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before pictures were taken, counts based on colony morphology were completed, and cells
were subsequently stained for Oct-4. To complete intracellular staining, cells were fixed in 4%
formaldehyde for 15 minutes at room temperature (RT) and permeabilized with 0.5% Triton-X100 at RT for 15 minutes. After blocking for 30 minutes in 5% BSA/1X PBS, cells were
incubated with mouse -human primary antibody (1µg), specific for human Oct-4 or the
matched isotype control, in 5% BSA/1X PBS for 1 hour at RT. Coverslips were washed three
times with 1X PBS and incubated with Alexafluor 488 labeled secondary -mouse antibody (1
µg) at RT for 1 hour. Coverslips were mounted on glass microscope slides with ProLong Gold
plus DAPI (Invitrogen, Carlsbad, CA). Confocal images were acquired using a Zeiss LSM510
confocal system connected to a Zeiss AxioImager microscope (Thornwood, NY). Photographs
of human embryonic stem cells and C1.92 pro-B cells were taken using a Nikon Coolpix 990
camera. To complete phospho-smad2 staining, HOB cells were plated on coverslips and left
untreated or treated for 4 hours with 100µg/ml Melphalan, 100µM VP-16, or with conditioned
media from BMSC that were maintained in control media

untreated or treated with 100µg/ml

Melphalan or 100µM VP-16 for 24 hours. Staining and imaging was completed as described
above using a murine primary antibody (1.5µg/coverslip), specific for human phospho-smad2
(Cell Signaling Technology Inc., Danvers, MA) or matched isotype control.
Microarray
HOB cells were left untreated, or treated with 50µg/ml Melphalan, 10ng/ml rTGF- or
conditioned media from BMSC (treated with 50µg/ml Melphalan for 24 hours) for 6 hours. Total
RNA was isolated from HOB using the RNEasy RNA isolation kit (Qiagen,Valencia, CA) with
quality assessed by electrophoretic analysis on an Agilent Model 2100 Bioanalyzer. RNA
samples had integrity numbers greater than 8.0 (8.4-10).

RNA (250 ng) was used as the

template for synthesis of internally labeled cRNAs using the Agilent QuickAmp Labeling kit and
cyanine 3-CTP and cyanine 5-CTP (Perkin Elmer, Waltham, MA) and a modified QuickAmp
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protocol
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. A total of 825 ng of cyanine 3- and cyanine5-labeled cRNAs was combined and

hybridized onto Agilent Whole Human Genome 4 x 44 K microarrays at 65oC for 17 hours and
washed according to the manufacturer’s protocol. Slides were scanned on an Agilent DNA
Microarray Scanner. HOB treated with rTGF- and conditioned media were competitively
hybridized against untreated HOB in a balanced block design with six replicates. Melphalan
treated HOB and untreated HOB were hybridized against Stratagene Universal Reference RNA
(Agilent Technologies, Santa Clara, CA) in a universal reference design with four replicates.
Intersections of groups and corresponding statistically significant fold changes (details
described in the supplemental section) for each experiment were imported into Ingenuity
Pathway Analysis (IPA) software v 2.6 (Ingenuity Systems ®, Redwood City, CA,
www.ingenuity.com). We performed a core analysis in IPA, using default settings, to search for
networks associated with these lists of genes. Complete microarray data may be accessed at
the NCBI Gene Expression Omnibus (GEO) database (GSE17860).
Real Time Reverse Transcriptase PCR
Total cellular RNA was isolated from HOB using the RNAeasy RNA isolation kit
(Qiagen). Real time RT-PCR was performed using 50ng RNA per reaction using the QuantiTech
SYBR Green RT-PCR kit supplied by Qiagen. Primers specific for human CXCL12 were
obtained from SuperArray (Frederick, MD) with 0.25µl used per reaction. Primers specific for
TGF- and the housekeeping gene (HPRT-1) were purchased from Real Time Primers, LLC
(Elkins Park, PA). Samples were analyzed in triplicate using the Applied Biosystems 7500
Real-time PCR system (Foster City, CA). Amplification parameters included 50C for 30
minutes, 95C for 15 minutes, 94C for 15 seconds (x 45 cycles), 58C for 30 seconds, and
72C for 45 seconds. Changes in gene expression were determined using the Comparative Ct
method and analysis of relative gene expression data using real-time quantitative PCR and the
2(-Delta Delta C(T)) Method.
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Statistics
Data were analyzed using the Students–t test or ANOVA where appropriate with
statistical significance of p≤.05 denoted by an asterisk ( * ). Microarray data analysis is described
in the supplemental section.
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Results:
Direct Melphalan exposure or factors from chemotherapy damaged BMSC affect HOB.
Observations from our laboratory, and others, have demonstrated that BMSC treated
with chemotherapy have higher levels of active TGF- and a diminished capacity to support proB cells and normal hematopoiesis

15-17;35

. Additionally, retrospective studies of patients that

received allogeneic bone marrow transplants showed that they have serious and irreversible
stromal damage as measured by CFU-F frequencies that did not recover to the levels of normal
control patients even after 12 years, suggesting that the damage done to the supportive cells of
the bone marrow is irreversible 36.
To determine if direct chemotherapy damage to HOB cells results in increased active
TGF-, HOB were treated with Melphalan or VP-16 and the expression of total and active TGF was assessed. Data shown in Figures 1A and B show that direct exposure to chemotherapy
(left panels) does not alter the expression of TGF- mRNA or protein respectively. However,
direct treatment with rTGF- (right panels) does increase both TGF- mRNA and protein
expression. In contrast to total TGF- mRNA and protein expression, chemotherapy exposure
does result in increases in the levels of active TGF- capable of cell signaling reflected as
increased phosphorylation of Smad2 protein (Figure 1C). Additionally, to mimic the indirect
effects of soluble cues elaborated by damaged stroma on HOB, BMSC were treated with
Melphalan or VP-16, rinsed, and allowed to condition media that was then placed on HOB that
had not been exposed to chemotherapy. HOB exposed to conditioned media from damaged
BMSC have higher levels of phosphorylated Smad2 than their counterparts exposed to
conditioned media from untreated stroma.
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Chemotherapy or rTGF- treatment diminishes the ability of osteoblasts to support
human stem cells and diminishes the physical interaction of HOB and pro-B cells
One of the critical functions of osteoblasts in the endosteal niche is to support stem cells,
and post-transplantation, osteoblasts are crucial to efficient and sustained hematopoietic
reconstitution

37;38

. Therefore, we investigated how chemotherapy or rTGF- modulates the

ability of osteoblasts to support human stem cells. Figure 2 shows that in the absence of
treatment, osteoblasts are able to support undifferentiated stem cell colonies characterized by
morphology of dense round colonies with definitive, regular, cell borders. In contrast, after HOB
pre-treatment with Melphalan, VP-16 or rTGF-, there is an increase in the number of
differentiated stem cell colonies with irregular borders and a decrease in the number of
undifferentiated colonies (Figure 2A) supported by the pre-treated feeder layers. OCT-4 staining
was completed on stem cell colonies as a measure of pluripotency potential, with a decrease in
the ability to support OCT-4 positive colonies observed in HOB that had been pre-treated with
chemotherapy or rTGF- (Figure 2B).
Alterations in osteoblast function after aggressive treatment could impact transplant
engraftment and hematopoietic reconstitution

11;30;39

. For technical ease we utilized CXCR-

4+/VLA-4+ C1.92 and JM-1 pro-B cells to investigate the effects of chemotherapy on the ability
of HOB to support immature hematopoietic progenitor cells. HOB

were

pre-treated with

Melphalan, VP-16 or rTGF- and C1.92 adhesion to HOB was analyzed as described. Data
shown in Figure 2C indicates that following HOB pre-treatment with chemotherapy or rTGF-,
C1.92 pro-B cells did not adhere to the pre-treated HOB as efficiently as their untreated control
counterparts. To determine if alterations in adhesion molecule expression were associated with
decreased adhesion between C1.92 and HOB, VCAM-1, CD44 and Hyaluronan expression
were evaluated on the HOB in the presence and absence of chemotherapy. No modulation of
these proteins was detected on the HOB during chemotherapy exposure suggesting that,
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changes in expression of classical adhesion proteins does not appear to be responsible for
decreased pro-B cell adhesion to Melphalan treated HOB (data not shown).
Chemotherapy or rTGF- diminishes HOB expression of CXCL12 coincident with reduced
support of pro-B cell chemotaxis
Inhibition of CXCL12 in the bone marrow has been shown to have a negative impact on
chemotaxis leading to deficits in HSC homing and engraftment 19;40;41. To further investigate the
impact of chemotherapy and rTGF- treatment on expression of osteoblast derived CXCL12,
real time RT-PCR and ELISA were completed as described. Pre-treatment of HOB with
chemotherapy or rTGF- decreased the amount of CXCL12 mRNA and protein detected by real
time RT-PCR and ELISA, respectively (Figure 3A and B) 42. Additionally, as a functional readout
of a potential CXCL12 deficit in our model, chemotaxis of JM-1 cells toward HOB that were
untreated or pre-treated with chemotherapy or rTGF- was completed. Figure 3C summarizes
data suggesting that chemotaxis of progenitor cells toward adherent layers of HOB was
impaired by Melphalan or rTGF- treatment.
Direct and indirect chemotherapy induced damage result in global changes to osteoblast
gene expression
To elucidate the global changes that occur in osteoblasts with direct and indirect insult
from chemotherapy, HOB were exposed to either rTGF-β to mimic increased active TGF-β
released by neighboring, damaged stroma or Melphalan to investigate direct insult of
osteoblasts by chemotherapy.

In addition, HOB were exposed to conditioned media from

BMSC that had been pre-treated with Melphalan (drug removed prior to collection of conditioned
media) to recapitulate signaling that may occur in response not only to active TGF-β elaborated
by BMSC, but also in response to the collective soluble factors elaborated by BMSC in
response to chemotherapy induced stress.

Microarray analysis of gene expression was

performed as described. The genes for which expression changed in each group individually,
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and common gene targets that overlap between treatment groups, are indicated in the Venn
diagram (Figure 4A). HOB exposure to recombinant TGF-β resulted in the most pronounced
effect on gene expression for the treatment groups compared, the highest number of genes
influenced across the treatment groups evaluated, with Melphalan exposure also resulting in a
robust effect. Twenty-five common genes significantly changed when the intersection of all
treatment groups was considered. The Venn and network diagrams show the modulations of
genes due to treatment, and potential relationships between some of the responsive genes.
BCL2A1, which has been shown to be regulated by NFB and up-regulated during stress to
prevent apoptosis, emerges as one point of convergence in the pathway analysis shown
(Figures 4-7). The genes that were commonly up-regulated (indicated in red) or down-regulated
(in green) between treatment groups are shown and numerically were: 4 up-regulated, 2 downregulated (Figure 4, Intersection of all 3 treatments), 16 up-regulated, 3 down-regulated (Figure
5, CMM:Melphalan), 26 up-regulated, 11 down-regulated (Figure 6, TGF:CMM), and 97 upregulated, 188 down-regulated (Figure 7, TGF:Melphalan). This summary can be compared
with those genes that were influenced, but in opposing directions, between groups
(Supplemental Figure 1).
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Discussion:
Ablative therapy followed by stem cell reinfusion is used to treat hematopoietic, and brain
tumors as well as childhood sarcomas, and immune deficiencies

43-45

. As the primary site of

postnatal hematopoiesis, the functional integrity of the bone marrow microenvironment is critical
for hematopoietic recovery subsequent to stem cell transplantation.

Earlier reports have

suggested that BMSC are vulnerable to functional damage imposed by aggressive
chemotherapeutic agents 46;47. These studies have focused largely on the ability of stromal cells
to generate fibroblastic colonies (CFU-F) or to support survival or expansion of committed
progenitor cells when isolated from patients following treatment of subsequent to in vivo drug
exposures 48.
Murine models of ablative treatment and stem cell transplant have shown long-term
deficits in hematopoietic recovery and in vitro models have paralleled these documenting the
inability of transplanted cells to migrate efficiently to the necessary anatomical niches for
engraftment

49

.

Observations of long-term hematopoietic deficits in bone marrow of

transplantation patients suggest that the functionality of the developmental niches required for
appropriate support of stem cells may have been compromised by aggressive pre-transplant
therapies. One study observed that at 1 year post transplant 61% of patients have subnormal
values in one or more hematopoietic lineages

50

. Further, Nieboer et al. showed that at 5 years

post transplant 15% of the patient population analyzed had low values in one or more
hematopoietic cell lineages

51

. Investigation of the mechanisms that underlie damage of the

hematopoietic and stem cell niche is further encouraged by retrospective studies of patients that
received allogeneic bone marrow transplants in which patient HSC did not recover to the levels
of control patients, even after 12 years, as measured by CFU-F frequencies, suggesting that the
damage of the structural, hematopoietic supportive cells of the bone marrow can be sustained
36

.
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In the current study we characterized the impact of direct and indirect damage on
osteoblasts and their subsequent ability to support progenitor and stem cells. Following
transplantation and during development, HSC home to the endosteal niche which acts as a
critical regulator of stem cell quiescence, proliferation, and conservation of the stem cell pool.
Direct contact between osteoblasts and HSC is required for HSC survival
relationship demonstrated by the ability of HSC to

52-54

with a dynamic

regulate the cytokines expressed by

osteoblasts in order to enhance their own survival. Studies by Calvi et al., and others, have
shown that number of osteoblasts present in the niche directly modulates the numbers of HSC
that can be supported by the niche 10;11;30.
In light of the delicate balance between osteoblasts and HSCs, it is not surprising that
either direct, or indirect damage via factors elaborated by other populations of cells within the
niche, to osteoblasts results in a deficit in the HSC pool. Our data has shown that both direct
exposure to chemotherapy as well as exposure to conditioned media from chemotherapy
damaged BMSC increases the activity of osteoblast derived TGF-, one of the known negative
regulators of HSCs (Figure 1C) 15-17. Consistent with the literature suggesting that TGF- activity
leads to decreased expression of HSC surface cytokine receptors and a deficit in the stem cell
pool,

55;56

Figures 2 and 3 summarize data that show the decreased ability of chemotherapy

damaged osteoblasts to interact with, and support, both human embryonic stem cells as well as
more differentiated pro-B cells. Direct treatment of HOB with active TGF- results in a
comparable reduction in pro-B cell adhesion and chemotaxis as well as diminished ability to
support Oct-4 positive stem cells. Collectively, these data suggest that chemotherapy induced
increases in active TGF-, from damaged BMSC and HOB, could contribute to deficits in the
stem cell pool
Another consideration when evaluating the dynamic balance of the niche is the role of
adhesion molecules physically tethering progenitor cells to supportive cells of bone marrow,
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which provides signals for their maturation and survival

57

. Earlier reports have described the

role of the VCAM-1/VLA-4 interaction in hematopoiesis. Ryan et al demonstrated that adhesion
of B cell precursors to BMSC was dependent on this interaction and Dittel et al elucidated how
cytokines could alter the surface expression of VCAM-1

26;27

. Studies in murine models showed

that a VCAM-1 knockout was embryonic lethal, while a conditional deletion led to decreases in
immature B cells found in the bone marrow with a subsequent impairment in immune response
28

.
In addition to the VCAM-1/ VLA-4 interaction, the CD44/ hyaluronan (HA) interaction has

also been recognized for its role in hematopoiesis and homing of primitive cells to the bone
marrow

58;59

.

Avigdor et al demonstrated the important roles of CXCL12 with respect to the

migration and anchorage of progenitors to the bone marrow through CD44/ HA

60

. It was based

on these observations that we investigated the effects of chemotherapy on VCAM-1, CD44, and
HA in our model of osteoblast damage. Figure 2C shows that pro-B cells co-cultured with
chemotherapy or rTGF-β pre-treated osteoblasts are unable to adhere to the osteoblasts
efficiently. However, investigation of the adhesion molecules VCAM-1, CD44 and Hyaluronan
indicated no altered expression with either chemotherapy or rTGF-β exposure.

These

observations suggest that the deficit in hematopoietic support, in our model, is the result of
changes in a soluble factor acting in either an autocrine or paracrine manner to diminish optimal
cell:cell interaction. Paracrine effects could be modulated, in part, through alteration of integrin
activity, which would not have been detected in our assay. These observations also suggest
very specific effects of chemotherapy on stromal and osteoblast components of the niche,
emphasizing the need to understand each population individually to understand the total
response of the niche to therapy.
In light of the data suggesting that decreased expression of specific adhesion molecules
was not obviously responsible for the inability of damaged osteoblasts to support stem and
progenitor cells, we examined the effect of chemotherapy damage on osteoblast derived
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CXCL12.

Data in Figure 3 shows that both chemotherapy and rTGF-β decrease CXCL12

mRNA and protein in osteoblasts

42

. The decrease in CXCL12 correlated with a decrease in

chemotaxis of CXCR4+ cells towards osteoblasts pre-treated with either Melphalan or rTGF-β.
However, in contrast to previous experiments in which we reported chemotactic deficits in VP16 treated BMSC

21

, no significant reduction in chemotactic support of CXCR4+ cells was

noted in the VP-16 treated HOB groups, even though they exhibited the decrease in CXCL12.
These data suggest potential drug specific effects in which Melphalan may target CXCL12
expression as well as other critical chemotactic factors in HOB while VP-16 does not as globally
affect chemotaxis regulators, allowing some maintenance of chemotactic support. One such
factor for future investigation would include stem cell factor, SCF, which has been shown to
synergize with CXCL12 in homing of stem cells and retention in their developmental niche 61;62.
Collectively, these data suggest that generation of active TGF-β in the endosteal niche
can negatively affect production of CXCL12, thus impairing progenitor cells from homing to the
bone marrow, engrafting, and reconstituting the patient’s immune system. This observation of
vulnerability of gene expression to genotoxic stress in HOB prompted us to attempt to
understand the magnitude of direct and indirect chemotherapy-induced damage to osteoblasts
by microarray analysis. After only 6 hours of treatment the diverse changes observed in HOB
gene expression alone allow for a better understanding of the significance of the potential
damage to the niche and the subsequent impact on hematopoietic reconstitution that relies on
balanced expression of several proteins. Previous reports suggest that NF-B can be activated
by both TGF- and TNF- leading to the transcription of BCL2A1, to suppress chemotherapy
induced apoptosis

63;64

. Interestingly, all 3 HOB treatments (rTGF-, Melphalan and conditioned

media from Melphalan pre-treated BMSC) evaluated in the microarray analysis had the
convergence point of increased BCL2A1 mRNA, suggested by the network analysis to be
regulated by NF-B (Figures 4-7).

As with all gene expression pathway analysis, in the
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absence of targeted genetic manipulation or biochemical analysis, the interactions remain
hypothetical. The most pronounced value of these data in the current study is to provide a
sense of the responsiveness of osteoblasts to genotoxic stress as well as to factors from other
structural components in the stem cells niche. Points of convergence, such as BCL2A1 as just a
single example, may then provide the focus for a more mechanistic understanding of cell
signaling downstream of stress in the bone marrow microenvironment.
Central to our investigation was an interest in the influence of active TGF-β released
from chemotherapy treated HOB as well as TGF-β that may be released from neighboring
BMSC in a damaged microenvironment as just two potential sources of this growth factor.
Understanding the role of TGF-β in the bone marrow microenvironment is extremely important
when attempting to modulate therapeutic intervention to reconstitute the niche post-transplant.
Studies by Batard et al have described the importance of low levels of TGF-β in the bone
marrow microenvironment for maintenance of the stem cell pool through up-regulation of the
CD34 antigen, a marker of primitive HSC

55

. Consistent with the need for rigorous control of

total TGF-β levels, a number of studies have shown the benefit of TGF-β neutralization in cases
where TGF-β levels are increased in response to therapy

65;66

. Lagneaux et al showed that

stromal cells isolated from B-CLL patients had increased TGF-β production correlated with
decreased colony-stimulating activity which was corrected by neutralizing TGF-β activity

17

.

Using a murine model of breast cancer, Biswas et al showed that radiation or doxorubicin
treatment increased levels of TGF- which correlated with increased circulating tumor cells and
increased metastasis

67

. These effects were

abrogated by anti-TGF-β antibodies providing

rationale for utilization of TGF-β inhibitors, such as GC1008 in clinical trials in the setting of
renal cell carcinoma and malignant melanoma

68

. Based on our observations, application of

TGF-β neutralizing antibodies may have utility in restoration of the stem cell pool as well,
through influence on both stem cells and the niche in which they develop.
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Our observations indicate that HOB, a critical regulator of stem cell development, are
susceptible to genotoxic stress documented by both functional deficits and broad alteration of
gene expression profiles. Further investigation will identify targets that may prove useful in
augmenting hematopoietic recovery through “balancing” the stem cell niche following therapyinduced damage. Long-term hematopoietic deficits may, in fact, derive in part from the
immediate changes in the stem cell niche that are imposed by aggressive therapeutic regimens.
This aspect of marrow function may highlight an area in which better understanding could
identify new therapeutic strategies to augment efficient patient recovery follow bone marrow
transplantation.
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Figure legends:
Figure 1: Direct and indirect damage increase HOB levels of active TGF- β. A) HOB were
treated with 50g/ml Melphalan, 50M VP-16, or 10ng/ml rTGF- for 24 hours and real time
RT-PCR for TGF- β was performed. B) HOB were treated with 50g/ml Melphalan, 50M VP-16 (left
panel), or 10ng/ml rTGF- (right panel) for 24 hours. The HOB layer was rinsed and new media was
added and allowed to condition for 24 hours before being evaluated by ELISA to quantitate the amount
of secreted TGF-. C) HOB were treated directly for 4 hours with chemotherapy (100M VP-16,
100g/ml Melphalan) or with media from BMSC that had been left untreated (BMSC CM control) or pretreated with 50g/ml Melphalan (BMSC CM Melphalan) or 50M VP-16 (BMSC CM VP-16) for 24
hours. HOB cells were then fixed and stained for detection of phospho-Smad2 (green) and DAPI (blue).

Figure 2: Chemotherapy or rTGF-β exposure diminished the ability of HOB to support
Oct-4 positive human embryonic stem cells and diminish HOB interaction with pro-B
cells

HOB were pre-treated with 10ng/ml rTGF-β, 50 g/ml Melphalan or 50M VP-16 for 24

hours. HOB were rinsed thoroughly and embryonic stem cells were co-cultured in complete
media as recommended by WiCell. After 2 days of co-culture, stem cell colonies were counted
and designated as undifferentiated or differentiated based on classic morphology of well defined
borders (A) and were stained for Oct-4 as an indicator of potential for pluripotency (B). HOB
were treated with 10ng/ml rTGF-β, 50 g/ml Melphalan or 50M VP-16 for 24 hours. Adherent
layers of HOB were rinsed thoroughly and co-cultured with 1x105 fluorescently labeled pro-B
cells. After 24 hours the media was aspirated and non-adherent pro-B cells were gently rinsed.
Remaining HOB and pro-B cells adherent to the HOB layer were then trypsinized and events
within the easily distinguishable lymphoid gate, based on fluorescence and forward/side scatter,
were counted on high flow rate for 30 seconds to enumerate number of pro-B cells attached to
the HOB (C).
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Figure 3: Chemotherapy or rTGF- diminishes HOB expression of CXCL12 and support of
pro-B cell chemotaxis. A) HOB were treated with 10ng/ml rTGF-β, 50 g/ml Melphalan or
50M VP-16 for 24 hours. RNA was isolated and Real Time RT-PCR was performed for
CXCL12. B) HOB were treated with 10ng/ml rTGF-β, 50 g/ml Melphalan or 50M VP-16 for 24
hours. Growth factor or chemotherapy was removed and fresh media was added, allowed to
condition for 24 or 48 hours, and then evaluated in a CXCL12 specific ELISA. C) HOB were
treated with rTGF-β, 50 g/ml Melphalan or 50M VP-16 for 24 hours. 350ul of the supernatant
was then removed and placed into the bottom chamber of a transwell. 1x105 JM-1 progenitor
cells were placed in the top chamber and allowed to migrate for 4 hours. After 4 hours the cells
migrated were read on high flow rate for 30 seconds on a flow cytometer.

Figure 4: Intersection of global gene changes during direct and indirect chemotherapy.

HOB

cells were treated for 6 hours with 10ng/ml rTGF-β, 50 g/ml Melphalan, or conditioned media from
BMSC (CMM) pre-treated with 50 g/ml Melphalan for 24 hours. BMSC exposed to Melphalan were
rinsed and fresh media was place on adherent layers to condition and to remove drug prior to
stimulating HOB. After the 6 hour treatment, HOB RNA was isolated and microarray analysis was
completed to evaluate global changes in gene expression. A) The Venn diagram summarizes the
number of HOB genes that changed within each group as well as the changes between the groups. B)
A gene summary was made of the genes that commonly were up-regulated (4, red) or down-regulated
(2, green) for the intersection of all 3 treatments (rTGF-:CMM:Melphalan). C) A network diagram was
generated that highlight potential paths that converged upon the commonly increased gene, BCL2A1,
for the intersection of all 3 groups. All genes listed were generated using a 2.5% FDR and 1.5 fold
significant cut off.
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Figure 5: Soluble factors in BMSC exposed to chemotherapy induce HOB gene expression
changes in common with those subsequent to Melphalan exposure. HOB cells were treated for 6
hours with 50 g/ml Melphalan, or conditioned media from BMSC pre-treated with 50 g/ml Melphalan
for 24 hours. BMSC exposed to Melphalan were rinsed and fresh media was place on adherent layers
to condition and to remove drug prior to stimulating HOB. After the 6 hour treatment, HOB RNA was
isolated and microarray analysis was completed to evaluate global changes in gene expression. A)
Gene changes for the intersections of the CMM:Melphalan groups were analyzed based on the genes
that commonly increased (16, red) or decreased (3, green). B) A network diagram was generated that
highlight potential paths that converged upon the commonly increased gene, BCL2A1, for the
intersection of CMM:Melphalan groups. All genes listed were generated using a 2.5% FDR and 1.5 fold
significant cut off.

Figure 6: Soluble factors in BMSC exposed to chemotherapy induce HOB gene expression
changes in common with those subsequent to rTGF- exposure. HOB cells were treated for 6
hours with 10ng/ml rTGF-β, or conditioned media from BMSC pre-treated with 50 g/ml Melphalan for
24 hours. BMSC exposed to Melphalan were rinsed and fresh media was place on adherent layers to
condition and to remove drug prior to stimulating HOB. After the 6 hour treatment, HOB RNA was
isolated and microarray analysis was completed to evaluate global changes in gene expression. A)
Gene changes for the intersections of the TGF-:CMM groups were analyzed based on the genes that
commonly increased (26, red) or decreased (11, green). B) A network diagram was generated that
highlight potential paths that converged upon the commonly increased gene, BCL2A1, for the
intersection of TGF-:CMM groups. All genes listed were generated using a 2.5% FDR and 1.5 fold
significant cut off.
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Figure 7: rTGF- exposure

induces HOB gene expression changes in common with those

subsequent to Melphalan exposure. HOB cells were treated for 6 hours with 10ng/ml rTGF-β, or with
50 g/ml Melphalan for 24 hours. After the 6 hour treatment, HOB RNA was isolated and microarray
analysis was completed to evaluate global changes in gene expression. A) Gene changes for the
intersections of the TGF-:Melphalan groups were analyzed based on the genes that commonly
increased (97, red) or decreased (188, green). B) A network diagram was generated that highlight
potential paths that converged upon the commonly increased gene, BCL2A1, for the intersection of
TGF-:Melphalan groups. All genes listed were generated using a 2.5% FDR and 1.5 fold significant
cut off.
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3. Acute Lymphoblastic Leukemia
I. Acute Lymphoblastic Leukemia
As previously mentioned, normal B lymphopoiesis occurs in the bone marrow and gives
rise to mature B cells that express immunoglobulin and are responsible for humoral immunity. In
some cases, normal B cells acquire stage specific mutation(s) and undergo developmental
arrest, while continuing to proliferate and expand, without being functional modulators of
immunity. This leads to an accumulation of blasts, or immature B cells, in the bone marrow and
subsequently in the periphery, that are indistinguishable from their normal counterparts and are
representative of the disease clinically classified as Acute Lymphoblastic Leukemia.
Acute lymphoblastic leukemia (ALL) is the most common malignancy in children, with
the peak incidence being ages 2-5, and approximately 5,700 new cases will be diagnosed this
year in the United States1;2. Although a direct cause of leukemia is not known, exposure to
chemicals such as benzene, high levels of radiation or chemotherapeutic agents increases the
chance of leukemia, as do certain viruses, and inherited diseases such as Down's syndrome,
but it is believed that these represent less than 5-10% of diagnosed leukemias. Literature
suggesting high birth weight being associated with leukemia is becoming more prevalent, but
much more research is needed to attempt to determine the causation of the disease3. The start
of the disease is unknown, and it has been suggested that some leukemias may start in utero
while others state that the first mutation in the multistep pathway may start in a hematopoietic
stem cell (HSC) with multi-lineage developmental capacity or a progenitor cell committed to
specific lineage4.
Additionally, the presence of chromosomal abnormalities is relevant to the disease but is
ruled out as the sole causation since screening of neonatal cord blood has shown that potential
leukemic clones with the TEL-AML fusion gene (aka ETV6-RUNX1) has been found in 1% of
newborn babies which is a frequency 100 times higher than the incidence of ALL with this fusion
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gene in childhood5. The Philadelphia chromosome (Bcr/ABl , Ph+) has also been detected in
circulating cells of healthy people who never develop leukemia further substantiating that the
single translocations are not enough to cause the full disease6-11. At diagnosis, risk assessment
is based on age, white blood cell count, and the presence of chromosomal abnormalities12.
Diagnosis is further classified by surface expression of T or B-lineage markers, and prognostic
significance is based on these classifications as well as initial response to therapy. Further
discussion will focus specifically on B-lineage ALL.
B-lineage Acute Lymphoblastic Leukemia is responsible for 75-80% of ALL and is a
malignant disease characterized by an accumulation of blasts, or immature cells, that undergo
clonal expansion resulting in suppression of normal hematopoiesis and potential infiltration of
extramedullary sites13. Clinically it is seen as fever, effects of anemia such as severe fatigue
and malaise, an absence of functioning granulocytes (proneness to infection and inflammation),
and thrombocytopenia (hemorrhagic diathesis) 12. The 5 year overall survival rates for B-lineage
ALL are 60-70 percent overall; 90.9 percent for children under 514-16. However, these numbers
are altered by expression of negative cytogenetic markers. Chromosomal abnormalities
detected at diagnosis are used for both risk assessment as well as deciding on treatment
regimens

12;17;18

. Common translocations found in B-Lineage ALL are high hyperploidy (51-65

chromosomes) and TEL/AML1 fusion; t(12;21) which are typically associated with younger
patients (1-10yrs old, 22-50% of ALL children, 2-10% of ALL adults) with low leukocyte counts
and are correlated with a favorable prognosis18. Other common alterations and translocations
include: hypodiploidy (fewer than 44-45 chromosomes), intra-chromosomal amplification of the
AML1 gene on chromosome 21 (Iamp21), and rearrangements of the Mixed Lineage Leukemia
gene (MLL, 11q23), E2A-PBX1 t(1:19). These alterations are all associated with a poor
prognosis and high risk of relapse. MLL (4;11, most common and significantly poor prognosis in
children under 1 with overall survival ~50%) and the Bcr/Abl t(9;22) (poor prognosis in children
and adults)17;18.
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The Philadelphia chromosome (Ph+, t(9;22)(q34;911) is a reciprocal translocation of the
long arms of chromosomes 9 and 22 . It was discovered in 1960 by Peter C. Nowell in Chronic
Myelogenous Leukemia (CML),19;20 but it was not until the early 1970’s that improved
cytogenetics techniques allowed the origin of the translocation, chromosomes 9 and 22, to be
known21. The Ph+ increases in frequency with age, from 3-5 percent in children to 20 percent in
adults to more than 50 percent in patients older than 50 years 22 18. Interestingly, in patients with
ALL who have t(9;22), the Philadelphia chromosome, children one to nine years of age have a
better prognosis than adolescents with the same disease, who in turn fare better than adults 22.
Treatment for ALL typically consists of 3 phases: remission induction, consolidation or
intensification and maintenance therapy12;17;22;23. The goal of remission induction is to eradicate
99% of the leukemia burden and to restore normal hematopoiesis and performance status.
Patients with 1% or greater leukemic blasts at the end of 4–6 weeks of remission induction
therapy fare nearly as poorly as those who do not achieve clinical remission by the accepted
morphological standard (≥5% leukaemic cells), where people who achieve molecular or
immunological remission (<0・01% leukemic cells) have an excellent outcome

17;24-27

. Children

that have high risk or very high risk ALL, as well as most adults, tend to receive four or more
chemotherapeutic drugs during this aggressive therapy.
Remission induction usually lasts approximately a month and typically includes
HyperCVAD. Hyper refers to hyperfractionated nature of the chemotherapy, which is given in
smaller doses, more frequently, to minimize side-effects and CVAD is an acronym for the
chemotherapeutic agents utilized: Cyclophosphamide, Vincristine, Daunorubicin (Adriamycin,
Ara-C, or Doxorubicin) and Dexamethasone (Prednisone)

25;28

.

Additionally, based on the

patient's prognostic factors, some regimens may also include L-asparaginase, etoposide, and/or
high doses of methotrexate or cytarabine (Ara-C) as part of the induction phase. During
remission induction, prophylactic treatment is also given to keep the leukemia from spreading to

77

the CNS (Central Nervous System). This treatment may include intrathecal chemotherapy
(injected directly into the spinal fluid), high dose methotexate IV, high dose Ara-C or cranial
irradiation. The number of rounds of therapy depends on age and tolerability of therapy, but
generally consists of 8 cycles of treatment

12;29

.

For Ph+ ALL disease, patients also receive

Imatinib or Dasatinib as part of therapy and throughout maintenance.
Consolidation therapy occurs when a patient is considered to be in remission (both
cytogeneic and hematopoietic recovery) and is a short course (a few months) of the same
chemotherapy as remission induction, CNS treatment. Patients with a high risk phenotype
(Ph+), or that had a poor initial response to treatment, may have allogeneic bone marrow
transplants after the induction of remission. Transplant is decided in the first remission based
on several factors: 1. age at diagnosis, 2- chromosome abnormalities at diagnosis (ie Ph+,
11q23 abnormalities, etc a ‘poor risk), - 3- WBC at diagnosis, 4- availability of a donor (do they
have a matched sibling available)

17;29

. If patients are going to transplant in first remission, they

generally complete 4 cycles of therapy, then go to transplant. If patients are staying on
treatment, they generally proceed through therapy. If they relapse, they get further therapy to
try to get into remission, then go through transplant (in second remission)

17;29

. After the initial 8

cycles, patients then receive maintenance therapy with methotrexate, vincristine, prednisone,
and 6-MP, on a monthly schedule for 2 more years.
These treatments, though aggressive in nature, often do not result in eradication of
disease. Minimal residual disease (MRD) and subsequent relapse typically occur in the bone
marrow and monitoring of patient disease status has been revolutionized by the Campana
laboratory, and others24;30;31.

MRD could previously be detected only by morphological

microscopic analysis and did not allow for efficient detection of relapse or monitoring of
response to treatment. Approximately 30 years ago, Janossy and colleagues were one of the
first groups to attempt to identify residual tumor cells using more than morphology, and they
observed that T-lineage ALL cells co-expressed both TdT and T-cell marker, which normal

78

blood and bone marrow cells did not

32;33

. The most widely used techniques for detection of

MRD are PCR and flow cytometry which allow for the detection of chromosomal translocations
and immunoglobulin gene rearrangements and are able to observe a single tumor cell in the
background of thousands to millions of normal cells

34;35

. Currently, the ability to utilize

immunologic markers allows for the detection of the unique tumor phenotypes that cause MRD
in both T and B lineage ALL.
II. Tumor stem cell phenotype
Tumor cells with diverse phenotypes have been shown to both interact with, and alter,
their microenvironment with leukemia cells also having the potential to change the ability of
normal HSC to proliferate and function in shared niches36;37. Although many microenvironments
have been shown to be protective to multiple types of tumors, numerous studies from the Dalton
and Campana laboratories laid the seminal ground work for the hypothesis of the bone marrow
microenvironment being protective to hematopoietic tumors, as well as a key site of metastasis
for solid tumors25;38. Therefore, the bone marrow microenvironment has unique biological
relevance and its interaction with tumors with a stem- like phenotype is the focus of the following
section.
On the surface, leukemic cells express identical proteins to their normal immature
hematopoietic cell counterparts. This stems from the fact that a B-lineage, acute lymphoblastic
leukemia (ALL) cell is, for all intents and purposes, a normal B cell that is arrested in a pre-pro
progenitor stage and is unable to differentiate to become a mature, functional B cell but has
extreme proliferative capacity. Blunted differentiation leads to the rapid accumulation of
immature B-lineage cells, or leukemic blasts in the acute phase. The hallmark difficulties in
treatment then become not only eradicating the proliferative leukemic blasts, but also their
ability to be protected by the microenvironment by utilizing normal B cell/stromal
microenvironment interactions resulting in residual tumor that can contribute to relapse of
disease. As mentioned previously, normal B cells interact with the microenvironment through
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physical interactions (Integrins, VLA-4/VCAM-1 interactions) as well as through soluble cues
(CXCL12, SCF, IL-7, TGF-B). Although it is hypothesized that leukemic cells have a stage of
stromal cell dependence,39

40

blast cells are commonly found in the blood and periphery at

advanced stages of disease, suggesting that part of the evolution of this malignancy is a loss of
stromal cell dependence that would normally control expansion of pre-pro-B cells. Our
laboratory, as well as others, have focused on the factors that influence survival of B-lineage
ALL during chemotherapy with respect to the protection given by the bone marrow
microenvironment41-45.
The data presented in Chapters 2 and 3 summarizes our investigation of specific
aspects of Philadelphia chromosome positive ALL cells that may help them survive
chemotherapy exposure more efficiently than their Ph- counterparts. In addition to having the
Bcr/Abl translocation leading to high Abl kinase activity, these cells also express vascular
endothelial cadherin (VE-cadherin) and high levels of -catenin, a pro-survival protein. These
cells additionally have a stem-like phenotype, expressing markers expressed in pluripotent stem
cells including Oct-4, HIF-2, CD133, TRA-1-61, and TRA-1-80.

Stem cell properties are

sustained by co-culture with BMSC contact during chemotherapy leading to the survival of these
Ph+ cells during treatment.
The existence of a cancer stem cell was first suggested in the 1960’s

46;47

and has been

thoroughly investigated by the Weinberg, Dick, Lapidot and Weissman labs, as well as
others41;48-55. Tumor initiating cells (TIC) or tumor stem cells have been found in both
hematopoietic tumors, with the foundational work being done in AML (Acute Myeloid
Leukemia)51;56, and in solid tumors including breast cancer, ovarian cancer, pancreatic cancer,
colon cancer, prostate cancer,

hepatocellular carcinoma,

melanoma,

lung cancer,

glioblastoma, other brain tumors, and neuroblastoma43;48;57-67. The initial classification of a
cancer stem cell was that it could be isolated from the tumor of one animal, transferred to an
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immuno-compromised recipient animal and subsequently establish disease. This has been
expanded upon to include a panel of markers that are in common with embryonic and adult
hematopoietic stem cells and that slightly differ between tumor types. These makers typically
consist of CD133, CD34, CD44 as well as Oct-4, BMI-1, and other markers of pluripotentcy,
although in different cancers there is a slightly different stem cell profile
breast cancer stem cells are CD44+ and CD24-

68-71

. For example,

72

. Leukemic stem cells tend to be lineage -,

cKithigh, Sca-1-, CD34+, CD38-, (AC) CD133+. John Dick’s lab found that in Acute Myeloid
Leukemia (AML) a CD34+ CD38- (leukemic stem cell, LSC) fraction was always able to give
rise to leukemia when transplanted into immunodeficient mice and that targeting of CD44 led to
a diminished ability of these cells to interact with supportive niches and evade treatmentinduced apoptosis

51;73

. In addition to their unique phenotype, cancer stem cells from multiple

tumor types are able to interact with the bone marrow microenvironment and utilize cues
derived from it to evade treatment leading to both minimal residual disease as well as relapse
74;75

.
Although controversy remains regarding the relevance of cancer stem cell markers in

murine models as well as the potential for species incompatibility, leading to cancer stem cells
that are unable to engraft, it is consistent that these markers give insight on the progress of the
disease and allow for in vivo therapeutic manipulation76;77.
III. Rodent models of tumor stem cells and leukemia
In the late 1970’s mouse models of ALL consisted of subcutaneous injection of primary
patient cells or cell lines into nude mice which result in solid tumors that were uncharacteristic of
the disease. A study in 1978 by Watanabe et al. documented the ability of ALL patient cells to
grow in the hematopoietic tissues of a nude mouse

78

. This study, however, was done using an

aneuploid T ALL originally established and maintained as an ascites tumor in nude mice; the
animals died within 2 to 4 weeks and growth as an ascites does not reflect the normal course of
the disease

78

. In 1989 Dick and colleagues revolutionized the study of ALL by creating an in
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vivo model of B-lineage ALL that progressed with the same clinco-pathology as patient
disease79. They demonstrated the ability to engraft patient samples of pre-B-lineage ALL into
irradiated SCID (Severe Combined Immunodeficiency) mice through intraperitoneal or
intraveneous injection.
SCID mice are homozygous for an autosomal recessive mutation on chromosome 16
resulting in disruption of the protein kinase DNA activated catalytic polypeptide (Prkdc) gene loci
preventing the activation of a DNA recombinase enzyme, which in turn leads to impaired
immunoglobulin and T-cell receptor gene rearrangements and consistent apoptosis of T and B
cells

80;81

. These mice are therefore deficient in both humoral and cellular immunity but retain a

virtually fully functional innate immune system with normal levels of tissue macrophages, natural
killer (NK) cells, marginal zone B-cells, serum complement activity and myelopoiesis

80;81

.

Additionally, despite the immune deficiencies, the haematopoietic microenvironment of SCID,
including the thymic stroma, remains intact. These properties result in the mice being unable to
reject allogeneic or xenogeneic organ grafts. Unfortunately, one of the major limitations of SCID
mice as hosts for xenotransplantation is due to the incomplete penetrance or ‘leakiness’ of the
SCID mutation 82. Although strain dependent, leakiness results in the spontaneous development
of partial immune reactivity, with up to 90% of old (>1 year) mice exhibiting high levels of
immunoglobulin and functional lymphocytic rearrangements which has the potential to interfere
with graft acceptance in the host 82.
Currently, the most widely used mouse model of ALL is the NOD/SCID (Non Obese
Diabetic/ Severe Combined Immunodeficiency) model, which in addition to the immunological
deficits of the SCID, also exhibits multiple defects in adaptive and innate immunologic function
including lack of functional lymphoid cells, exhibiting little or no serum immunoglobulin with age,
lack of

C5 and complement activation,

secretion of IL-1

83;84

lack of NK cell activity and a poor macrophage

. This results in a functionally less mature macrophage population in

comparison to the parental SCID and therefore has been proven to be the better host, with or
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without additional immune suppression, for human hematopoietic cells and leukemic blasts than
SCID mice 83;85;86.
More recent studies have been done comparing, even further, the engraftment of
NOD/SCID mice to their NOD/scid/b2 null (lack of MHC class I expression and decreased NKcell function) and NOD/scid/IL-2Rcnull (IL-2Rg-chain deficiency impairs the signaling through
multiple cytokine receptors blocking NK development and results in additional defects in innate
immunity) counterparts. Engraftment of malignant cells (primary and cell line ALL, AML and
CML)

was

measured

using

clinico-pathological

criteria,

PCR,

flow

cytometry

and

immunohistochemistry. Interestingly, the NOD/scid/IL-2Rcnull had the greatest engraftment in
both cell lines and patient samples (31/39 and 15/22) followed by the NOD/scid/b2 null (19/38
and 9/28) and finally the NOD/SCID (13/38 and 7/25) 87.
In addition to the murine models of leukemia, a 2005 paper by Bernard et al.
demonstrated the ability to chemically induce leukemia in a rat model 88. This paper was the first
time a chemically induced model of leukemia was used, and although it isn’t a widely used
model, they did prove that through administration of N-butylnitrosourea (BNU), an alkylating
agent for 24 weeks that the rats would develop B lineage ALL that could be serially transplanted
into healthy rats. Murine models of leukemia are currently not only being used to study the
dissemination of disease but are also being utilized as models of drug efficacy in pre-clinical
studies. In this context, the microenvironment warrants careful consideration as a novel
therapeutic target.
IV. Therapeutic strategies for leukemia.
Acquired resistance of tumor cells to treatment can develop over time as a result of
sequential genetic changes that ultimately culminate in complex therapy-resistant phenotypes.
De novo resistance occurs typically in two ways, through both physical interactions (VLA4/VCAM-1) and soluble factor interaction (CXCL12, VEGF, TGF-B) of the tumor cells and their
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surrounding microenvironment. This allows for protection of the tumor cells during
chemotherapy and has been found to be especially prominent in the leukemia stem cell pool.
Studies have shown that not only can leukemia cells respond to the microenvironment
as a protective force during treatment, but additionally the microenvironment supports selection
of those cells inherently resistant to treatment. A study from Mishra et al. demonstrated that
exogenous SDF-1 (CXCL12) in the absence of bone marrow stromal cells, or bone marrow
stromal cell co-culture, resulted in selection of Imatinib-resistant Bcr/Abl P190 lymphoblasts
with less dependence on Bcr/Abl tyrosine kinase activity89. This selection of resistant cells and
protection has also been shown by Mudry et al. and others, who showed that physical
interaction between VCAM-1 on the stromal cell and VLA-4 on the leukemic cell alone is enough
to confer protection during chemotherapy44;90;91. Although some treatments such as AMD3100
(inhibitor of the CXCR4 receptor for the CXCL12 ligand) allow for inhibition of tumor cell
interaction with the microenvironment, it also inhibits the required physical interactions that
normal hematopoietic cells need for the microenvironment to promote their survival 92;93.
Other mechanisms that underlie leukemic cell survival during chemotherapy include
alterations in leukemic cell surface molecule expression or activity. The Weissman lab has
recently shown that leukemic cells express high levels of CD47, an immunoglobulin-like protein
that is known to interact with integrins and thrombospondin-1, to function as an anti-phagocytic
signal53. CD47 is typically found on normal hematopoietic cells to ensure that autologous cells
are not inappropriately phagocytosed. Therefore CD47 may serve as a useful therapeutic target
if inappropriately up-regulated at high levels on tumor targets on which it could be more readily
interrupted than on the normal hematopoietic cells.
In order to identify more efficacious therapeutic targets an in depth understanding of the
biology of specific subclasses of leukemia, in our studies, or specific tumor types in general
other categories of malignancies is required to allow therapeutic strategies that target from
multiple angles. For example, autophagy is usually thought of as an alternative death
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mechanism distinct from apoptosis or necrosis. It is defined as is a degradative process in
eukaryotic cells that results in the breakdown of intracellular material within lysosomes under
homeostatic conditions or in response to stress signals, allowing cells to adapt to environmental
and/or developmental signals. It is a genetically controlled process, which progresses through
definite steps, leading to the engulfment of long-lived proteins and whole organelles into multimembraned vacuoles, called autophagosomes, that fuse with lysosomes for final destruction
and recycling94. However, autophagy is also a process by which cells can adapt their
metabolism to starvation caused by a decrease in metabolite concentrations or extracellular
nutrients, a typical consequence of loss of growth factor signaling, allowing cells to evade
programmed cell death95. Bellodi et al. showed that Imatinib treatment rapidly activates an
autophagic process, which follows the induction of ER stress and relies on intracellular Ca2+.
More importantly, inhibition of autophagy by pharmacological inhibitors potentiates Imatinibinduced cell death in CML cell lines and primary CML cells, including those carrying partially IMresistant BCR/ABL mutants94. This study suggests that induction of autophagy provides a
survival mechanism to IM-treated BCR/ABL-expressing cells, including the stem cell population,
and that inhibition of autophagy may improve the therapeutic efficacy of Imatinib. These results
were also seen by the Adachi lab with the Abl kinase inhibitor INNO-406 (NS-187), which is a
specific dual Bcr-Abl/Lyn kinase inhibitor96.
Currently, dual kinase inhibitors, proteasome inhibitors, histone deactylase inhibitors
(HDACI) and aurora kinase inhibitors are becoming therapeutic options for leukemia

12;22;23

. Abl

kinase inhibitors such as Imatinib (Imatinib Mesylate, Gleevec) are currently being used to treat
Ph+ ALL and CML. Do to the high level of mutations of the Abl kinase domain and resistance to
therapy, new more effective single abl kinase inhibitors, as well as dual inhibitors and the use of
multiple types of inhibitors together are currently being investigated 97.
Dasatinib (BMS-354825, Sprycel) is a dual Src family kinase, Abl kinase inhibitor that
also targets PDGFR, kit and Ephrin receptor kinases. It has been through phase I and II clinical
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trials and has been shown to be approximately 300-fold more effective than Imatinib, potentially
due to its ability to bind both the active and inactive conformation of Bcr/Abl

98

. Dasatinib is

unable to inhibit the T315I mutation but is capable of suppressing many of the Imatinib resistant
mutations. Bosutinib (SKI-606) is an inhibitor of both Src and Abl kinases but does not have the
off-target PDGFR and Kit effects of Imatinib or Dasatinib

99

. It has been shown to be well

tolerated in Phase I trials, can bind to both the active and inactive conformation of Abl, but is
not effective against all Bcr/Abl mutations. Nilotinib (Tasigna, AMN107) is an Abl kinase (and
other, not Src) inhibitor that has been shown to an efficacy 20 fold higher than Imatinib and
more readily crosses the blood brain barrier 100.
Proteasome inhibitors act to disrupt the degradation of ubiquitinated proteins with small
molecule inhibitors against one or more catalytic β-subunit

101

. They induce cell cycle arrest and

function to induce apoptosis by inhibition of NF-KB and by endoplasmic reticulum stress and
subsequent generation of reactive oxygen species. Additionally, they stabilize pro-apoptotic
proteins such as p53, Bax, Bik, and Bim while reducing levels of anti-apoptotic proteins such as
Bcl-2 and have been shown to be more effective against leukemic cells than normal cells

102

.

Bortezomib is currently in Phase 1 and 2 clinical trials for CML and other hematologic
malignancies.
Histone deacetylases (HDAC) remove the acetyl groups from the lysine residues leading
to the formation of a condensed and transcriptionally silenced chromatin

103

. Reversible

modification of the terminal tails of core histones constitutes the major epigenetic mechanism for
remodeling higher order chromatin structure and controlling gene expression. HDAC inhibitors
(HDACI) block this action and can result in hyperacetylation of histones, therefore affecting
gene expression

104;105

. However, there are significant gaps regard specifically how HDI cause

apoptosis of leukemic cells. HDAC inhibitors that are undergoing extensive clinical evaluation
include the pan-HDAC inhibitors, such as vorinostat and panobinostat, and more selective
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inhibitors, such as R306465, romidepsin and MS-275 and are starting to be analyzed for their
use in ALL.
The aurora kinases are a family of serine/threonine kinases involved in cellular
processes including progression through mitosis via regulation of spindle formation,
chromosome segregation and cytokenesis

106

. They are commonly over-expressed in leukemia

and several aurora kinase inhibitors are currently in clinical trials such as VX680, MLN8054,
AZD1152,R766, R763, PHA-739358. VX-680 (MK-0457) is a pan-aurora kinase inhibitor that
has shown in vitro activity against wt and Bcr/ABl mutants including T3151 as well as against
Imatinib and Dasatinib resistant clones. In a recent phase I/II study it was shown to be active in
patients with the refractory T3151 phenotype.
All of the agents discussed will only realize their full utility when the influence of the
marrow microenvironment on the leukemic target is understood well enough to delineate its
effect on critical regulatory proteins in the survival or proliferative pathways that are targeted by
the unique classes of drugs and inhibitors. While some of these proteins are generated by
unique chromosomal translocations, others are best described as anti-apoptotic, with additional
factors associated with maintenance of a stem cell phenotype that is coincident with
chemoresistance.

Examples of each are described in the following section in the context,

predominantly, of Ph+ ALL.
V. Bcr/Abl, Beta-catenin, HIF-2alpha, VE-cadherin, and Oct-4 in normal cells and leukemic
cell biology
In addition to the cytogenic changes seen in ALL (Bcr/Abl, TEL-AML, MLL etc.)
alterations in protein expression as well as activity have been shown to influence both the tumor
stem cell phenotype as well as survival during treatment. The proteins that will be discussed in
this section are relevant to the aggressive nature of Ph+ Acute Lymphoblastic Leukemia or the
stem cell phenotype and consist of Bcr/Abl, Beta-catenin, VE-cadherin, HIF-2 alpha and OCT-4.
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The Bcr/Abl fusion protein (also known as the Philadelphia Chromosome, Ph+) occurs
due to a reciprocal translocation of the long arms (q) of chromosomes 9 and 22. This
translocation results in a fusion protein that has 2 forms, 190 and 210, named so due to their
molecular weight. The proteins have the same regions of Abl but differ in their regions of
BCR107. The hallmark of this disease is that the Bcr/Abl translocation results in constitutive, high
levels of Abl kinase activity (regardless of 190 or 210) resulting in abnormal and promiscuous
signaling cascades

108-110

. There is literature to suggest that the different fusion proteins (190 vs

210) have both conserved (P-CrkL, Src family members, Ras, PI3K, Erk, CyclinD2
specific downstream targets (Rho, Rac and CDC42

111-114

) and

115

) but more studies are needed to confirm

and elaborate on these findings. In addition to turning on a multitude of signaling cascades,
studies have shown that Bcr/Abl can also turn off regulatory phosphatases such as Protein
phosphatase-2A (PP2A)116. The PP2A activator FTY720 is currently in clinical trials and murine
in vivo data suggests that it is effective against Imatinib and Dasatinib resistant Ph+ ALL and
CML stem cells carrying the T1351 mutation without negative consequence to the normal
CD34+ and CD34+/CD19+ bone marrow cells117-119.
The Bcr/Abl fusion gene and subsequent fusion protein is commonly seen in Chronic
Myelogenous Leukemia (CML, 210) and in Acute Lymphoblastic Leukemia (mostly 190 but
some 210) and in ALL is associated with poor prognosis, aggressive disease, and relapse. The
frequency of the Bcr/Abl translocation is almost 100% in CML and lack of this fusion protein is
actually a poor prognostic indicator for CML. In ALL the fusion protein occurs in approximately
3-5% of pediatric and 25-50% of adult ALL cases. Imatinib (Imatinib Mesylate, Gleevec) is an
Abl kinase inhibitor used clinically to treat Ph+ ALL and CML. It acts by binding to ATP pocket
and inhibits the activity of the Abl kinase

120

. Unfortunately, mutations in the Abl kinase pocket

(M244V, G250E, Y253F/H, E255K/V, T315I, M351T, and F359V)
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result in resistance to this

treatment and therefore combined therapies such as Dasatinib and Nilotinib (Src/Abl inhibitor
and more potent Abl inhibitor, respectively) along with proteasome inhibitors, HDAC inhibitors
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and aurora kinase inhibitors, are currently in clinical trials in attempts to improve outcome and
survival. While elevated Abl kinase activity has been associated with diverse impacts on tumor
cells including altered cytoskeletal dynamics and proliferation in addition to altered cell survival,
other types of proteins impact on tumor phenotype through predominantly regulation of antiapoptotic pathways specifically, with one that is relevant to the work being currently described
being beta-catenin.
Beta-catenin is a protein that is classically known for being a transcription factor that
influences, predominantly, the expression of survival proteins and can be regulated

via

ubiquitination and proteasomal degradation122;123. It is from a family of proteins that contain 6
armadillo repeat domains which are specialized for protein binding. Beta-catenin has been
shown to bind to cadherins (VE-cadherin etc.) as well as be regulated by phosphorylation for
stabilization (tyrosine) or targeted for degradation (serine/threonine) in the proteasome

124-130

.

When beta-catenin is phosphorylated at tyrosine 86 and 654 it can translocate to the nucleus to
act as a transcription factor for proteins such as c-myc, cyclin D1, and survivin

131

. It has been

shown to not only be important in the survival of Ph+ leukemia, as well as other cancer, but has
also been shown to physically interact with, and be stabilized by, the Bcr/Abl fusion protein due
to phosphorylation at Y86 and Y654 residues126. A recent publication by the Li lab has shown
that Beta-catenin is essential for the survival of leukemia stem cells and that it, not resistance to
Bcr/Abl, was responsible for leukemic stem cell survival during treatment

132

. Additionally, Beta-

catenin has been shown in both normal cells, such as endothelial cells, as well as cells that
have undergone EMT (epithelial to mesenchymal transition) to be able to bind to the
cytoplasmic tail of cadherins as well as other proteins. This binding results in stabilization of
beta-catenin and allows it to act as a scaffold for other proteins to bind which initiate signaling
cascades that promote both metatstasis and survival123;129;133.
VE-cadherin (Vascular Endothelial cadherin, aka CD144 and Cadherin 5) is one of the
cadherins to which beta-catenin can bind and is a protein that our laboratory has shown to be
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important in Ph+ ALL. VE-cadherin is calcium-dependent and interacts homotypically with itself
through the N-terminal five extracellular cadherin repeats to form adherens junctions between
endothelial cells, regulate vascular permeability and leukocyte extravasation

134;135

. VE-cadherin

also contains a transmembrane region and a highly conserved cytoplasmic tail to which proteins
such as beta-catenin, plakoglobin, p120 can bind

134;135

. These proteins are important to the

regulation of VE-cadherin and their phosphorylation status can alter the stability of VE-cadherin
on the surface of endothelial cells.
The main mechanism of regulation for VE-cadherin, in endothelial cells in which it has
been most thoroughly studied, is clathrin coated endocytosis, via p120, and recycling of VEcadherin back to the membrane surface

136

. More recent potential mechanisms of VE-cadherin

regulation suggest that in response to VEGF, a Src dependent phosphorylation of the guanine
exchange factor Vav2 occurs, leading to the activation of the GTPase Rac and subsequent
phosphorylation of serine 665 of VE-cadherin

137;138

. This phosphorylation results in the

recruitment of -arrestin2, thereby promoting internalization of VE-cadherin. Additionally, studies
have shown that the tyrosine phosphorylation status of VE-cadherin at y731, and potentially
658, can be altered by a process that required Src and the proline-rich tyrosine kinase 2 (Pyk2), and that the phosphorlyation status could further be altered by the VE-cadherin specific
receptor type protein tyrosine phosphatase VE-PTP in normal endothelial cells 139-141.
An elegant study from the Cheresh lab, using CHO cells lacking endogenous cadherins,
showed that tyrosine phosphorylation of VE-cadherin at 731 or 658 was sufficient to prevent the
binding of p120- and β-catenin, respectively, to the cytoplasmic tail of VE-cadherin142.
Phosphorylation at either site led to the inhibition of cell barrier function and mutants of 731 or
658 that were not able to be phosphorylated resulted in enhanced cell migration and an invasive
phenotype142. Interestingly, VE-cadherin has been shown to be unexpectedly expressed in a
variety of cancers such as melanoma, ewings sarcoma, breast cancer, prostate cancer and our
laboratory has shown the expression, and functional significance, of VE-cadherin in Ph+ Acute
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Lymphoblastic leukemia

41;143-145

. Studies in both endothelial cells, as well as cancer cells, have

been varied on the mechanisms by which VE-cadherin surface expression is regulated. Recent
studies have focused on the potential for VE-cadherin regulation at the level of transcription
potentially by the hypoxia sensitive transcription factor HIF-2 alpha (Hypoxia inducible factor 2
alpha)

146

which, in our model of ALL was shown to be modulated by Abl kinase activity as well

as bone marrow microenvironment signals.
HIF-2 is a transcription factor composed of a constitutively expressed  subunit (HIFβ,
also known as aryl receptor nuclear translocator, ARNT) and an oxygen-regulated α subunit
(HIFα)

147

. Both subunits are basic-helix-loop-helix (bHLH) transcription factors and contain a

Pax/Aryl hydrocarbon receptor/Sim (PAS) domain. HIFβ is not regulated by oxygen and
interacts with several bHLH factors other than HIFα148;149 . Although there are 3 isoforms of the
alpha subunit (1, 2/EPAS, and 3) only 1 and 2 are commonly studied.150
The regulation of the HIF proteins occurs through both the C terminal oxygen dependent
domain (ODD) and the N terminal transactivation domain. During high levels of oxygen, or
normoxia, an ODD specific proline residue (p531) within the LXXLAP cores are hydroxylated
and this posttranslational modification is an absolute requirement for its degradation150;151.
When

hydroxylation occurs this proline residue is recognized by the protein pVHL, the

substrate recognition component of an E3 ubiquitin ligase complex that targets HIF for
proteosomal degradation152-154. During hypoxia the alpha subunits are stabilized and HIF can
translocate to the nucleus where they heterodimerize with ARNT and bind to the HRE (hypoxia
responsive elements) within the HIF target genes

155;155

. Regulation of transcription via the N-

terminal transactivation domain (NTAD) occurs via hydroxylation of an asparagine residue
within the NTAD that inhibits its interaction with the transcriptional co-activator p300.
Interestingly, the enzymes that catalyze both of these reactions are from the family of 2oxoglutarate-dependent dioxygenase (2-ODD) which require molecular oxygen as a cosubstrate for their catalytic reactions

156

. The interaction between HIF and p300/CBP is also
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regulated in an oxygen-dependent manner by factor inhibiting HIF-1 (FIH-1). FIH hydroxylates
asparagine residues located within the HIF-a C-terminal transactivation domain (CTAD) and
prevents p300/CBP binding

155

. Thus, full activation of HIF transcriptional activity requires both

HIFa stabilization and CTAD activation.
HIF-2 shares approximately 48% amino acid homology with HIF-1 but HIF-2 alpha,
unlike HIF-1, is less ubiquitously expressed and is thought to be limited to cells in the CNS,
lung, heart and endothelium149. Expression of HIF-2 alpha is found in hypoxic environments
such as the bone marrow and within tumors and has been shown to have distinct targets

156 157

,

compared to HIF-1, such as OCT-4, VE-cadherin, c-myc, flk-1, tie2, VEGF, CXCR4, TWIST and
has been shown to regulate VE-cadherin in normoxia

146;158-162

. In more recent literature HIF-2

alpha’s mechanism of regulation in normoxia has become of interest to many groups based on
studies showing that it can be expressed during normoxia and has been found at high levels in
many tumor models such as colorectal, lung, melanoma, bladder and neuroblastoma

67 163-166

.

Murine knockout models of HIF-2 alpha lead to midgestation lethality (E9-E13.5) and defective
vascular remodeling during embryonic development. Additionally, HIF-2 alpha knockout mice
died from irregularities in cardiac hypertrophy, hepatic steatosis, retinopathy, lung maturation,
hypocellular bone marrow and mitochondrial dysfunctions

167;168

compared to neural tube

defects, lack of cephalic vascularization and cardiovascular malformations in the HIF-1 mice
suggesting further the distinct target genes of these proteins 169-171. Additionally, HIF-2 alpha has
been shown to be critical for normal hematopoiesis and our interest in the potential stem-celllike characteristics of Ph+ cells compelled us to look at Oct-4, which is a transcriptional target of
HIF-2 alpha shown to be crucial in the maintenance of pluripotentcy 158;172.
OCT-4 (Octamer-4) is a transcription factor of the POU class 5 Homeobox 1 family
(POU5F1) that is critically involved in stem cell renewal and pluripotentcy

173;174

. It was originally

investigated in the context of embryonic stem cells where it was found to maintain them in an
undifferentiated state and since then has become associated with tumors and is a regulator of
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the tumor “stem cell” phenotype

173

. In embryonic stem cells a delicate balance of Oct-4 is

needed as, too much can lead to differentiation into primitive endoderm and mesoderm

175

. In

contrast, repression of Oct-4 results in failure to form the inner mass and induces loss of
pluripotency and dedifferentiation to trophectoderm

176

. OCT-4 has been shown to be a single

factor that is capable of reprogramming differentiated cells back into a stem-cell state and is
thought to be responsible for treatment resistance in some tumor stem cell models

177

. Many of

these critical proteins described up to this point were uniquely found to be co-expressed in the
Ph+ ALL cells that were utilized in our some of our studies, elaborated on below.

VI. Unique phenotype of leukemia cells utilized in our model and rationale for our studies
Seminal work from the Hendrix lab showed the unexpected expression VE-cadherin on
aggressive melanoma cells and additional labs have shown the expression of VE-cadherin on
other cancers such as breast and Ewing Sarcoma41;143-145. This prompted our lab to investigate
VE-cadherin expression, as well as stem cell marker expression, in our ALL cells that were
Bcr/Abl+, or Ph+, and Ph- cells. In the manuscripts listed below we show the expression of both
VE-cadherin and PECAM-1 on the surface of BCR/ABL positive cells. Additionally, we show that
these cells have a stem-like phenotype, expressing HIF-2 alpha as well as markers of
pluripotentcy such as OCT-4, SSEA-1, TRA-1-80 etc in addition to normal B lineage markers
such as CD19. The publications also show that VE-cadherin expression can be regulated by
BMSC, potentially through Abl kinase activity, HIF-2, and beta-catenin and that knockdown or
inhibition of VE-cadherin can sensitize cells to treatment even in the presence of BMSC. The
relevance of these proteins (Bcr/Abl, Beta-catenin, VE-cadherin, HIF-2 alpha and Oct-4) in
normal and leukemic cells were previously discussed.
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Abstract:
Although leukemic stem cells (LSCs) demonstrate a symbiotic relationship with bone marrow
microenvironmental niches, the mechanism by which the marrow microenvironment contributes to
self-renewal and proliferation of LSCs remains elusive. In the present study, we identified a unique
subpopulation of Ph+ ALL cells co-expressing markers of endothelial cells (including VE-cadherin,
PECAM-1 and Flk-1) and committed B-lineage progenitors. Following long-term co-culture with bone
marrow stromal cells, tumor cells formed hematopoietic colonies and cords, expressed early stem cell
markers, and demonstrated endothelial sprouting. Gene expression profiles of LSCs were altered in
the presence of stromal cell contact. Stromal cell contact promoted leukemic cell VE-cadherin
expression, stabilized β-catenin and upregulated Bcr-abl fusion gene expression. Our study indicates
that these specific tumor cells are uniquely positioned to respond to microenvironment-derived selfrenewing and proliferative cues. Ph+/VE-cadherin+ tumor subpopulation circumvents the requirement
of exogenous Wnt signaling for self-renewal through stromal cell support of leukemic cell VE-cadherin
expression and upregulated Bcr-abl tyrosine kinase activity. These data suggest that strategies
targeting signals in the marrow microenvironment that amplify Bcr-abl/VE-cadherin/β-catenin axis
may have utility in sensitizing drug-resistant leukemic stem cells.
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Introduction:
The bone marrow microenvironment plays an important role in maintaining the quiescence
and plasticity of hematopoietic stem cells (HSCs). The stem cell properties are controlled by ligandreceptor signaling and cell-cell adhesion molecules within microenvironmental niches. These
anatomical sites predominantly consist of spindle-shaped, N-cadherin positive endosteal osteoblasts
at the bone surface and VE-cadherin positive sinusoidal endothelium at the thin-walled blood vessels
(sinusoids). 1,2 The molecular mechanisms underlying interactions between stem cells and their niche
are better understood in the context of Drosophila germ stem cells and mouse bone marrow than in
humans. In Drosophila ovary, the molecular hinge that anchors germ stem cells to cap cells (niche
stromal cells) is E-cadherin and β-catenin.3 In the mouse model of HSC microenvironment,

N-

cadherin is expressed in both quiescent HSCs and osteoblasts, and an increase in the number of Ncadherin+ osteoblasts is correlated with an increase in N-cadherin+ HSCs.1,4
While the impact of bone marrow niches on normal hematopoietic stem/progenitor cells has
been extensively investigated, less is known about how the same microenvironment influences
leukemic stem cells (LSCs). Although LSCs demonstrate a symbiotic relationship with the specialized
bone marrow microenvironment,5 the role of bone marrow fibroblastic stromal cells in supporting selfrenewal of acute lymphoblastic leukemia (ALL) LSCs remains largely unclear. Recent studies
indicated that the canonical Wnt/β-catenin signaling pathway plays a pivotal role in B-lineage
hematopoietic stem/progenitor cell development.6 In addition to the destruction and transcription
complexes involved in Wnt signaling pathway, β-catenin also exists in the cadherin-catenin-actin cellcell adhesion complex.7 VE-cadherin (vascular-endothelial cadherin) is one of the classic Ca2+dependent, homophilic adhesion molecules primarily expressed in endothelial cell adherens
junctions. The intracellular domain of VE-cadherin physically interacts with p120 catenin, β-catenin, αcatenin and the actin cytoskeleton. Tyrosine phosphorylation of the C-terminus of β-catenin at
Tyr142, or the VE-cadherin intracellular domain at Tyr 658/731 by Src family kinases, alters the
binding affinity of β-catenin to VE-cadherin.8,9
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Interplay between β-catenin and cadherin family proteins may modulate the stem cell
properties of normal HSCs. Whether this interaction influences LSC maintenance and progression,
and how this interaction contributes to sustained leukemic cell self-renewal warrant further
investigation. We present data showing that a putative LSC subset of ALL utilizes Bcr-abl/VEcadherin/β-catenin axis to bypass the requirement of externally stimulated Wnt/β-catenin. While
dependence on microenvironment cues for self-renewal is lost, the ability of leukemic cells to respond
to stromal signals is maintained. Stromal cells regulate self-renewal and proliferation of this Ph+/VEcadherin+ LSC-like subpopulation by upregulation of VE-cadherin and Bcr-abl expression.
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Materials and methods:
Cells and reagents
Ph+ ALL cell line Sup-B15 (p185 Bcr-abl+) was obtained from ATCC. Nalm27 (p210 Bcrabl+). Nalm20 and Nalm29 ALL cell lines were kindly provided by the Fujisaki Cancer Center. Control
cell lines JM1, RS4;11, REH, Jurkat, HL60, K562 were also from ATCC. Ph+ OP-1 was a gift from Dr.
Dario Campana (St. Judes Children’s Research Hospital). Maintenance of human bone marrowderived stromal cell line PatX and murine stromal cell line S-10 (provided by Dr. Kenneth Dorshkind
of the University of California) has been previously described in detail.10 To establish long-term coculture of stromal and leukemic cells, Sup-B15 and Nalm27 cells were seeded onto 70% confluent
stromal cells, and maintained by subculture of a portion of Sup-B15 or Nalm27 cells onto new stromal
cells weekly for more than 12 months. Bcr-abl kinase inhibitors imatinib mesylate (IM) and AG957
were obtained from Novartis (Basel, Switizerland) and Sigma (St. Louis, MO), respectively. Src
kinase inhibitor PP2 and proteosome inhibitor MG132 were purchased from Calbiochem (San Diego,
CA). All recombinant cytokines and growth factors were purchased from R & D systems (Minneapolis,
MN).
Plasmid constructs, lentiviral and retroviral vectors
Human VE-cadherin (referred to as CDH5/wild type, wt), VE-cadherin lacking the C-terminal
222-nt β-catenin binding domain (referred as ∆bcat) and VE-cadherin lacking the C-terminal 449-nt
cytoplasmic domain (referred to as ∆cyto) coding DNA sequences (CDSs) were amplified with highfidelity DNA polymerase pfx (Invitrogen, Carlsbad, CA) from a HUVEC cDNA library and
subsequently ligated into the pENTR-D/TOPO entry vector using the TOPO cloning strategy
(Invitrogen). The two truncated derivates and the wt VE-cadherin pENTR entry plasmid constructs
were recombined with the pLenti6.2-Dest/V5 lentiviral vector via LR recombination using the Gateway
cloning technology (Invitrogen). The pLenti6.2-Dest/V5 empty vector control (referred to as vect) was
generated via recombination of the destination lentiviral vector with a circularized empty pENTRD/TOPO plasmid to replace the attR1-CmR-ccdB-attR2 toxic protein from the pLenti6.2-Dest/V5
vector.
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The murine stem cell retroviral (MSCV) vectors pMigR1-210 and pMigR1-185 carrying the
Bcr-abl (p210 and p185) full-length fusion gene cDNAs were kindly provided by Dr. Pendergast of
Duke University. Both plasmid constructs are bicistronic with an internal ribosomal entry site (IRES)
upstream of the enhanced green fluorescent protein (eGFP) coding sequence. To generate the
matched empty vector control pMSCV-IRES-eGFP (pMiG), the 7.2-kb EcoRI fragment coding for
p210 Bcr-abl fusion protein was released and the vector re-ligated with T4 DNA ligase.
To construct the β-catenin/Tcf reporter gene system, the synthetic sense and antisense
strands of the Tcf-binding sites 1 (TBS-1) and Tcf-binding sites 2 (TBS-2) were denatured at 94°C
and annealed at room temperature.11,12 The ds-TBS-1/2 were 3’ adenine-tailed with Taq DNA
polymerase at 72°C for 15 minutes followed by in vitro phosphorylation of the 5’-OH ends with T4
polynucleotide kinase. The resultant double-stranded ds-TBS-1/2 were inserted into pGEM/Tesay
vector (Promega, Madison, WI) via T/A cloning. The TBS-1/2 inserts flanked by Xho I and Hind III
sites were excised from the T/A vector and the released TBS-1/2 oligonucleotides were ligated into
the Xho I-Hind III site of the multiple cloning site in phRL-null Renilla luciferase vector (Promega). To
construct the Tcf optimal promoter (TOP)/ minimal thymidine kinase (mTK) chermic promoter
upstream of the Renilla luciferase coding sequence, a 531-bp Bgl II-Pvu II cohesive-blunt fragment of
the thymidine kinase promoter region was deleted from the phRL-TK vector (Promega) and replaced
with the Bgl II-Sma I cohesive-blunt fragment containing the TBS-1/2 fragments released from the
phRL-TBS-1/2.
To construct the Bcr-abl promoter reporter, the pMigR1-210 was first digested with BamH I.
The resulting BamH I 5’-overhangs were fill-in blunted with Klenow. A 640-bp EcoR I-BamH I
fragment (pp210S) and an approximately 1.5-kb BamH I-EcoR I fragment (pp210L), spanning the
putative Bcr-abl promoter region and part of the first exon,13 was further released from the linearized
pMigR1-210 and inserted directionally (for pp210S) and in reverse direction (for pp210L) into the
EcoR I-Sma I site of the phRL-null Renilla luciferase vector.
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All the synthetic oligonucleotides for long and accurate-PCR (LA-PCR) amplification of
relevant gene CDSs, or for construction of TOP-mTK chimeric promoters, are indicated in Table 1
(Data supplement). At the 5’-end of each forward primer, a CACC 5’-overhang was added to the
primer to ensure directional ligation into pENTR-D/TOPO vector and to constitute the Kozak
consensus sequence (CACCATGC/G) for efficient translational initiation. At the 3’-end of each
reverse primer, the TGA/TAG stop codons were site-directedly mutated into AGA to allow
downstream V5 epitope expression. For the Tcf binding sites 1 and 2, the Xho I and Hind III
restriction sites are underlined, respectively.
Production of lentiviral and retroviral stocks
To generate replication-incompetent lentiviral particles carrying the CDH5-wt, ∆bcat, ∆cyto
and vect, the pLenti6.2-Dest/V5 vectors containing the gene CDSs described were co-transfected
with pLP1 (gag/pol), pLP2 (rev) and pLP3 (VSV-G, Vesicular Stomatitis Virus-G pseudotype)
plasmids (Invitrogen) into 293FT packaging cells (Invitrogen). To generate the replicationincompetent murine stem cell retroviruses expressing the p210/p185 Bcr-abl fusion protein, the
pMigR1-210, pMigR1-185 or pMiG empty vector constructs were transfected into the RetroPack PT67
packing cells (BD-Clontech), in which the gag/pol, rev and the pseudotyped VSV-G envelope coding
sequences have been stably integrated into the PT67 genome. For detailed protocols of collection,
titration and cell infection, see data supplement.
Dual-luciferase Reporter (DLR) assay
To evaluate transactivation of the β-catenin/Tcf signaling and Bcr-abl transcription activity
initiated by long-term stromal cell co-culture or enforced expression of VE-cadherin in Sup-B15 cells,
cells were transiently co-transfected in triplicate with pGL4.13-CMV/Luc2 (Promega) firefly luciferase
expression vector (as an internal transfection efficiency control) and the Renilla luciferase TOP1/2mTK or Bcr-abl pp210S/pp210L promoter reporter constructs. For collection, cell lysis and
bioluminescence assay, see data supplement.
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Knockdown of VE-cadherin expression by RNAi
SmartPool short interfering RNAs (siRNAs) corresponding to coding sequences of VEcadherin was obtained from Dharmacon (Lafayette, CO). Transient siRNA transfection of Sup-B15
cells was completed as previously described with use of scrambled siRNA sequence controls.10
Endothelial differentiation
Evaluation of endothelial cell differentiation (i.e. sprouting) of Sup-B15 and Nalm27 cells was
completed as recommended by the manufacturer (Stemcell technologies, Toronto, Canada). Briefly,
LTCC Ds-Red labeled Sup-B15 or eGFP labeled Nalm27 were collected and incubated in the
EndoCult liquid medium supplemented with EndoCult supplements on coverslips. 48 hours following
induction of differentiation, cells were fixed in formaldehyde and analyzed by confocal microscopy.
Microarray analysis
Wnt, Notch, HSC and CSM (cell surface marker) pathway-focused microarray analyses of
mRNA transcripts in Sup-B15 LTMC/LTCC were performed according to the manufacturer’s
instructions (SuperArray, Frederick, MD). For a brief protocol, see data supplement.
In vitro poly-ubiquitination of β-catenin
In vitro poly-ubiquitination was performed as described previously.14 Briefly, β-catenin was
immunoprecipitated either from 293FT expressing eGFP-210 or eGFP alone, or from Ph+ Sup-B15 or
Ph- REH leukemic cells. The ubiquitin-protein conjugation reaction was performed at 37°C waterbath
for 3.5 hours in a volume of 20 μL containing 50 mM HEPES, pH 7.5, 2mM DTT, 5mM MgCl 2 , 5mM
ATP, Fraction A (including human E1 and E2 enzymes), Fraction B (containing human E3 enzyme),
10 g of recombinant ubiquitin (BostonBiochem, Boston, MA) and immunoprecipitated β-catenin in
the presence of 2M ubiquitin C-terminal hydrolase (UCH) inhibitor ubiquitin aldehyde (Ub-ald). The
reaction was terminated by the addition of 10 L 3x SDS sample buffer and boiling at 100°C for 5
minutes.
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Confocal microscopy, immunoprecipitation, immunoblotting and flow cytometry
All the antigen-antibody based evaluations were completed as described previously. 10,15 Antibodies
are described in detail in data supplement.
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Results:
Identification and characterization of a leukemic stem-cell like population that expresses both
endothelial and hematopoietic progenitor cell surface markers.
Both p185 (Sup-B15) and p210 (Nalm27) Bcr-abl positive ALL cells exhibit either as floating
aggregates or adherent patches, distinct from Ph- leukemic cells during in vitro culture. Screening a
panel of adhesion molecules including VCAM-1, PECAM-1, ICAM-1 and the cadherin family of
proteins (data not shown) in Ph+ ALL cells revealed that Bcr-abl positive cells uniquely express VEcadherin. Leukemic cell VE-cadherin was calcium-sensitive and predominantly localized on the cell
surface (Fig 1A). Pretreatment of cells with the calcium chelator EGTA diminished the VE-cadherin
fluorescent signal on leukemic cells, whereas addition of Ca2+ enhanced the calcium-mediated
fluorescent signals (Fig 1A). Expression of VE-cadherin is absent on Ph-negative ALL cells, while all
the Ph+ ALL cell lines tested, including K562 Ph+ CML (blast crisis), express VE-cadherin (Fig 1B).
RT-PCR confirmed VE-cadherin expression in Ph+ leukemic cells, but not in Ph- leukemic cells, at
the mRNA level (data not shown). Immunophenotypic characterization of the Ph+/VE-cadherin+
subset of ALL cells indicated that hematopoietic stem/progenitor cell surface markers CD34, CD38
and c-kit, mature B-cell lymphoid markers CD19, CD45, and the endothelial antigens Flk-1, PECAM-1
and VE-cadherin are co-expressed on Sup-B15 cell surface (Fig 1C). Approximately 12% of Sup-B15
cells also expressed the early endothelial marker CD133 (Fig 1C). Thus, Ph+/VE-cadherin+ identifies
a unique subpopulation of ALL cells distinctive from Ph-negative ALL cell population.
Ph+/VE-cadherin+ leukemic cells form hematopoietic colonies/cords on bone marrow niche
stromal cells and differentiate into endothelial cells in vitro.
Long-term co-culture (LTCC) of Sup-B15 or Nalm27 leukemic cells on either S10 or PatX
stromal cells supported the formation of hematopoietic colonies (“hemospheres”, Fig 2A), resembling
neurospheres generated by neural stem cells or mamospheres formed by breast cancer stem
cells.16,17 Hemospheres formed on stromal cells morphologically resembled both type I (compact
colony, Fig 2A upper right) and type II (colony with a dense center surrounded by migrating cells, Fig
2A lower right) but not type III (diffuse colonies of mobile differentiating cells) as characterized
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previously.18,19 However, unlike cancer stem cell colonies derived from solid tumors, formation of
hemospheres from Ph+/VE-cadherin+ leukemic cells are stromal-cell dependent, with hemospheres
only initiated in physical association with a monolayer of VCAM-1-positive stromal cells. Of all the ALL
cell lines tested, only the Ph+ subset was capable of hemosphere formation, whereas Ph- ALL cell
lines did not form hemospheres during LTCC for up to 6 months (data not shown). Moreover,
hemospheres are resistant to EDTA-free trypsin digestion during regular subculture, while leukemic
cell aggregates in long-term medium culture (LTMC) can be disrupted by mechanic vibration.
Formation of flame-like, finger-shaped hematopoietic cords from Ph+/VE-cadherin+ LTCC on
both human and murine stromal cells follows formation and growth of hemospheres (Fig 2B,
supplementary video clips 1-6). Hematopoietic cords were characterized by a bamboo shoot-like
structure comprised of distinct cellular constituents localized to the peripheral or central regions (Fig
2B). In a typical hematopoietic cord, the inner column is comprised of CD133+VE-cadherin+ cells
with the periphery of the cord constituted by more differentiated CD133-VE-cadherin+ leukemic cells
(Fig 2B, supplementary video clip 3&4). To further examine the stem-cell potential of the leukemic
cells that comprised the hemospheres and hematopoietic cords, we stained the hemosphere and
hematopoietic cord cells with early stem cell (ESC) markers (Fig 2C & 2D). Confocal microscopy
revealed distinct expression and distribution patterns of ESC markers. Oct-4 was uniquely expressed
in the peripheral region of the hemospheres (Fig 2D), while SSEA-1, SSEA-3, SSEA-4, Tra-1-61 and
Tra-1-80 positive cells were limited to the central region (Fig 2C). Migratory leukemic cells
surrounding the hemospheres were negative for ESC marker staining (Fig 2C & 2D).
When LTCC Ph+/VE-cadherin+ cells were incubated in EndoCult, we observed endothelial
sprouting of Ph+VE-cadherin+ Sup-B15 or Nalm 27 cells (Fig 2E). Many Ph+VE-cadherin+ LTCC
cells differentiated from round, floating cells to spindle-shaped, adherent cells within 2 days (Fig 2E).
Thus, deprivation of stromal cell support in the presence of endothelial-trophic growth factors leads to
a rapid endothelial switch of Ph+/VE-cadherin+ cells following long-term stromal cell contact.
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LTCC with bone marrow stromal cells promotes self-renewal activity of Ph+/VE-cadherin+
leukemic cells independent of the Wnt/β-catenin signaling pathway.
To investigate the signaling pathway(s) potentially involved in the stem-cell like phenotypes of
Ph+/VE-cadherin+ ALL cells following LTCC with stromal cells, pathway-focused microarrays were
completed to compare the gene expression profiles in LTMC and LTCC Sup-B15. Sup-B15 genes
involved in the Wnt/β-catenin signaling pathway respond to S10 or PatX stromal cell signals
differentially (Fig 3 & Table 2, data supplement). Tcf/β-catenin target genes, including Cyclin D1
(CCND1), Cyclin D3 (CCND3) and c-Myc (MYC), were increased by 2-2.5 fold, 2-2.5 fold and 3-3.5
fold following LTCC, respectively. The β-catenin transcriptional co-activator Bcl-9 (BCL9) was
upregulated 1.5-2 fold while its transcriptional co-repressor Tcf (TCF7) and the Wnt inhibitory factor 1
(WIF1) were down-regulated 2 and 1.5 fold, respectively. However, expression of the intracellular
signaling mediator β-catenin (CTNNB1) and β-catenin binding protein 1 (CTNNB1P1) remained
unchanged. Further, the leukemic cell autocrine Wnts, including Wnt1, Wnt2 and Wnt3A, were downregulated by 2-2.3 fold in LTCC Sup-B15 as compared to those of LTMC Sup-B15, which were
coincident with down-regulation of the Wnt co-receptor Frizzled (FZD3, 1.5-fold) and the secretory
Wnt precursor-processing protein (PORCN, 2-fold). Thus, Wnt signaling cascades downstream of
ligand/receptor occupancy were aberrantly intercepted and reinforced while the extracellular
component of the signaling pathway was attenuated or disabled in Ph+/VE-cadherin+ ALL cells
during LTCC.
Stromal cells up-regulate VE-cadherin expression and stabilize β-catenin in Ph+/VE-cadherin+
cells.
The convergence of β-catenin in cadherin-catenin mediated cell-cell adhesion and
morphogenesis, and as an intracellular mediator of the canonical Wnt signaling pathway, prompted
us to hypothesize that VE-cadherin expression may contribute to self-renewal and proliferation of
Ph+/VE-cadherin+ cells. Following LTCC of Sup-B15 with both murine and human marrow stromal
cells, VE-cadherin expression was upregulated, coincident with elevated Src expression and βcatenin accumulation (Fig 4A). Screening a panel of stromal cell soluble growth factors and cytokines
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showed that TGF-β1, bFGF and VEGF stimulated VE-cadherin expression on Sup-B15 cells by 2.0,
1.5 and 1.8 fold, respectively (Fig 4B). To determine whether upregulated VE-cadherin contributes to
stabilizing β-catenin in Ph+/VE-cadherin+ ALL cells, reciprocal co-immunoprecipitaton revealed that
the amount of β-catenin complexed with VE-cadherin in tumor cells derived from either S10 or PatX
LTCC were 2-3.5 fold higher than those from LTMC alone (Fig 4C).

Because microarray data

indicated that β-catenin expression is not influenced by stromal cell contact (Fig 3), we hypothesized
that upregulated VE-cadherin plays a major role in sequestering and stabilizing β-catenin in Ph+/VEcadherin+ cells. T
To investigate this possibility, lentiviral transduction of Sup-B15 and 293FT cells with vectors
carrying the wild type and two mutant forms of VE-cadherin, ∆bcat and ∆cyto, were established (Fig
4D). Expression of the wt VE-cadherin, but not VE-cadherin lacking either the cytoplasmic or βcatenin binding domains, led to approximately 4 fold more β-catenin accumulation in both 293FT
(Figure 4D, upper) and Sup-B15 (Fig 4D, lower) cells. Thus, stabilization of β-catenin in the presence
of VE-cadherin may be a common molecular event in non-endothelial cells. To further investigate the
relationship between VE-cadherin and β-catenin in Ph+/VE-cadherin+ leukemic cells, VE-cadherin
siRNA or scrambled control dsRNA was transiently transfected into Sup-B15 cells. Knockdown of VEcadherin expression in Sup-B15 cells resulted in diminished β-catenin in a time- (Fig 4E, upper) and
concentration-dependent manner (Fig 4E, lower). Therefore, bone marrow niche stromal cells may
modulate Ph+/VE-cadherin+ leukemic cell self-renewal activity, at least in part, by influencing VEcadherin expression and subsequent β-catenin stabilization.
β-catenin is constitutively activated in leukemic stem-like cells that over-express VE-cadherin
during LTCC.
To examine the β-catenin/Tcf transcriptional activity, Sup-B15 LTMC or LTCC cells were
transiently co-transfected with phRL-TOP1 or phRL-TOP2 (Renilla luciferase) with an internal control
plasmid, pGL4.13-CMV-Luc2 (firefly luciferase). Stromal cell contact resulted in a 5 to 13 fold
increase in relative luciferase activity in LTCC (Fig 5A). Moreover, enforced expression of the wt, but
not ∆bcat and ∆cyto VE-cadherin, significantly promoted β-catenin/Tcf transcriptional activity in Sup-
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B15 cells (Fig 5B). In contrast, depletion of VE-cadherin expression by siRNA resulted in an
unexpected, transient elevation of β-catenin activity during the first 8 hours after transfection, followed
by a persistent declining in relative luciferase activities in a time- (Fig 5C, upper) and siRNA
concentration-dependent manner (Fig 5C, lower). One interpretation of this interesting phenomenon
is that the initial reduction of the docking protein VE-cadherin releases -catenin capable of driving
luciferase reporter expression due to the release of excessive, free -catenin that cannot be efficiently
targeted for proteosome mediated degradation. However, long-term reduction of VE-cadherin may
diminish its capability to protect -catenin from targeted ubiquitination and degradation that is typically
achieved through physical interaction. Stromal cell signals also altered the intracellular distribution of
β-catenin in Ph+/VE-cadherin+ cells. Translocation of β-catenin from the cytoplasm to the nucleus in
Sup-B15 cells was sporadically observed in actively dividing cells in LTMC (Fig 5D), however, longterm co-culture of Sup-B15 cells consistently promoted nuclear translocation of β-catenin in most of
the leukemic cells on hematopoietic cords (Fig 5D).
Bcr-abl fusion protein is essential for maintaining the VE-cadherin/β-catenin axis in the
leukemic stem-like cells.
In 293FT cells transduced with various forms of VE-cadherin expressing lentiviral vectors,
forced wild type VE-cadherin stabilized β-catenin as compared to vector control, ∆bcat or ∆cyto VEcadherin (Fig 4D, upper). However, the β-catenin/Tcf transcriptional activity did not dramatically
change following transduction of vect, ∆bcat, ∆cyto or even wt VE-cadherin in 293FT cells (data not
shown). Therefore, VE-cadherin expression alone is likely necessary, but not sufficient, to maintain
enhanced β-catenin activity in VE-cadherin+ leukemic cells. We hypothesized that Bcr-abl fusion
protein, with constitutive tyrosine kinase activity, may synergize with VE-cadherin expression to
contribute to the unique phenomenon of leukemic cell self-renewal and proliferation. To test this, we
examined alteration of Bcr-abl protein expression in LTMC and LTCC leukemic cells and observed
that stromal cell contact upregulated both Abl and Bcr-abl protein expression by 1.5-2 fold (Fig 6A,
upper). To confirm the observation at the transcriptional level, the Bcr-abl fusion gene promoter
region was cloned into the phRL-null luciferase reporter vector. The relative luciferase activity was
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upregulated 2- to 4-fold in Sup-B15 LTCC with S10 or PatX as assayed by the pp210S, but not the
pp210L reporter (Fig 6A, lower). To further investigate the role of the Bcr-abl fusion protein, Sup-B15
cells were infected with retroviruses carrying either the p185 or p210 Bcr-abl full-length cDNA.
Retroviral transduction of both p185 and p210 Bcr-abl resulted in forced expression of p185 or p210
protein in Sup-B15 cells (Fig 6B, upper). In Sup-B15 cells over-expressing the p185-eGFP or p210eGFP proteins, upregulation of VE-cadherin was also detected as above the parental baseline (Fig
6B, lower). Consistent with upregulated VE-cadherin expression, β-catenin/Tcf activity was also
increased 7- to 14 fold in p185-eGFP and p210-eGFP expressing cells, as compared to eGFP
expression alone (Fig 6C). In contrast, inhibition of Bcr-abl activity with the tyrosine kinase inhibitors
imatinib mesylate (IM) or AG957 down-regulated VE-cadherin expression in a concentrationdependent fashion in Sup-B15 cells, coincident with β-catenin cleavage (Fig 6D). In contrast,
treatment of Ph+/VE-cadherin+ leukemic cells with the proteosome inhibitor MG132 diminished
imatinib-induced cleavage of β-catenin in both Sup-B15 and Nalm27 cells (Fig 6E).
Tyrosine

phosphorylation

of

β-catenin

mediated

by

Bcr-abl

kinase

diminishes

its

ubiquitination-proteosome dependent degradation.
To dissect the signaling pathway by which constitutive Bcr-abl kinase activity maintains higher
VE-cadherin/β-catenin in Ph+/VE-cadherin+ ALL cells, Ph-/VE-cadherin- 293FT cells were cotransduced with lentiviruses encoding VE-cadherin and retroviruses encoding p210 Bcr-abl fusion
protein. VE-cadherin/p210 dual transduction resulted in the most pronounced stabilization of βcatenin in 293FT cells as compared to VE-cadherin transduction alone (Fig 7A). Immuoprecipitation
of β-catenin from the same samples indicated that β-catenin and Src co-existed in the same
immunocomplexes and β-catenin was tyrosine-phosphorylated following transduction with p210 Bcrabl kinase (Fig 7B). This was consistent with the most pronounced β-catenin transcriptional activity
being detected in p210 and VE-cadherin co-transduced cells (Fig 7C). Inhibition of Src activity with
PP2, or Bcr-abl with imatinib, was correlated with modest reduction of β-catenin recognized by a
monoclonal antibody specific for its active form. The combinatory inhibition of Src and Bcr-abl kinase
activity was associated with a further reduction in -catenin (Fig 7D). VE-cadherin was
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immunoprecipitated from the same panel. While expression of Bcr-abl protein resulted in a number of
tyrosine phosphorylated proteins, VE-cadherin appeared not to be affected by this constitutively
active kinase (Fig 7E). To investigate whether tyrosine phosphorylated β-catenin is more stable or
resistant to the ubiquitin-proteosome mediated protein degradation pathway, β-catenin that was
immunoprecipitated from Ph+/- leukemia or 293FT expressing eGFP-p210/eGFP was subjected to an
in vitro ubiquitination and degradation assay. In the presence of endogenous (Ph+) or exogenously
expressed Bcr-abl (eGFP-Bcr-abl), β-catenin had less mono-, poly-ubiquitination and degraded
fractions. This effect was demonstrated by comparison of Ph+ Sup-B15 or 293FT/eGFP-p210 to PhREH or 293FT/eGFP cells (Figure 7F).
Thus, consistent with the recent reports that Bcr-abl fusion protein promotes Src activation
and that Bcr-abl mediates tyrosine phosphorylation and subsequent stabilization of β-catenin in Ph+
ALL cells,

20,21

our data indicated that upregulated Bcr-abl fusion protein contributes to constitutively

active β-catenin activity by promoting VE-cadherin expression (physical stabilization) and
subsequently converting VE-cadherin-stabilized β-catenin to the active form through Src-mediated
tyrosine phosphorylation (functional stabilization). These data also suggest that tyrosine
phosphorylation and serine/threonine phosphorylation may differentially influence the fate of β-catenin
by affecting its subsequent ubiquitination.

129

Discussion:
As compared to the LSC model of AML, the origin of ALL LSCs is less well characterized.
Recent studies indicated that primitive HSCs were the target for ALL LSC transformation.22-24 In
contrast, Castor and colleagues demonstrated that different genetic alterations may target different
stages of hematopoiesis in ALL.25 The p210 Bcr-abl targeted primitive HSCs, whereas p185 and TELAML1 can transform CD34+CD19+ B-cell progenitors,25 raising the question whether LSCs for Ph+
ALL may also derive from committed B-cell progenitors.
Our data support the hypothesis that LSCs of B-cell Ph+ ALL can originate from committed
progenitor cells. In the current study, we identified a CD34+CD38+CD19+ Ph+-ALL subpopulation
with leukemic stem-cell like properties (Fig 1 & Fig 2). Formation of hematopoietic colonies
(hemospheres) and cords, induction of endothelial sprouting and reactivation of early stem cell genes
in this CD34+CD38+CD19+ subset during LTCC are consistent with a leukemic stem cell phenotype
(Fig 2). Expression of a panel of endothelial cell surface markers, including VE-cadherin, does not
necessarily imply hemangioblast origin. Rather it may represent one of the biological consequences
of Bcr-abl expression in this unique setting (Fig 6). In agreement with this possibility, a recent report
showed that Bcr-abl fusion transcripts can be detected in endothelial cells derived from transplanted
bone marrow cells from a CML patient.26 This in vivo observation, together with our in vitro induction
of endothelial differentiation of Ph+/VE-cadherin+ ALL cells (Fig 2), supports the conclusion that Bcrabl alone may promote VE-cadherin expression (Fig 6) and contribute to vascular endothelium
potential.26 Intriguingly, normal myeloid progenitors can also differentiate into endothelial cells,27
further supporting the notion that determination of endothelial fate is not restricted to the
hemangioblast or HSC stage, but rather reflects the close developmental relationship between the
hematopoietic and vascular systems.
VE-cadherin expression in non-endothelial cells has been identified and characterized in two
additional cell types to date. Increased VE-cadherin expression on cytotrophoblast stem cells was
required for normal placentation and successful endovascular invasion.28 In addition, VE-cadherin
was expressed in highly aggressive melanoma, and contributed to vascular mimicry.29 Notable are
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the observations that gestational trophoblastic neoplasia and aggressive melanoma are highly
metastatic with frequent central nervous system involvement.30,31 It is also widely recognized that, as
compared to acute non-lymphoblastic leukemia, non-Hodgkin’s lymphoma or Hodgkin’s lymphoma,
ALL is clinically manifested with a much higher frequency of CNS involvement. Because nonendothelial cells with VE-cadherin expression identified so far share a common clinical feature, CNS
involvement, it is tempting to speculate that VE-cadherin expression plays an important role in
mediating invasion of Ph+/VE-cadherin+ ALL cells into the CNS.
Identification of the importance of the Bcr-abl/VE-cadherin/β-catenin axis, and lack of reliance
upon Wnt initiated signals, indicates that this subset of tumor cells can circumvent the requirement of
exogenous Wnts for sustained self-renewal activity (Fig 4 & Fig 5). This self-renewal autonomy is
sustained by stabilized β-catenin in the presence of VE-cadherin expression (Fig 4) coincident with
high Bcr-Abl kinase activity. Thus, these Ph+/VE-cadherin+ cells can bypass the de novo signaling
cascade initialized by Wnt ligands for self-renewal and proliferation. Therefore, our data characterize
a novel model in which the molecular basis underlying the self-renewal autonomy of Ph+ ALL LSCs
can be further investigated.
While Wnt/β-catenin mediated self-renewal is similar in many tumor models, the epigenetic
and genetic alterations imposed on the tumor by the microenvironment are diverse. Self-renewal
autonomy conferred by intrinsically active β-catenin reflects one of the differences between normal
hematopoietic stem cells and leukemic stem cells, since normal stem cells exquisitely rely on selfrenewal signals from supportive niches,32 whereas cancer stem cells can somewhat escape this
dependency. However, a lack of reliance by tumor cells on niche-derived signals does not indicate a
loss of ability to respond to these important microenvironmental cues. In our model, bone marrow
stromal cells modulate the β-catenin mediated self-renewal capacity by up-regulating VE-cadherin
and Bcr-abl expression (Fig 4 & Fig 6). This observation is consistent with a recent report that
upregulation of Bcr-abl transcripts, followed by nuclear translocation of β-catenin, plays an important
role during LSC transformation to CML blast crisis.33 Co-expression of VE-cadherin and Bcr-abl are
unique to the subset of putative LSCs utilized in this model, with our data suggesting that
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microenvironmental factors remain influential in augmenting the self-renewal potential of specific
LSCs.
In addition, recent studies indicated that conditional expression of constitutively active βcatenin in knock-in mice led to the exhaustion of the long-term hematopoietic stem cell pool and loss
of stem-cell repopulating activity.34,35 This raised the question whether constitutively active β-catenin
also impairs the plasticity of leukemic stem cells. Although β-catenin is constitutively active in LTCC
Ph+VE-cadherin+ cells, in the presence of stromal cells, many early stem cell genes were reactivated
in Ph+ ALL leukemic cells physically located in hemospheres (Fig 2). These early stem cell markers
were previously shown to be expressed in primitive embryonic stem cells, and serve as indicators of
quiescence and pluripotency of embryonic stem cells.36 The observation that tumor cells expressed
early stem cell markers in a very specific anatomical configuration, with hemosphere structure
initiation supported by physical attachment to bone marrow stromal cells, was striking. This
observation suggests that stromal cell dependency distinguishes primitive leukemic stem cells from
more differentiated progeny leukemic cells. Further, our data also suggest that leukemic cells in longterm co-culture with stroma are highly heterogeneous, and in vitro LTCC may partially mimic the
hierarchical differentiation of the hematopoietic stem/progenitor cells in the bone marrow
microenvironment.
The concept of “re-programming” differentiated cells to a stem cell-like phenotype has been
addressed by several groups, including a recent report that the combination of four transcriptional
factors, Oct-3/4, Sox2, c-myc and klf4, can reprogram terminally differentiated mouse fibroblasts into
pluripotent embryonic stem cells.37 Our data suggest that Ph+/VE-cadherin+ ALL cell gene
expression profiles may be uniquely modified by stromal cells, and support the hypothesis that
formation of hemospheres with distinct stem cell marker expression may reflect an attempt by bone
marrow stromal cells to balance the proliferating pool with the primitive, quiescent pool of LSCs.
Therefore, unlike their normal hematopoietic counterparts,34,35 the LSC subpopulation of Ph+VEcadherin+ ALL cells may not be exhausted even if constitutively active β-catenin is driving cell cycle
entry, due to stromal cell conversion of a pool of LSCs to a quiescent state. Thus, self-renewal
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autonomy and stromal cell dependence of Ph+VE-cadherin+ ALL cells may be integrated in a way
that positions them to contribute to relapse of disease through characteristics they share with normal
HSCs.
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Figure legends:
Figure 1. Identification and characterization of a leukemic stem-cell like population that
expresses both endothelial and hematopoietic progenitor cell surface markers.
(A) Confocal laser scanning microphotographs (LSMs) of Ph+ ALL Sup-B15 cells stained with antiVE-cadherin in the presence of 10 mM EGTA and 5 mM CaCl 2 . Cell nuclei were counterstained with
propidium iodide (PI). (B) Cell lysates prepared from Ph-negative acute leukemia cell lines JM1,
RS4;11, REH, Jurkat, HL60 and Ph+ acute leukemia cell lines K562, Sup-B15, OP-1, Nalm20,
Nalm27 and Nalm29 were Western blotted with anti-VE-cadherin. The same membranes were
stripped and re-probed with anti-β-tubulin as a loading control. (C) Immunophenotyping of Ph+/VEcadherin+ Sup-B15 cells by flow cytometry. Cells were surface stained to evaluate hematopoietic
stem/progenitor cell and classic endothelial markers.

Figure 2. Ph+/VE-cadherin+ leukemic cells form hematopoietic colonies/cords on bone
marrow niche stromal cells and differentiate into endothelial cells in vitro.
(A) Phase contrast micrographs of Ph+ ALL Sup-B15 (upper panel) and Nalm27 (lower panel) cells
cultured in medium alone (Long-Term Medium Culture, LTMC) or long-term co-cultured (LTCC) on
murine stromal cell line S10 (top & bottom right). (B) Confocal LSM microphotographs of
hematopoietic cords formed on stromal cells. Cells were surface stained with anti-CD34, CD19, VEcadherin, and CD133 respectively. Nucleic DNA dyes include Sytox (green), PI (red) and TO-PRO-3
(blue). Z-stacks were 3-D reconstructed with LSM510 software (Zeiss, version 3.2). The turning axis
is the Y axis and turning angle for the displayed static pictures is 45. (C) Confocal micrographs of
hematopoietic colonies (“hemospheres”) stained with a panel of early stem cell (ESC) markers.
Stromal monolayer cells underneath hemospheres were counterstained with anti-VCAM-1. Cell nuclei
were counterstained with DNA dyes PI (red fluorescence) or SYTOX Green (green fluorescence) to
be compatible with the flurochrome tag of the secondary antibodies of anti-ESC antibody. Merged
images of 3-channel colors are shown in the final column. (D) 3-dimensional reconstruction of z-
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stacks showing the distribution of transcriptional factor Oct-4 within a hematopoietic cord. Cell nuclei
were counterstained with PI (red) and localization of Oct-4 was labeled with green fluorescence. The
turning axis is the Y axis. The tip of the hematopoietic cord was pressed flat by the coverslip. (E)
DsRed red fluorescent protein labeled Sup-B15 cells (top left) or eGFP labeled Nalm27 cells (bottom
left) were cultured in standard medium, or in EndoCult endothelial-defined medium (top & bottom
right). White arrows denote individual endothelial sprouting observed for individual Ph+/VE-cadherin+
ALL cells.

Figure 3. LTCC with bone marrow stromal cells promotes self-renewal activity of Ph+/VEcadherin+ leukemic cells independent of the Wnt/β-catenin signaling pathway.
Clustering analysis of gene expression profiles in Sup-B15 cells following LTCC with S10 or PatX
stromal cells. The hierarchical clusters were created with GEASuite software based on the similarity
of gene expression. The green color at the farthest left end of the color scale corresponds to the
minimal value; the red color at the farthest right end of the color scale corresponds to the maximum
value, Black corresponds to the average value of expression. BAS2C, HSPCB, ACTB and GAPDH
served as housekeeping gene controls. Analysis of the representative Wnt pathway is shown.

Figure 4. Stromal cells up-regulate VE-cadherin expression and stabilize β-catenin in Ph+/VEcadherin+ leukemic cells.
(A) Western blot analysis of Sup-B15 cells in LTMC (Med) or in LTCC with either S10 (S10) or PatX
(PatX) stromal cells. The same membrane was probed with anti-VE-cadherin, anti-β-catenin and antiSrc, respectively. GAPDH was used as the lane loading control. (B) Western blot of cell lysates
isolated from Sup-B15 cells exposed to recombinant human cytokines, chemokines, or growth factors
compared to untreated control cells (Cont). (C) Reciprocal co-immunoprecipitation of Sup-B15 cell
lysates from LTMC (Med) or LTCC (S10 and PatX) with anti-VE-cadherin or anti-β-catenin specific
antibodies. Membranes were reciprocally probed with anti-β-catenin and anti-VE-cadherin,
respectively. IgG heavy chains served as the loading control. “Input” denotes sample with antibody
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alone, lacking cell lysate. (D) Western blot analysis of cell lysates from 293FT (top panel) or Sup-B15
cells (bottom panel) transduced with lentiviruses carrying the wild type VE-cadherin (WT) or VEcadherin lacking either the cytoplasmic domain (∆cyto) or β-catenin binding domain (∆bcat) CDSs
(Coding DNA Sequences).

“Vect” denotes the empty lentiviral vector encoding the blasticidin

resistance protein without a CDS insert. (E) Western blot analysis of Sup-B15 cells transiently
transfected with VE-cadherin siRNA or scrambled (Scr) control siRNA sequence. Time-course (top
panel) and dose-response (bottom panel) of VE-cadherin siRNA transfected samples were probed
with anti-VE-cadherin and β-catenin specific antibodies.

Figure 5. β-catenin is constitutively activated in leukemic stem-like cells over-expressing VEcadherin during LTCC.
(A) Dual-luciferase reporter assays (DLR) of Sup-B15 LTMC (Med) or LTCC cells (S10 or PatX)
transiently co-transfected with phRL-TOP1 or phRL-TOP2 Renilla luciferase reporters with an internal
control pGL4.13-CMV-Luc2 firefly luciferase reporter. Experimental Renilla luciferase activity was
normalized to that of control firefly luciferase and is shown as relative luciferase units (RLU). Data
were presented as mean +/- SD (n=3). (B) DLR assays of cell lysates from Sup-B15 cells transduced
with wild type or the two truncated forms of VE-cadherin. Data were presented as mean +/- SD (n=3).
“*” denotes significant differences as compared to Vect controls (p<0.01) based on the Student’s t
test. (C) Sup-B15 cells transfected with 100nM VE-cadherin siRNA for 8-72 hours (top panel) or at a
concentration of 50-200nM for 24 hours (bottom panel). Data are shown as the mean +/- SD (n=3).
(D) Confocal micrographs of LTMC or LTCC Sup-B15 cells stained with anti- active β-catenin
antibody. Cell nuclei were counterstained with SYTOX Green. The photograph of LTMC was made
from cytospin preparation and the photograph of LTCC Sup-B15 cells was taken from a portion of one
hematopoietic cord.
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Figure 6. Bcr-abl fusion protein is essential for maintaining the VE-cadherin/β-catenin axis in
Ph+ ALL.
(A) Upper panel: Western blot analysis of Bcr-abl expression by Sup-B15 in LTMC (Med) or LTCC
(S10 or PatX). Lower panel: DLR assays of LTMC (Med) and LTCC (S10 and PatX) Sup-B15 cells
transiently co-transfected with the Bcr-abl promoter reporters phRL-pp210L or phRL-pp210S with an
internal control pGL4.13-CMV-Luc2 firefly luciferase reporter. Data were shown as mean +/- SD
(n=3). “*” denotes statistically significant differences as compared to values from cells in media alone
(p<0.01) based on Student t test. (B) Western blot analysis of Bcr-abl expression by Sup-B15 cells
transduced with retroviruses containing p185-eGFP or p210-eGFP forms of Bcr-abl, or the empty
vector control (MSCV-IRES-eGFP, MiG) alone (top western blot). Dual-color flow cytometric analysis
of VE-cadherin expression in Sup-B15 cells over-expressing the exogenous Bcr-abl fusion proteins or
empty retroviral control vector (bottom flow cytometry). Baseline VE-cadherin was set to “zero” for
comparison of the net increases following retroviral transduction. (C) DLR assay of Sup-B15 cells
infected with p185-eGFP, p210-eGFP or MiG vector control retroviruses. Data are shown as mean +/SD (n=3). “*” denotes significant differences as compared to MSCV empty vector controls (p<0.01)
based on Student t test. (D) Western blot analysis of cell lysates from Sup-B15 cells treated with the
Bcr-abl kinase inhibitors Imatinib Mesylate or AG957 at various concentrations. (E) Western blot of
Sup-B15 or Nalm27 leukemic cells treated with 20 M Imatinib Mesylate, 10 M proteosome inhibitor
MG132, or a combination of both inhibitors for 16 hours.

Figure 7. Tyrosine phosphorylation of β-catenin mediated by Bcr-abl kinase diminishes
β-catenin ubiquitination-proteosome-dependent degradation.
(A) Western blot analysis of cell lysates from 293FT cells co-transduced with lentiviral vector (LentiVect), lentiviruses carrying WT VE-cadherin (Lenti-VE-cad), retroviral vector (Retro-MiG) or
retroviruses encoding p210-eGFP (Retro-MiG-p210). β-catenin was densitometrically normalized to
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GAPDH with the control value set at 1.0 and all other values shown relative to the control. (B)
Immunoprecipitation of β-catenin was done using the above cell lysates and Western blots were
probed with anti-P-Tyr (Phospho-Tyr102), anti-β-catenin, anti-phospho-Src and anti-Src antibodies.
IgG heavy chain served as the loading control. (C) DLR assays from the above 293FT cells
transiently co-transfected with the phRL-TOP1 and phRL-TOP2 reporters and an internal pGL4.13CMV-Luc2 firefly luciferase reporter. Data are shown as mean +/- SD (n=3). “*” denotes significant
differences as compared to vector controls (p<0.01) based on Student’s t test. (D) Western blot
analysis of β-catenin stabilization from 293FT cells co-expressing VE-cadherin/eGFP-p210 or VEcadherin/eGFP treated with 10 M Src kinase inhibitor PP2, 10 M Bcr-abl inhibitor Imatinib Mesylate
or both inhibitors for 16 hours. β-catenin was densitometrically normalized to VE-cadherin with the
untreated control value of expressing MiG vector alone set to 1.0. All other ratios are normalized to
this control value. (E) VE-cadherin was immunoprecipitated from 293FT cells co-expressing VEcadherin/eGFP-p210 or VE-cadherin/eGFP. The immunoprecipitates and cell lysates were loaded in
parallel and probed with anti-phospho-Tyrosine (4G10) and VE-cadherin, c-Abl and eGFP antibodies.
(F) β-catenin immunoprecipitated either from 293FT expressing eGFP-210 or eGFP alone, or from
Ph+ Sup-B15 or Ph- REH leukemic cells was in vitro labeled with recombinant ubiquitin and subjected
to in vitro degradation assay as described in Materials and Methods.
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Abstract:
The mechanisms by which the bone marrow microenvironment regulates tumor cell survival are
diverse. This study describes the novel observation that in addition to Philadelphia chromosome
positive (Ph+) acute lymphoblastic leukemia (ALL) cell lines, primary patient cells also express Hypoxia
Inducible Factor-2 (HIF-2) and Vascular Endothelial Cadherin (VE-cadherin), which are regulated by
Abl kinase. Tumor expression of the classical endothelial protein, VE-cadherin, has been associated
with aggressive phenotype and poor prognosis in other models, but has not been investigated in
hematopoietic malignancies. Targeted knockdown of VE-cadherin rendered Ph+ ALL cells more
susceptible to chemotherapy, even in the presence of bone marrow stromal cell (BMSC) derived
survival cues. Pre-treatment of Ph+ ALL cells with ADH100191, a VE-cadherin antagonist, resulted in
increased apoptosis during in vitro chemotherapy exposure. Consistent with a role for VE-cadherin in
modulation of leukemia cell viability, lentiviral-mediated expression of VE-cadherin in Ph- ALL cells
resulted in increased resistance to treatment-induced apoptosis. These observations suggest a novel
role for VE-cadherin in modulation of chemoresistance in Ph+ ALL.
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Introduction:
Acute lymphoblastic leukemia (ALL) patients are classified as “high risk” based on the presence
of tumor cells harboring the 9;22 translocation (Philadelphia chromosome; Ph+). This translocation
results in constitutively active Abl kinase, characteristic of cells resistant to standard chemotherapeutic
regimens {1, 2, 3, 4, 5}. Although advances in treatment have increased the 5 year event free survival
and cure rate, patients with Ph+ ALL continue to have a high incidence of bone marrow and central
nervous system (CNS) relapse relative to Ph- ALL {6, 7}.

While first line treatment with Imatinib

Mesylate (Gleevec, IM), in combination with conventional treatments, was initially thought to be
successful in Ph+ ALL, it has been demonstrated that specific mutations in the Abl kinase catalytic
domain render this drug ineffective {8, 9}. In addition to mutations inherent to the tumor cell, the role of
the microenvironment in modulating drug resistance has proven to be an important factor in the efficacy
of treatment in many tumors, including primary and relapsed ALL {10}. Previous reports indicate the
importance of the microenvironment in protection of tumor cell viability during disease initiation and
progression, and during treatment {11, 12, 13, 14, 15, 16, 17, 18, 19}.
We recently identified a unique population of Ph+ ALL cells that express Vascular Endothelial
Cadherin (VE-cadherin) on their surface and respond to bone marrow stromal cells (BMSC) through
stimulation of several anti-apoptotic pathways {20}. VE-cadherin expression is often discussed in the
context of vasculogenic mimicry, a process by which tumor cells gain characteristics normally restricted
to endothelial cells, allowing tumors to better utilize microenvironment cues contributing to increased
survival {21}. VE-cadherin expression has also been shown to be an indicator of poor prognosis in
melanoma and Ewings sarcoma {21, 22}.
The Hypoxia Inducible Factor (HIF) family of proteins are transcriptional regulators of proangiogenic and survival proteins that have been shown to be important in tumor cell progression and
aggressiveness {23}. HIF-2 can be regulated by Erk and Akt-induced phosphorylation cascades that
either directly phosphorylate HIF-2 or are involved in its trans-activation {24, 25, 26}. Relevant to our
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model, HIF-2 has been shown to regulate the transcription of VE-cadherin in other systems {27}.
Because HIF-2 can be active under normoxic conditions it is distinct from the more extensively
studied, and more rigorously hypoxia-driven, HIF-1. HIF-2 regulates transcriptional targets through
binding to distinct promoters, as well as promoters overlapping with HIF-1, and the ability of HIF-2 to
respond to signals outside hypoxia driven regulation positions it to have both constitutive and hypoxiainduced functions in Ph+ ALL {28}. HIF-2 is up-regulated in some primary tumors including bladder,
renal and high grade neuroblastomas and is associated with poor prognosis {23, 26, 29, 30, 31}.
Therefore, the regulation of HIF-2 and VE-cadherin expression by bone marrow stromal cells (BMSC),
and their role in hematopoietic tumor cell response to treatment, was investigated in the current study.
We demonstrate that, consistent with Ph+ ALL cell lines, primary Ph+ patient derived
leukapheresis samples also express surface VE-cadherin. Primary ALL (Ph+ and Ph-) bone marrow
core sections were positive for VE-cadherin expression by IHC. Exposure of Ph+/VE-cadherin+ ALL to
IM resulted in diminished HIF-2 and VE-cadherin. Abl kinase activity, as well as expression of VEcadherin and -catenin, are maintained by BMSC contact during in vitro exposure to chemotherapy with
lentiviral-mediated surface expression of VE-cadherin increasing chemoresistance. Disruption of VEcadherin by siRNA or the antagonist ADH100191 (ADH) led to increased sensitivity of Ph+ ALL cells to
chemotherapy, even in the presence of an adherent microenvironment, BMSC. Collectively, these
observations suggest that BMSC may provide cues that converge on hematopoietic tumor cell VEcadherin as one of the factors that modulate response to therapy.
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Materials and methods:
Cells and reagents
Ph+ SUP-B15, and Ph- REH, leukemic cell lines were obtained from the ATCC (CRL-1929 and
CRL-8286, Manassas, VA) and have been verified by both RT-PCR and fluorescent in situ hybridization
(FISH) for analysis of Bcr/Abl, and other, translocations. Primary de-identified Ph+ (IM resistant) and
Ph- ALL leukophoresis and bone marrow core biopsies were evaluated by fluorescent in situ
hybridization (FISH) for analysis of Bcr/Abl translocations.

Maintenance and derivation of human

BMSC has been previously described {11}. To establish long-term co-culture (LTCC) of BMSC and
leukemic cells, SUP-B15 cells were seeded onto 70% confluent BMSC, and SUP-B15 were subcultured onto new BMSC weekly for more than 12 months. Long term media cultures (LTMC) include
SUP-B15 cells cultured in media alone and were used in short term (24-120 hour) co-culture
experiments with adherent BMSC. The Bcr/Abl kinase inhibitor Imatinib Mesylate (IM) (LGM
pharmaceuticals, Boca Raton, FL) was reconstituted in DMSO and used at 10µM. Daunorubicin
hydrochloride (DNR) (Sigma, St. Louis, MO) was diluted in Iscove’s DMEM (CellGRO/Mediatech, Inc.
Herndon,VA) immediately prior to use at 0.01-0.1mg/ml. The peptide antagonist of VE-cadherin,
ADH100191, (ADH, Adherex Technologies Inc., Durham, NC) was used at a concentration of 1mg/ml.
Knockdown of VE-cadherin and HIF-2 expression by RNAi
SmartPool siRNA for VE-cadherin (CDH5) or HIF-2 (EPAS-1) was obtained from Dharmacon
(Lafayette, CO) and Qiagen (Valencia, CA), respectively. Transient transfection of SUP-B15 cells, with
sequence specific siRNA or scrambled control, was completed using oligofectamine (Invitrogen,
Carlsbad, CA), 200nM siRNA and 1.5x106 cells per reaction as previously described {20}. Cells were
then treated with DNR, and collected at 72 hours for evaluation of viability. Confirmation of knockdown
was completed by flow cytometric analysis (FACS).
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Confocal microscopy, flow cytometry and cell viability
Anti-human antibodies specific for HIF-2 (flow cytometry), VE-cadherin (flow cytometry) and
phosphorylated -catenin (confocal microscopy) were purchased from Novus (Littleton,CO clone
ep190b), R&D systems (Minneapolis, MN clone 123433) and Cell Signaling (Beverly, MA), respectively.
In addition, a polyclonal antibody to VE-cadherin utilized for confocal microscopy was purchased from
AXXORA LLC (San Diego, CA). Intracellular staining (for HIF-2 and phosphorylated -catenin) were
completed by fixing the cells in 10% formaldehyde for 30 minutes, followed by a 30 minute ethanol
permeabolization and a BSA block. For all staining, primary antibodies were used at 1µg per sample
and all experiments included matched isotype controls. Following incubation in secondary antibody
(Alexa fluor 488 or 555), cells were analyzed using a FACScalibur flow cytometer (BD, Franklin Lakes,
NJ) with 10,000 events collected. Remaining cells were observed by confocal microscopy. Confocal
images were acquired on a Zeiss LSM510 confocal system attached to an AxioImager Z1 microscope
using 40x and 63x/1.3 oil objective and the 405, 488, 543 and 633 nm lasers. DAPI was used as a
nuclear stain. The images were acquired and processed using the Zeiss LSM510 software version 3.21
(Carl Zeiss, Thornwood, NY) {20}. To assess viability, cells were enumerated via trypan blue exclusion,
or stained with Annexin V FITC (R&D systems, Minneapolis, MN) and analyzed by flow cytometry
(FACS). Flow cytometric data were analyzed using Win Midi software.
Immunohistochemistry
Bone marrow core biopsy samples were formalin-fixed, lightly decalcified and paraffinembedded with samples representative of Ph+ and Ph- patients at either primary or relapse stage of
disease as indicated. Five micron sections were hand stained using ducal breast carcinoma as control
tissue. In brief, the histologic sections were deparaffinized and antigen retrieval was performed by
heating in a tris based buffer for 30 minutes. The primary antibody (mouse monoclonal anti-human VEcadherin, clone BV6; Millipore Billerica, MA) was applied at a dilution of 1:10 for 24 hours; negative
controls used a 1:10 diluted mouse IgG2 matched isotype (BD Biosciences, San Jose CA). The slides
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were then incubated for 12 minutes with a conjugated secondary antibody and counterstained with
hematoxylin. The slides were then analyzed using routine light microscopy and all images shown are
400x.
Reverse Transcriptase (RT-PCR)
Total RNA was isolated from leukemic cells using the Micro-to-Midi Total RNA Isolation kit
(Invitrogen). Primers for HIF-2 (EPAS1, PPH02551B), VE-cadherin (CDH5, PPH00668E) and actin,
as a housekeeping gene control, were purchased from Superarray (Fredrick, MD). PCR conditions
were in the linear range of amplification. Images were cropped to show only data relevant to this paper.
However, all comparison data were run on the same gel.
Constitutive expression of VE-cadherin
Cloning of human VE-cadherin (CDH5) into pLenti6.2-DEST/V5 (Invitrogen), and generation of
the pLenti6.2-DEST/V5 empty vector control and lentiviral particles has been described {20}. To
generate lentiviral particles the pLenti6.2-Dest/V5 vectors were transfected into 293FT packaging cells
and viral particles were collected, filtered, and concentrated as described by Burns et. al. {32}. Lentiviral
stocks were titered with HT1080 (ATCC CCL-121) using the blasticidin-resistance colony assay. To
generate REH cell lines stably expressing empty vector (REHvect), or VE-cadherin (REHCDH5), cells were
infected with lentiviral supernatants with an MOI of 1. Clones stably expressing the genes of interest
were selected by blasticidin (3µg/mL) and expression was confirmed by quantitative real time RT-PCR,
flow cytometry and western blot.
Western Blot analysis
Anti-GAPDH (1:10,000) and anti-VE-cadherin (1:200) antibodies were purchased from
Research Diagnostics Inc., (Flanders, NJ). Anti--catenin (1:200) and anti-phosphorylated CrkL
(1:1000) antibodies were purchased from Santa Cruz (Santa Cruz, CA) and Cell Signaling Technology,
Inc. (Danvers, MA), respectively. Leukemic cells were lysed in complete cell lysis buffer, protein
concentrations were determined and westerns were performed as described by Wang et al {20}. Signal
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was visualized with enhanced chemiluminescence reagents (Amersham, Pharmacia Biotech,
Piscataway, NJ).

Images were cropped to show only data relevant to this paper. However, all

comparison data were run on the same gel.
Statistics
Where appropriate, data were analyzed using the Students–t test or ANOVA with statistical
significance of p≤.001 denoted by “#”, p≤.01 by “*”, and p≤ .05 by “+”. Annexin experiments were not
merged into one data set, but rather representative data from a single experiment are presented that
are indicative of the consistent trend. As such, no error bars are shown. While absolute values
between experiments may differ based on slightly different tumor cell viabilities at the start of the
experiment, the magnitude and trend of the response is consistent.
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Results
VE-cadherin is expressed in primary, patient derived ALL cells.
Several studies have documented the unexpected presence of VE-cadherin in aggressive
types of tumors {20, 22, 33, 34, 35}. Wang et al. showed that VE-cadherin was present in a panel of
Philadelphia chromosome positive (Ph+) cell lines that express a stem cell like phenotype {20}. To
further investigate our previous findings, primary patient derived Ph+ and Ph- ALL cells, obtained from
leukapheresis, were assessed for the presence or absence of VE-cadherin and HIF-2, a known
regulator of VE-cadherin. Transcripts for VE-cadherin and HIF-2 were detected in the Ph+ patient
leukapheresis cells while patient cells lacking the Ph translocation had minimal levels of both VEcadherin and HIF-2 mRNA (Figure 1A). Consistent with the gene expression profiles, Figure 1B shows
that VE-cadherin and HIF-2 proteins were expressed on the Ph+ patient cells (black line) but were
negligible on the Ph- patient cells (gray line). Additionally, 11/12 patient bone marrow core biopsies
were positive for VE-cadherin, with four representative samples shown (Figure 1C and Table 1).
Although IHC does not allow determination of the precise localization of VE-cadherin, the results are
consistent with intracellular flow cytometry staining of Ph- and Ph+ ALL following paraformaldehyde
fixation of cell lines in which expression of VE-cadherin was detected intracellularly (unpublished data)
while only being consistently detected on the surface of Ph+ tumor lines and primary cells. These data
demonstrate that the expression patterns and localization of VE-cadherin and HIF-2 in Ph+ primary
patient cells correlate with representative cell lines and suggest that SUP-B15 cells are a relevant
model of Ph+ ALL.
BMSC maintain expression of Ph+ ALL VE-cadherin during treatment.
It has been previously reported that VE-cadherin protein levels are decreased by treatment with
Imatinib Mesylate (IM) without significantly altering cell viability in the absence of additional stress, such
as chemotherapy {20, 36}. However, the mechanism that underlies this decrease, and the contribution
of bone marrow stromal cells (BMSC) to blunting this decrease, are unknown. To determine if the
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decrease in VE-cadherin occurs at the transcriptional level, and if BMSC can offset reduced
expression, SUP-B15 cells were co-cultured with BMSC in the presence of IM, or DMSO control, for 24
hours. The relative abundance of VE-cadherin transcripts were decreased by treatment with IM, but
co-culture with BMSC blunted the reduction (Figure 2A, left panel). In contrast, the HIF-2 transcript
was not affected by IM exposure (Figure 2A, right panel).
The mechanisms by which HIF-2, an upstream regulator of VE-cadherin, is regulated in Ph+
ALL, potentially through Abl kinase activity, has not yet been elucidated. Data from our laboratory
shows that the activity of Abl kinase can be increased, and maintained during cellular stress, by bone
marrow stromal cells (BMSC) and can physically interact with VE-cadherin and -catenin {20}.
Interestingly, Akt and Erk, both established regulators of HIF-2, can be regulated by both Abl kinase
and the stromal cell niche {12, 37, 38, 39}. Therefore, we investigated if HIF-2 and VE-cadherin were
regulated by Abl kinase activity in Ph+ ALL cells. SUP-B15 cells were treated with Imatinib with HIF-2
and VE-cadherin protein expression analyzed by FACS (Figure 2B). Inhibition of Abl kinase resulted in
diminished levels of HIF-2 and VE-cadherin protein without significantly altering cell viability when no
additional stress was applied to the cells, suggesting a link between Abl kinase activity and regulation
of the levels of VE-cadherin and HIF-2. The specific mechanism between Abl activity and HIF-2
remain to be determined in studies that are beyond the scope of this manuscript and may have
relevance in the setting of physiological levels of Abl kinase as well in tumors that do not harbor the
Bcr/Abl translocation.
We subsequently evaluated the ability of BMSC contact to modulate Imatinib-induced down
regulation of VE-cadherin at the protein level, and found that consistent with the observation at the
mRNA level, Imatinib induced a modest down regulation in VE-cadherin protein that was partially offset
by the presence of BMSC during treatment as demonstrated by flow cytometric analysis and confocal
microscopy (Figure 2C; top and bottom panels respectively). Due to the observations that Abl kinase
activity can be increased by BMSC, and that VE-cadherin expression can be maintained by BMSC
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during IM treatment, we investigated the ability of BMSC to maintain VE-cadherin, phosphorylated CrkL
(as an indicator of Abl kinase activity) and -catenin (a pro-survival factor) during chemotherapy. Figure
2D shows that during treatment with Daunorubicin (DNR) the levels of all 3 proteins are reduced in
leukemia cells in the absence of BMSC cues. However, BMSC co-culture increases the levels of all 3
proteins and maintains the increase in the presence of chemotherapy (Figure 2D). These data suggest
that HIF-2 and VE-cadherin protein expression is regulated by Abl kinase activity, with BMSC contact
maintaining the expression of Abl kinase, VE-cadherin and -catenin during treatment.
The bone marrow microenvironment regulates HIF-2
We have shown that leukemic cell Bcr/Abl kinase activity, as well as -catenin and VEcadherin, can be maintained by bone marrow stromal cells (BMSC), even in the presence of
chemotherapy (Figure 2) and we have previously shown a physical interaction between Bcr/Abl, catenin, VE-cadherin {20}. The current study, and previous publication, demonstrates that in addition to
a physical interaction, a signaling cascade may occur between Bcr/Abl and subsequent stabilization of
HIF-2, VE-cadherin and -catenin (Figure 2D) {20, 40}. However, the modulation of HIF-2 by BMSC
has not been investigated. Therefore, we determined the influence of BMSC on HIF-2 expression.
LTMC and LTCC SUP-B15 cells were cultured in media alone or with BMSC. HIF-2 message and
protein expression were analyzed by RT-PCR and FACS, respectively. Data presented in Figure 3A
show that in both media alone and during co-culture with BMSC, the message levels of HIF-2 remain
constant. However, HIF-2 protein is increased by co-culture with BMSC, regardless of whether ALL
cells were originally from LTMC or LTCC conditions (Figure 3B). Consistent with this observation, VEcadherin levels increase with BMSC contact as well {Figure 2C, 20}. Additionally, when the baseline
HIF-2 expression in LTMC and LTCC cells was compared, by placing SUP-B15 cells from LTMC or
LTCC in media for 24 (Figure 3C), or 120 hours (data not shown), the LTCC derived Ph+ ALL cells had
higher levels of HIF-2. This was intriguing as the LTCC cells also have increased resistance to
treatment compared to the LTMC cells, and have higher levels of VE-cadherin at baseline {20} (data
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not shown). To further substantiate the functional significance of BMSC increasing HIF-2 protein
levels, Oct-4, a stem cell marker and direct transcriptional target of HIF-2, was evaluated and shown
to increase in the presence of BMSC (Figure 3D).Taken together, these data suggest that BMSC
increase HIF-2 protein, as well as targets of HIF-, Oct-4 and VE-cadherin, in our model.
Modulation of VE-cadherin reduces chemotherapy-induced apoptosis
To further investigate the roles of HIF-2 and VE-cadherin in regulation of apoptosis, SUP-B15
cells were treated with siRNA specific to HIF-2, VE-cadherin, or scrambled control sequence. After 72
hours, efficiency of knockdown was determined by FACS (Figure 4A). The labels above the histogram
represent the specific siRNA utilized for that experiment compared to the scrambled (Scr) control while
the labels on the X axis correspond to the staining detected for either HIF-2 or VE-cadherin in those
cells. HIF-2 has been shown to directly regulate the transcription of VE-cadherin and as expected,
when HIF-2 was down-regulated, VE-cadherin decreased as well (Figure 4A top panel).
Surprisingly, when VE-cadherin was down-regulated, slightly less HIF-2 protein was detected
(Figure 4A bottom panel). There are potentially intermediate regulators in this pathway, along with the
possibility that HIF-2 is acting directly as a transcription factor for VE-cadherin gene expression, as
documented in studies from other laboratories {27}.

Following down-regulation of HIF-2 or VE-

cadherin, SUP-B15 cells were treated with Imatinib Mesylate (IM), Daunorubicin (DNR) or a
combination of IM/DNR and viability was evaluated. Cells in which either VE-cadherin or HIF-2 were
down-regulated were more susceptible to chemotherapy-induced death than their controls, and VEcadherin down-regulation rendered the cells susceptible, even when co-cultured with BMSC (Figures
4B and 4C).
To confirm the potential role of surface VE-cadherin in modulation of therapeutic response, Ph/surface VE-cadherin- REH cells were transduced with a lentiviral vector containing full length VEcadherin (REHCDH5) or empty vector control (REHVect). Western blot and FACs analysis confirmed
expression of VE-cadherin (Figure 5A, data not shown). REHCDH5 and REHVect expressing cells were
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challenged with DNR and viability was evaluated. Ph- REH cells expressing surface VE-cadherin show
a modest, but statistically significant, increase in survival during chemotherapy compared to their VEcadherin negative vector control (Figure 5B).
Disruption of VE-cadherin signaling as a therapeutic target
To address the role of VE-cadherin as a potential therapeutic target in Ph+ ALL, ADH100191
(ADH), a specific peptide inhibitor directed against the surface cell adhesion recognition sequence of
the VE-cadherin extracellular domain, was utilized. SUP-B15 cells were pre-treated with 1 mg/ml ADH
for 6 hours prior to treatment with Daunorubicin (DNR). ADH pretreated Ph+/surface VE-cadherin+
leukemic cells were more susceptible to DNR as shown by trypan blue exclusion and Annexin-V-FITC
staining (Figure 6A). This effect was consistent and was partially sustained in the presence of BMSC
(Figure 6B). In experiments where all cells shown were treated with chemotherapy, ADH/IM, in
combination with DNR, increased the sensitivity of the Ph+ cells in media alone with the increased
sensitivity sustained in the presence of BMSC (Figure 6C). In contrast, Ph-/surface VE-cadherin- REH
cells pre-treated with ADH100191 (ADH) prior to Daunorubicin (DNR) had no increase in response to
chemotherapy, demonstrating the specificity of the ADH for surface VE-cadherin positive cells poised to
respond to a signaling antagonist (Figure 6D). Due to the specificity of the VE-cadherin antagonist
ADH100191 (ADH) for surface VE-cadherin, and the ability of VE-cadherin to be endocytosed from the
membrane, we evaluated the expression of surface VE-cadherin in the presence of ADH100191
(Figure 6E).
Our laboratory has previously shown physical interaction between Bcr/Abl, VE-cadherin and catenin in Ph+ cells, a stabilization of -catenin in cells expressing all 3 proteins, and the ability of
BMSC to increase their expression and maintain expression during treatment (Figure 2C) {20}. We
have additionally determined that Ph+ cell lines have higher baseline levels of -catenin compared to
Ph- cell lines (unpublished data). Therefore, we sought to determine if the mechanism by which VEcadherin signaling influences response to cytotoxic agents was potentially -catenin mediated.
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Treatment of SUP-B15 cells with ADH100191 (ADH) for 6 hours showed an increase in the amount of
Ser(33,37)/Thr(41) phosphorylated -catenin, characteristic of that targeted for degradation, compared
to untreated control cells (Figure 7A). Additionally, after treatment with the VE-cadherin antagonist ADH
for 24 hours there was a decrease in total -catenin protein detected (Figure 7B).
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Discussion:
In the current study we characterize the impact of VE-cadherin on the sensitivity of Philadelphia
chromosome positive (Ph+) ALL cells to Daunorubicin (DNR) and Imatinib Mesylate (IM) in vitro. While
VE-cadherin surface expression in this unique and difficult to treat, sub-type of ALL, and its expression
in a panel of patient samples, was somewhat surprising initially, it is not the first description of its
expression in non-endothelial cells. Previous studies have shown the expression of VE-cadherin in fetal
liver cells with expression subsequently lost in adult stem cells and not present on the surface of Blineage cells {41, 42}. Recent studies have also demonstrated that VE-cadherin is induced during
epithelial-to-mesenchymal transition (EMT) in mammary tumor cells {35}, contributes to vascular
mimicry in highly aggressive melanoma {43, 44} is required for successful endovascular invasion and
normal placentation in cytotrophoblast stem cells {45}, is involved during trans-endothelial migration of
metastatic cancer cells and is up-regulated in neighboring vasculature during tumor induced
angiogenesis {46, 47, 48, 49}, and is a critical regulator of TGF- signaling in endothelial cells {50}.
Therefore, it is tempting to speculate that the surface expression of VE-cadherin in Ph+ ALL cells would
position these tumors to better interact with signals from the microenvironment that promote tumor cell
survival, including TGF-. Interestingly, unpublished data from our laboratory observed that BMSC
knock down of TGF- diminishes the ability of bone marrow stromal cells (BMSC) to protect B lineage
leukemic cells from treatment.
Implications of VE-cadherin as a mediator of aggressive phenotype underscore our interest in
understanding its regulation by the microenvironment in which ALL cells thrive. One upstream factor of
interest, based on its stabilization by microenvironment-derived cues, and its influence on VE-cadherin
expression, is HIF-2 which can respond to low oxygen levels but also regulates VE-cadherin
independent of hypoxia {27}. Therefore, HIF-2 supported VE-cadherin expression would allow for
homotypic tumor interactions as well as interactions with endothelial cells in bone marrow niches or
other anatomical locations that include VE-cadherin positive cells. The expression of high levels of both
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HIF-2 and VE-cadherin in primary ALL cells is consistent with the literature describing the role of
these two proteins in other aggressive tumor models (Figure 1) {23, 26, 33, 34, 35, 46, 51}. Although
one caveat of staining formalin fixed bone marrow core biopsy samples is the lack of specific cellular
protein localization determination, it is intriguing to detect expression of VE-cadherin on the majority
(11/12) of samples and on the surface of Ph+ leukapheresis samples (Figure1). While the interpretation
of the IHC staining is limited, it supports the assertion that VE-cadherin protein expression is observed
in primary B lineage ALL, with the potential that it is stabilized and regulated uniquely in the context of
high Abl kinase activity characteristic of Ph+ ALL. Accumulation of high levels of VE-cadherin may
result in stabilization of -catenin and transcription of downstream targets as we have previously
published via binding to the TCF/LEF consensus sequence {20} while also being presented on the cell
surface where it may respond to inhibition via signaling antagonists such as ADH.
Data presented in the current study also show that forced surface expression of VE-cadherin in
Ph- cells significantly increased their viability during treatment (Figure 5). In our model, bone marrow
stromal cells (BMSC) modulated and maintained HIF-2, Oct-4 and VE-cadherin in Ph+ ALL cells
(Figure 2, 3) {20}. Our data suggests that the signaling pathway relies on active Abl kinase influencing
HIF-2, VE-cadherin and subsequently -catenin (Figures 2 and 7) with potential intermediate effector
proteins still to be determined. Importantly, the targeted inhibition of either HIF-2 or VE-cadherin,
during chemotherapy exposure in vitro, significantly diminished cell viability even in the presence of
BMSCs (Figures 4 and 6) suggesting relevance in the context of the marrow microenvironment in which
leukemic cells are often refractory to therapy, at relapse in particular. Somewhat speculative in nature,
but worth consideration, is the possibility that BMSC cues influence tumor resistance to therapy, in part,
by maintaining proteins associated with a tumor stem cell phenotype that is coincident with resistance.
HIF-2 has been documented to increase expression of at least two factors relevant to the stem
like phenotype of the Ph+ ALL cells in this study; Oct-4 (Oct-3/4, Pou5F1) {52} and VE-cadherin {27}
under hypoxic and normoxic conditions, respectively. Of note, evaluations of anatomical regions within

174

the marrow that support hematopoietic stem cells were localized predominantly to areas of low oxygen
perfusion {53}. Recent literature suggests that over expression of HIF family members, and particularly
HIF-2, promoted differentiation of BMSC to the endothelial lineage {28}. The hypoxic nature of the
stem cell niche in the marrow emphasizes the need to consider the influence of hypoxia on the
expression and activity of factors, including the hypoxia inducible factors (HIF-1 and HIF-2), that can
regulate genes that sustain tumor cell survival, proliferation, and self-renewal.
HIF target specificity has been shown to originate through its N-terminal trans-activation domain
and distinct target genes have been identified for these two factors, with little functional redundancy
even though they have the potential to bind comparable DNA motifs {54}. The co-factors that contribute
to their specificity of binding and gene regulation appear to be cell, tissue, and “circumstance” specific,
and investigation of the details are underway to better understand these important factors in regulation
of growth, survival, and differentiation. Relevant to our model is the unique role of HIF-2 in support of
VE-cadherin expression, and therefore its potential importance as a transcription factor that may
regulate therapeutic response. Further investigation will determine if BMSC derived cues impact on
binding partners of HIF-2 that may influence its effect on ALL cells beyond its role as a transcription
factor for VE-cadherin.
Exciting reports have recently emerged describing the use of diverse agents, including the
microtubule destabilizing agent CA4P, to selectively disrupt VE-cadherin in endothelial cells {55, 56}.
CA4P was shown to increase tumor cell apoptosis without negatively affecting smooth muscle cells or
the normal vasculature, highlighting its promise as a therapeutic agent. Our recent observations
suggest that, in general, agents designed to disrupt vasculature and tumor angiogenesis, particularly
those that target VE-cadherin, may have previously unappreciated benefit through their direct effects on
hematopoietic tumor cells while not damaging

normal cells or the stem cell pool {41, 42}.

Our

utilization of the VE-cadherin antagonist, ADH100191 (ADH), demonstrates the importance of VEcadherin in Ph+ ALL cells, with the VE-cadherin antagonist having no effect on Ph- ALL cells (Figure
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6D) while decreasing the viability of Ph+ cells during chemotherapy (Figures 6 and 7). The fact that
hematopoietic tumor cells lacking surface VE-cadherin were spared any effect by ADH100191
underlies speculation that normal hematopoietic cells might also be unaffected by this agent making it a
potentially useful chemo-sensitization therapy. It also suggests that while the majority of both Ph+ and
Ph- primary cells expressed VE-cadherin protein when a “total” protein IHC approach was utilized, the
efficacy of VE-cadherin antagonists may be logically limited to those tumors in which the VE-cadherin is
presented on the cell surface. The modulation of -catenin in response to inhibition of VE-cadherin in
our model of lymphoid leukemia (Figure 7) is consistent with a recent report documenting that -catenin
is essential for survival of Ph+ myeloid leukemic stem cells {57, 58}. Although the changes in viability
when VE-cadherin signaling is inhibited are quantitatively modest, they remain relevant in the context of
the significant proliferative potential of a small residual tumor load in the setting of aggressive leukemia
which may subsequently contribute to relapse of disease.
Potentially, signals from the bone marrow microenvironment culminate on targets that are also
impacted by the hypoxic nature of protective niches. Sustained expression of surface VE-cadherin in
Ph+ ALL cells, supported by signals inherent to the tumor such as high Abl kinase activity and through
microenvironment cues that influence transcriptional regulators including HIF-2 and -catenin, provide
us a model in which we can begin to investigate the complexity of survival signals in the marrow milieu.
From these models we can optimize novel therapeutic strategies designed to target residual tumor cells
that are refractory to standard therapy by understanding the critical targets on which survival signals
converge. Pathways that we have traditionally considered in the context of a solid tumor cell survival
and support of vasculogenesis and angiogenesis warrant further consideration in the biology of
hematological malignancies as well.
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Figure Legends:
Figure 1: Patient derived ALL cells express VE-cadherin and HIF-2. A) RNA was isolated from
5x106 patient derived cells and RT-PCR was performed for HIF-2, VE-cadherin or actin. B) 1x106
patient derived Ph+ (black line) and Ph- (gray line) cells were obtained from leukapheresis and stained
to detect HIF-2 (intracellular), VE-cadherin (surface) , or matched isotype control and analyzed by
FACS. C) Ph+ and Ph- primary patient bone marrow core biopsies were stained for VE-cadherin or
matched isotype control. 11/12 samples were positive for VE-cadherin and 4 representative samples
are shown. All samples were positive for CD19, CD10, CD22, HLADR and TDT.
Figure 2: Bone marrow stromal cells
Imatinib treatment.

maintain Ph+ ALL expression of VE-cadherin during

A) SUP-B15 cells were cultured in media alone or co-cultured with BMSC and

subsequently treated with 10µM Imatinib Mesylate (IM). RT-PCR was performed for VE-cadherin, HIF2 and actin. B) SUP-B15 cells were exposed to DMSO as the control solvent, or to 10uM IM, for 24
hours. HIF-2 and VE-cadherin proteins were evaluated by FACS. C) SUP-B15 cells were cultured in
either media alone, in contact with BMSC, or in contact with BMSC and Imatinib for 24 hours. Tumor
cells were subsequently fixed with 4% PFA, permeabilized with 0.5% Triton-X 100 and stained with
anti-VE-cadherin antibody or a matched isotype control for evaluation by confocal microscopy (images
shown are 63X with no zoom) or following the standard protocol described in materials and methods for
flow cytometric analysis. D) SUP-B15 cells were cultured in media alone, or in the presence of BMSC
for 24 hours, and subsequently treated with 0.1mg/ml DNR overnight. Cells were collected, lysed and
western blots were completed to analyze Bcr/abl activity as well as VE-cadherin and -catenin
expression. GAPDH was used as a loading control. Loading of gels is as follows: Lane 1 is media
alone, Lane 2 is DNR treatment, Lane 3 is co-culture with BMSC and Lane 4 is co-culture with BMSC
and DNR treatment.
Figure 3: Bone marrow stromal cells modulate HIF-2. A & B) LTMC and LTCC SUP-B15 cells
were cultured in media alone or in the presence of BMSC. HIF-2 mRNA and protein were evaluated
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by RT-PCR and FACS, respectively. C) LTMC and LTCC cells were placed in media for 24 hours and
their baseline expression of HIF-2 was evaluated by FACS. D) SUP-B15 cells were cultured in media
alone or in the presence of BMSC and evaluated for expression of Oct-4.
Figure 4: Modulation of VE-cadherin results in altered chemosensitivity. A) SUP-B15 cells were
transiently transfected with scrambled, HIF-2, or VE-cadherin siRNA and conformation of downregulation was determined using FACS. B & C) siRNA transfected cells were subsequently cultured in
media alone or in the presence of BMSC and exposed to 10uM IM or DMSO and 0.01mg/ml DNR. Cell
viability was determined by trypan blue exclusion and Annexin-V-FITC.
Figure 5: Expression of VE-cadherin decreases leukemic cell sensitivity to chemotherapy. A)
Ph-/surface VE-cadherin- REH cells were transduced with virus containing empty vector control
(REHVect) or wild type CDH5 (REHCDH5). Western blot was completed to demonstrate expression of VEcadherin. B) REHVect and REHCDH5 cells were challenged with 0.6mg/ml DNR for 48 hours and viability
was evaluated by trypan blue exclusion.
Figure 6: Disruption of VE-cadherin signaling using the VE-cadherin antagonist ADH increases
Ph+ ALL sensitivity to apoptosis. A & B) SUP-B15 were cultured in media alone or co-cultured with
BMSC for 24 hours. The cells were then pre-treated with 1mg/ml ADH, or media control, for 6 hours
and subsequently challenged with chemotherapy (0.1mg/ml Daunorubicin (DNR)/24 hours). Viability
was determined by trypan blue exclusion and Annexin-V-FITC. C) SUP-B15 cells we cultured in media
alone or in the presence of BMSC for 24 hours, pre-treated with either media/DMSO, IM, ADH or a
combination of IM & ADH for 6 hours prior to treatment with DNR. Cell viability was then determined by
trypan blue analysis. Statistical significance is shown comparing both the SUP-B15 on BMSC treated
with DNR to the IM/DNR, ADH/DNR or IM/ADH/DNR groups as well as the comparison between the
IM/DNR or ADH/DNR to IM/ADH/DNR. D) Ph- REH cells were pre-treated with 1mg/ml or 2mg/ml ADH
for 6 hours and subsequently treated with 0.6mg/ml DNR. Viability was determined by Annexin-V-FITC.
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E. SUP-B15 cells were treated with media alone or with 1mg/ml ADH for 24 hours and surface stained
for VE-cadherin.
Figure 7: Inhibition of VE-cadherin signaling leads to targeted degradation of -catenin. A)
SUP-B15 cells were treated with 1mg/ml ADH or media control for 4 hours and subsequently stained
for phospho--catenin (Ser33/37 and Thr41) or matched isotype control. Cells were analyzed by
confocal microscopy (images shown are 40X with zoom). B) SUP- B15 cells were treated with 1mg/ml
ADH or media control for 24 hours and analyzed by western blot to observe changes in total -catenin.
Samples shown were run on the same gel, in outer lanes, and therefore the image was cut to show
only bands relevant to the current study.

Table 1:

Table 1: Patient derived ALL cells express VE-cadherin. Table is representative of patient history of
samples stained for VE-cadherin. All samples were positive for CD19, CD10, CD22, HLADR and TDT.
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6. Discussion:
The broad goals of the studies presented in this work were two-fold. They are
unified by an interest in understanding critical biological events that occur in the bone
marrow microenvironment. First, we sought to better understand the direct and indirect
damage of aggressive chemotherapy on supportive cells in the marrow, with focus on
osteoblasts.

As critical regulators of steady state hematopoeisis, as well as

hematopoietic recovery following transplantation, we focused this investigation on the
functional vulnerability of marrow osteoblasts and the mechanistic underpinnings of
treatment-induced changes in osteoblasts that would negatively influence their capacity
to support human stem, and progenitor, cell development. Based on the capacity of the
marrow to nurture development of normal hematopoietic cells
particular

1;2

, and B lineage cells in

3-5

, we next sought to evaluate interactions between B lineage hematopoietic

tumors (ALL) and the marrow microenvironment.

This investigation further drew on

similarities that exist, and the fine line between, normal hematopoiesis and the
development of hematopoietic malignancies – processes that share common signaling
pathways and anatomical location 6;7. Investigations into ALL cell support by the marrow
microenvironment, and mechanisms by which microenvironment derived cues modulate
chemosensitivity as well as a “tumor stem cell” phenotype, brought into focus regulatory
proteins that had not been previously appreciated in this context, including VE-cadherin.
To evaluate the effect of ablative chemotherapy on the endosteal niche, a key
regulatory component of stem cell development in the bone marrow microenvironment,
human primary derived osteoblasts (HOB) were utilized and treated with a high dose of
Melphalan and Etoposide (VP-16) which are clinically relevant chemotherapeutic agents
for high-dose therapy prior to stem cell transplant 8. The translational relevance of this
study is drawn, in part, from the observation that patients who have received ablative
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therapy and stem cell transplantation report deficits in hematopoietic recovery up to 15
years post transplant compared to their normal counterparts 9. This suggests that even
after transplant there is residual damage to the microenvironment that alters the ability of
the transplanted cells to normally incorporate and differentiate in the stem cell niche.
While our mechanistic studies could not recapitulate this time frame, they did offer
insight into possible reasons that underlie these reported deficits including alterations of
cytokine and chemokine profiles subsequent to stress. Obtaining a better understanding
of therapy induced damage has the potential to identify critical pathways that could be
modulated during the aggressive pre-transplantation stage of treatment to increase the
efficiency of hematopoietic recovery, and diminish the risks to patients, during this critical
stage.
Initial studies included chemotherapy treated osteoblasts examined for both
alterations in gene and protein expression as well as through functional assays. Studies
from our laboratory and others had previously shown that ablative therapy increased the
amount of active TGF- (transforming growth factor-) secreted by bone marrow stromal
cells 10-12. Although results from patient tissues vary, some studies have shown that bone
marrow stromal cells taken from patients who received ablative therapy had increases in
active TGF- compared to their normal counterparts

11

. This led us to the hypothesis

that osteoblasts in the endosteal niche may not only be damaged directly by ablative
chemotherapy (ie: high dose Melphalan or VP-16) but also indirectly from the high levels
of TGF- being secreted by the BMSC. Based on this question, we initiated experiments
to determine if ablative chemotherapy would result in an increase in osteoblast secreted
active TGF- and alter the ability of osteoblasts to support human embryonic stem cells
and pro-B cells.
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These studies confirmed that dose escalated Melphalan or VP-16, at
concentrations that mimic those reported in serum of patients prior to bone marrow
transplantation, resulted in increases in the amount of active TGF- secreted by the
osteoblasts, as measured by SMAD-3 phosphorylation. Additionally, HOB treated with
high dose Melphalan, VP-16, or recombinant TGF- had diminished capacity to support
pluripotent embryonic stem cell colonies, as measured by expression of the pluripotent
stem cell protein Oct-4. Osteoblasts treated with chemotherapy or

rTGF- had

diminshed CXCL12 mRNA and protein as well as reduced pro-B cell chemotaxis and
adherence to the HOB. Collectively, these results suggest that ablative therapy alters
the osteoblasts’ secretion of active TGF-, suggesting that chemotherapy damage may
result from both direct, and indirect effects, on the osteoblasts through paracrine and
autocrine

mechanisms. These data correlate with retrospective patient data and

suggests a role for TGF- in the inability of engraftment and correct differentiation of
stem cell transplants.
The overall conclusions of this study show for the first time that osteoblasts are
damaged in response to both direct chemotherapy, as well as indirect TGF- secretion
from damaged BMSC, and that both types of damage diminish the osteoblasts ability to
support primitive and progenitor cells. This work gives insight into the broad damage
done by ablative chemotherapy and a potential mechanism for the inhibition of
engraftment and differentiation of transplanted HSC. Although this work answers some
questions regarding damage during pre-transplant ablative therapy, it emphasizes the
need for further studies to observe: 1) the impact of ablative therapy on MSC to
determine if damage to the progenitor cells that osteoblasts and BMSC are derived from
retain the damage caused by chemotherapy in a heritable manner, 2) studies in mouse
models and subsequently patients to determine if the same damage seen in vitro is

194

occurring in vivo consistent with hematopoietic deficits seen in patients post transplant
as well as the incidence of minimal residual disease and relapse, 3) the determination of
other factors that may be playing a role, and if the damage can be reversed, or
diminished by the use of inhibitors such as the TGF- inhibitors (p144, LY2109761 and
GC1008) currently in clinical trials, 4) in vitro and in vivo studies focusing on the
mechanisms by which TGF- alters the engraftment and differentiation of HSC
transplants and finally 5) an increase in the number of retrospective studies to better
understand the potential genetic or epigenetic changes that may be present in patients
who successfully have their marrow reconstituted after transplant, without delayed
hematopoietic recovery, compared to those that do not. Interestingly, the infusion of
MSC during hematopoietic stem cell transplants is beginning to be explored to treat
other diseases such as stroke, auditory defects, type 1 diabetes and genetic diseases
and clinical trials are underway to determine if it may be useful in the setting of ablative
chemotherapy to help replace the damaged cells as well.
Our laboratory is not only interested in the marrow microenvironment as the
home for normal hematopoieis, or hematopoietic recovery following transplantation, but
also as a site of sanctuary for hematopoietic tumors. The similarity between normal proB cells and their malignant counterparts that comprise B lineage leukemia is intriguing,
but also clinically challenging. Our investigation of tumor cell interactions with the bone
marrow were focused on a sub-type of ALL that expresses the Bcr/Abl translocation.
Patients that have this mutation are automatically placed in a high risk of relapse, poor
prognosis group regardless of any other factor. They are typically resistant to therapy,
and although it is a subpopulation of patients (3-5% of pediatric ALL and 25-50% of adult
ALL), the survival rates for this disease with chemotherapy alone are 20% or less and
chemotherapy treatment with allogeneic transplant only increases to survival rate to 30-
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50%

13;14

. Therefore, it is relevant to study the phenotype of the cells, and our

observations suggested this class of tumor may have stem cell like properties that could
be contributing to therapeutic resistance.
Our first study was initiated, in part, based on the work of Mary Hendrix. Her
group determined, in a melanoma model, that particularly aggressive tumor cells
expressed VE-cadherin and were able to create neovasculature and form networks that
imitated endothelial cells, a process termed “vasculogenic mimicry”

6;8;15

. Therefore in

our model of aggressive, Ph+ ALL we chose to look at the phenotype of these cells and
the expression of stem cell markers. We determined that the Ph+ cells had a unique
phenotype of surface VE-cadherin expression that is more readily detected than in their
Ph- counterparts, as well as PECAM-1. Ph+ cells also generated hemospheres when
cultured with bone marrow stromal cells, that were reminiscent of mammospheres or
neurospheres propagated from the stem cell pool of breast and neural cells
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.

Additionally, these VE-cadherin +, PECAM-1+, PH+ ALL cells had the ability to sprout
branches like normal endothelial cells when grown in endocult giving endothelial signals.
The Ph+ cells and their hemospheres also had a stem-like phenotype and had
the expression of Oct-4 as well as CD133 (promin-1). We further evaluated the effect of
BMSC co-culture and soluble factors on this phenotype and determined, between our
two tumor studies, that VE-cadherin, beta-catenin, HIF-2 alpha, Src, Oct-4 and Bcr/Abl
kinase activity could all be increased by BMSC contact, and in the presence of
chemotherapy most of these proteins are maintained by BMSC contact. We investigated
the relationship between beta-catenin and VE-cadherin and noticed that Ph+ cells had
higher levels of beta-catenin at baseline than Ph- cells (unpublished data). We then
determined that beta-catenin physically interacts with and is stabilized by VE-cadherin
and that both of these proteins are regulated by Bcr/Abl kinase activity. Treatment of
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Ph+ cells with the Abl kinase inihibitor Imatinib resulted in decreased VE-cadherin and
beta-catenin protein.
This inhibition of survival proteins with modulation of Abl kinase or VE-cadherin
led us to investigate the potential

therapeutic importance of VE-cadherin. Although

Imatinib was initially very successful in the treatment of CML and Ph+ ALL, patients who
relapse tend to have mutations in the Abl kinase domain (E225K, T315I, as well as
alternative splicing of Bcr/Abl). These mutations leave the patients resistant to Imatinib
suggesting that proteins downstream of Abl kinase activity may be relevant therapeutic
targets.
To confirm our previous results in cell lines, we obtained primary, patient
leukapheresis and bone marrow core samples from Ph- and Ph+ patient and examined
them for the presence of VE-cadherin. The Ph+ leukapheresis samples had VE-cadherin
on their surface while the Ph- samples did not. The staining of the bone marrow core
samples was intracellular and all samples had VE-cadherin which correlated with our cell
line data showing stabilized VE-cadherin on the surface of Ph+ ALL but found
intracellularly on Ph+ and Ph- ALL. We treated SUP-B15, a Ph+ ALL cell line, with
Imatinib and determined that VE-cadherin and HIF-2 alpha protein were both decreased
in the presence of Imatinib but that VE-cadherin could be maintained in the presence of
BMSC. Baseline protein expression of VE-cadherin, HIF-2 alpha, Oct-4 and beta-catenin
could all be increased by BMSC contact, and during chemotherapy VE-cadherin and
beta-catenin protein were maintained (HIF and Oct were not tested.)
This led us to the hypothesis that Bcr/Abl was regulating HIF-2 alpha which
subsequently could act as a transcription factor for VE-cadherin and Oct-4 and lead to
VE-cadheirn mediated stability of beta-catenin and stem cell phenotype, respectively.
When HIF-2 alpha or VE-cadherin were inhibited with siRNA, the Ph+ leukemic cells
were more susceptible to daunorubicin treatment, even in the presence of BMSC.
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Inhibition of VE-cadherin signaling with ADH100191 (ADH) , a VE-cadherin antagonist
that binds to the extracellular domain, resulting in diminished viability during treatment as
well as increased Ser/Thr phosphorylated beta-catenin targeted for degradation. Our
data suggest that VE-cadherin is a novel and relevant therapeutic target that regulates
beta-catenin expression which has been shown to be critical in leukemic (CML) stem cell
survival during treatment

17

.

The collective observations of the studies discussed in chapters 2 and 3
demonstrates the importance of microenvironmental regulation of tumor cell signals
during chemotherapy treatment. Not only is it clinically important and particularly
challenging in the setting of hematopoietic malignancies to attempt to find markers on
tumor cells that are not on normal cells, but it is also crucial to determine the functional
relevance and regulation of these aberrantly expressed proteins. The expression of VEcadherin in leukemia, as well as breast, prostate and other tumors that commonly
metastasize to the bone marrow, may not only play a role in tumor resistance to
chemotherapy but may also underlie a new mechanism by which tumor cells incorporate
into the vasculature.
A recent study by Alvero et al. showed that a stem-cell-like population of ovarian
cancer cells expressed CD34+, VE-cadherin and were able to form xenograft tumors
containing blood vessels, lined by human CD34+ cells

18

. Additionally, these cells

mimicked the behavior of normal endothelial cells, could form vessel like structures in 24
hours and could form vessels with extended branching and maturation after 7 days of
culture in matrigel

18

. Studies from multiple groups have shown an increase in

microvessel density in patients with different types of leukemia (AML, CLL, ALL etc.)
suggesting the potential broad therapeutic implications of specific VE-cadherin
antagonists for cancer therapy 19;20.
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Clinical trials are ongoing for drugs that have effects on VE-cadherin such as
Combrostatin-A-4-Phosphate (CA4P). CA4P results in the depolymerization of
microtubules resulting in detachment and apoptosis of endothelial cells. Although CA4P
seems to selectively target endothelial cells it is not specifically a VE-cadherin
antagonist. The Rafii lab has shown that CA4P can induce regression of unstable
nascent tumor neovessels and inhibit leukemic cell proliferation and survival in vitro and
in vivo in part by VE-cadherin/-catenin/Akt signaling pathway and disruption of
mitochondrial
respectively

membrane

potential

resulting

in

caspase-dependent

cell

death,

21;22

. These studies, as well as the studies performed in our own laboratory,

emphasize the ability of VE-cadherin inhibition, even in the presence of the protective
tumor microenvironment, to be a potential novel therapeutic option for aggressive tumors
that may express cadherin proteins as anti-apoptotic regulators and/or mediators of
contribution to new vasculature as tumors reach significant size. These data suggest we
should consider angiogenesis inhibitors in a novel context, that of hematological
malignancies.
In addition to this work converging “in” the bone marrow, the studies focusing on
normal leukemic cell survival also identified TGF- as an intriguing factor.

We know

from the studies shown here, as well as the studies previously published by our lab, that
both bone marrow stromal cells and osteoblasts secrete high levels of active TGF- after
treatment with chemotherapy

12

. In the normal hematopoieis model the secretion of

active TGF- is tightly regulated, and high levels inhibit the ability of osteoblasts to
interact with and support primitive stem cells as well as progenitor pro-B cells. However,
in the leukemia model TGF- increased the amount of VE-cadherin expression in the
Ph+ cells coincident with protection of tumor cells from chemotherapy. The Dejana lab
has shown that in normal endothelial cells VE-cadherin acts as a critical regulator of
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TGF- signaling, and a study by Labelle et al. demonstrated that VE-cadherin is induced
during EMT in mammary tumor cells and is aberrantly expressed in invasive human
breast carcinomas

23;24

. VE-cadherin expression in these tumors influences the levels of

Smad2 phosphorylation and expression of TGF-. These data suggest a link between
VE-cadherin and TGF- as well as a dual role for VE-cadherin , promotion of tumor
progression via angiogenesis and enhancement of tumor cell proliferation through the
TGF- signaling pathway.
These data remind us of the complexity of the marrow microenvironment in both
its hematopoietic support role and its capacity to serve as a tumor sanctuary. Further,
the studies emphasize the vulnerability of the “structural” components of the marrow,
including osteoblasts, that regulate diverse processes through their expression of
adhesion molecules, cytokines, chemokines, and ECM driven signals. Many questions
emerge from a common niche that can house and support both healthy and transformed
hematopoietic cells and is exposed to aggressive cytotoxic drugs in an attempt to
eradicate tumor, or conversely, to prepare for transplantation of healthy stem cells.
Future studies will be required for us to optimally modulate the bone marrow
microenvironment to increase its utility as a tool in the treatment of patients with cancer.

200

Reference List
1. Calvi LM, Adams GB, Weibrecht KW et al. Osteoblastic cells regulate the
haematopoietic stem cell niche. Nature 2003;425:841-846.
2. Gong JK. Endosteal marrow: a rich source of hematopoietic stem cells. Science
1978;199:1443-1445.
3. LeBien TW, Tedder TF. B lymphocytes: how they develop and function. Blood
2008;112:1570-1580.
4. McGinnes K, Quesniaux V, Hitzler J, Paige C. Human B-lymphopoiesis is supported
by bone marrow-derived stromal cells. Exp.Hematol. 1991;19:294-303.
5. Wu JY, Purton LE, Rodda SJ et al. Osteoblastic regulation of B lymphopoiesis is
mediated

by

Gs{alpha}-dependent signaling pathways. Proc.Natl.Acad.Sci.U.S.A

2008;105:16976-16981.
6. Campana D, Coustan-Smith E, Manabe A et al. Human B-cell progenitors and bone
marrow microenvironment. Hum.Cell 1996;9:317-322.
7. Colmone A, Amorim M, Pontier AL et al. Leukemic cells create bone marrow niches
that disrupt the behavior of normal hematopoietic progenitor cells. Science
2008;322:1861-1865.
8. Ryu KH, Ahn HS, Koo HH et al. Autologous stem cell transplantation for the treatment
of neuroblastoma in Korea. J.Korean Med.Sci. 2003;18:242-247.
9. Galotto M, Berisso G, Delfino L et al. Stromal damage as consequence of high-dose
chemo/radiotherapy in bone marrow transplant recipients. Exp.Hematol. 1999;27:14601466.

201

10. Barcellos-Hoff MH, Derynck R, Tsang ML, Weatherbee JA. Transforming growth
factor-beta activation in irradiated murine mammary gland. J.Clin.Invest 1994;93:892899.
11. Corazza F, Hermans C, Ferster A et al. Bone marrow stroma damage induced by
chemotherapy for acute lymphoblastic leukemia in children. Pediatr.Res. 2004;55:152158.
12. Wang L, Clutter S, Benincosa J, Fortney J, Gibson LF. Activation of transforming
growth factor-beta1/p38/Smad3 signaling in stromal cells requires reactive oxygen
species-mediated

MMP-2

activity

during

bone

marrow

damage.

Stem

Cells

2005;23:1122-1134.
13. Radich

JP.

Philadelphia

chromosome-positive

acute

lymphocytic

leukemia.

Hematol.Oncol.Clin.North Am. 2001;15:21-36.
14. Ravandi F, Kebriaei P. Philadelphia chromosome-positive acute lymphoblastic
leukemia. Hematol.Oncol.Clin.North Am. 2009;23:1043-63, vi.
15. Hendrix MJ, Seftor EA, Hess AR, Seftor RE. Vasculogenic mimicry and tumour-cell
plasticity: lessons from melanoma. Nat.Rev.Cancer 2003;3:411-421.
16. Bez A, Corsini E, Curti D et al. Neurosphere and neurosphere-forming cells:
morphological and ultrastructural characterization. Brain Res. 2003;993:18-29.
17. Hu Y, Chen Y, Douglas L, Li S. Beta-Catenin is essential for survival of leukemic
stem cells insensitive to kinase inhibition in mice with BCR-ABL-induced chronic myeloid
leukemia. Leukemia 2009;23:109-116.

202

18. Alvero AB, Fu HH, Holmberg J et al. Stem-like ovarian cancer cells can serve as
tumor vascular progenitors. Stem Cells 2009;27:2405-2413.
19. Padro T, Ruiz S, Bieker R et al. Increased angiogenesis in the bone marrow of
patients with acute myeloid leukemia. Blood 2000;95:2637-2644.
20. Negaard HF, Iversen N, Bowitz-Lothe IM et al. Increased bone marrow
microvascular density in haematological malignancies is associated with differential
regulation of angiogenic factors. Leukemia 2009;23:162-169.
21. Petit I, Karajannis MA, Vincent L et al. The microtubule-targeting agent CA4P
regresses leukemic xenografts by disrupting interaction with vascular cells and
mitochondrial-dependent cell death. Blood 2008;111:1951-1961.
22. Vincent L, Kermani P, Young LM et al. Combretastatin A4 phosphate induces rapid
regression of tumor neovessels and growth through interference with vascular
endothelial-cadherin signaling. J.Clin.Invest 2005;115:2992-3006.
23. Labelle M, Schnittler HJ, Aust DE et al. Vascular endothelial cadherin promotes
breast cancer progression via transforming growth factor beta signaling. Cancer Res.
2008;68:1388-1397.
24. Rudini N, Felici A, Giampietro C et al. VE-cadherin is a critical endothelial regulator
of TGF-beta signalling. EMBO J. 2008;27:993-1004.

John H.
Hagen

Digitally signed by John H. Hagen
DN: cn=John H. Hagen, o=West
Virginia University Libraries,
ou=Acquisitions Department,
email=John.Hagen@mail.wvu.
edu, c=US
Date: 2010.05.05 11:34:27 -04'00'

203

